

**AUSTRALIAN NSP SURVEY**  
**NATIONAL DATA REPORT**

**2005 - 2009**

**PREVALENCE OF HIV, HCV AND  
INJECTING AND SEXUAL BEHAVIOUR  
AMONG IDUs AT NEEDLE AND SYRINGE PROGRAMS**



National Centre in HIV  
Epidemiology and Clinical Research  
The University of New South Wales

June 2010

The Australian NSP Survey is funded by the Australian  
Government Department of Health and Ageing.  
The National Centre in HIV Epidemiology and Clinical  
Research is affiliated with the Faculty of Medicine,  
The University of New South Wales.

©National Centre in HIV Epidemiology and Clinical Research 2010

**ISSN 1448-5915**

This publication is available at: <http://www.nchechr.unsw.edu.au>

*Suggested citation:*

National Centre in HIV Epidemiology and Clinical Research.  
Australian NSP Survey National Data Report 2005-2009.  
National Centre in HIV Epidemiology and Clinical Research,  
The University of New South Wales, Sydney, NSW. 2010.

National Centre in HIV Epidemiology and Clinical Research  
CFI Building, Cnr Boundary and West Streets, Darlinghurst NSW 2010 Australia

Telephone: **02 9385 0900** Facsimile: **02 9385 0920** International prefix: **612** E-mail: [recept@nchechr.unsw.edu.au](mailto:recept@nchechr.unsw.edu.au)

AUSTRALIAN NSP SURVEY  
Prevalence of HIV, HCV and injecting and sexual behaviour  
among IDUs at Needle and Syringe Programs  
NATIONAL DATA REPORT  
2005 - 2009

Report prepared by Jenny Iversen, Libby Topp, Kerri Shying and Lisa Maher

National Centre in HIV Epidemiology and Clinical Research  
The University of New South Wales

June 2010

This report was funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. NCHECR is affiliated with the Faculty of Medicine, University of New South Wales.



## Acknowledgements

We would like to acknowledge everyone who assisted in the development and conduct of the 2009 Australian NSP Survey, including NSP clients, managers and staff at participating NSP survey sites. Special thanks go to laboratory staff at St Vincent's Centre for Applied Medical Research (AMR) and NSW State Reference Laboratory for HIV at St Vincent's Hospital, in particular Philip Cunningham, Celine Yan and Sharon Trevor. We are grateful to the project investigators and the original steering committee responsible for developing the survey methodology, to Dhara Kothary from NCHECR, and to Greg Smith at Educational Assessment Australia for scanning and validating completed surveys.

We acknowledge the support and input of the following members of the Australian NSP Survey advisory group during 2009: Ms Tracey Dobie (ACT); Ms Rose Mason (NSW); Mr Shayne Kilford (NT); Mr Robert Kemp/Mr Gregory Perry (QLD); Mr Stephen Lymb/Ms Jenny Grant (SA); Ms Tania Hunt/Ms Francine Smith (TAS); Mr Roland Jauernig (VIC); Ms Jude Bevan (WA); Ms Fiona Poeder (Australian Injecting and Illicit Drug Users League); Mr John Ryan (ANEX), and Dr Tony Butler (National Drug Research Institute). We are particularly grateful to Dr. Alex Wodak (Drug & Alcohol Services, St Vincent's Hospital) for chairing the group.

Ethical approvals for the survey were obtained from Institutional Ethics Committees associated with the investigators and participating NSP sites. The Australian NSP Survey is funded by the Australian Government Department of Health and Ageing. The National Centre in HIV Epidemiology and Clinical Research is affiliated with the Faculty of Medicine, The University of New South Wales.

While the survey is the result of collaboration between many organisations and individuals, its success is due to the dedication and vision of the late Dr. Margaret MacDonald, who was responsible for its development and conduct from 1994 to 2003.



## Table of contents

### Summary

Key Points .....	1
Introduction.....	3
Injecting behaviour .....	4
Sexual behaviour .....	6
HIV antibody prevalence.....	7
HCV antibody prevalence .....	8

### Tables

National .....	11
Australian Capital Territory.....	34
New South Wales.....	47
Northern Territory .....	70
Queensland.....	83
South Australia .....	106
Tasmania.....	129
Victoria .....	142
Western Australia .....	155

Methodological Notes.....	169
NSP Survey Questionnaire.....	172
Participating NSP sites .....	176
List of Tables.....	178





## Summary

### Key Points

#### HIV and HCV antibody prevalence:

- HIV antibody prevalence remained low, nationally, at less than two percent, except among male participants reporting homosexual identity (37.5% in 2009).
- HCV antibody prevalence declined significantly in 2009, from 61% to 62% during the period 2005 to 2008, to 50% in 2009.
- The decline in HCV antibody prevalence was observed in all states and territories with the exception of South Australia where a substantial decline in prevalence was observed in 2008.
- The decline in HCV antibody prevalence occurred in both women and men, among all groups defined by age and duration of injecting, and across injectors of all the major drug types.
- HCV antibody prevalence was lower among participants reporting methamphetamine as the last drug injected compared to those last injecting heroin. Conversely, HIV antibody prevalence was higher among participants reporting methamphetamine as the last drug injected compared to those who reported last injecting heroin.

#### Demographic characteristics:

- While the median age of survey participants increased in recent survey years, median age did not increase in 2009 and remained stable at 36 years in both 2008 and 2009.
- The proportion of participants aged less than 25 years remained relatively stable at between 9% and 12% between 2006 and 2009. The proportion of new injectors (participants who reported injecting for less than three years) also remained stable at 5% to 6% over the past four years.

#### Injecting behaviour:

- The proportion of participants reporting daily or more frequent injection in the month prior to the survey remained stable at between 47% and 50% over the last five years.
- Heroin and methamphetamine were the two most commonly reported drugs last injected in all survey years, accounting for around two thirds of participants.
- The proportion of participants reporting pharmaceutical opioids as the last drug injected increased from 9% in 2005 to 16% in 2009.
- Receptive sharing of needles and syringes was reported by around 15% of participants in all of the past five survey years. Reports of receptive sharing of ancillary equipment were more common, reported by around one third of participants. Around one quarter of participants reported reuse of needles and syringe in the month prior to survey completion.
- Despite being unlawful in most jurisdictions, in 2009 around one in three survey participants reported secondary exchange (onward supply) of needles and syringes in the month prior to survey completion.



## Introduction

The Australian Needle and Syringe Program Survey (ANSPS) monitors human immunodeficiency virus (HIV) and hepatitis C (HCV) antibody prevalence among people who inject drugs (PWID) in Australia. The survey also monitors behavioural indices of risk and provides important information that can be used for planning prevention, treatment and support policies and services. Each year, all clients attending participating NSP services during the designated survey period are invited to complete a brief, anonymous questionnaire and to provide a capillary blood sample for HIV and HCV antibody testing. This report presents national, state and territory data for the period 2005 to 2009.

Fifty one NSP sites participated in the survey in 2009, all of whom had participated previously. The majority of participants (84%) were recruited from survey sites that had participated in each of the last five years. The number of survey participants ranged from 1800 in 2005 to 2697 in 2009. The annual response rate varied from 39% to 44% (Table 1).

The male to female ratio was approximately 2:1 for all survey years with less than one percent of participants identifying as transgender. The majority of participants identified as heterosexual, with 9% identifying as bisexual and 3% as homosexual in 2009. The proportion of Indigenous participants and the proportion of participants born in Australia remained relatively stable over the last five years (10% to 12% and 84% to 86% respectively). The proportion of participants reporting incarceration in the 12 months prior to survey completion was also stable over the same period, at 13% to 14%. Among those reporting recent incarceration, approximately one in three reported injecting in prison (Table 1).

Participants reported relatively high rates of both HIV and HCV testing in all of the last five years. In 2009, approximately half the participants reported having a HIV test in the past twelve months, and a slightly greater proportion (57%) reported having a HCV test during that time. In addition, around a third of participants reported having a HIV or HCV test more than twelve months ago, with relatively few (11% or less) reporting having never been tested (Table 6).


Participants also reported high rates of engagement with drug treatment services, with 80% of 2009 participants reporting current or previous drug treatment. The proportion of participants reporting methadone maintenance treatment at the time of survey participation remained stable at between 31% and 33% over the last five years. In 2008 questions on buprenorphine and buprenorphine-naloxone treatment were included in the survey. In both 2008 and 2009, 13% of participants reported current buprenorphine treatment while 25% reported previous buprenorphine treatment. Current buprenorphine-naloxone treatment was reported by 8% of survey participants in 2009 with 15% reporting previous treatment (Table 3).

## Injecting behaviour

The median age at first drug injection remained stable at 18 years between 2005 and 2009. The median age at the time of survey completion was 36 years in 2009, the first year since 2000 that an increase in mean age was not observed. The median duration of injecting was 15 years in 2009, and has been stable over the past three years. The proportion of new injectors (injecting for less than three years) declined from 9% in 2005 but has remained stable at 5% to 6% since that time (Table 1).


In 2009, heroin was once again the most commonly reported drug last injected with around one third of participants reporting having last injected this drug. Around one quarter of respondents reported last injecting methamphetamine (speed, base, ice) in 2009, a decline from a high of 38% in 2006 (Figure 1). The proportion of participants reporting methadone as the drug last injected was stable at between 8% and 10% over the period 2005 to 2009. The proportion of participants who reported pharmaceutical opioids as the drug last injected increased annually over the same period, from 9% in 2005 to 16% in 2009. Relatively small proportions of participants reported the last drug injected as anabolic steroids (1%-2%), cocaine (2%-3%) and buprenorphine (3%-5%) over the past five years (Table 2).

Figure 1 Proportion of participants (%) reporting heroin, methamphetamine and pharmaceutical opioids as the drug last injected nationally, 2005 – 2009



As in previous survey years, in 2009 there was substantial variation among jurisdictions in the reports of the drug last injected (Figure 2). Heroin was the most commonly reported drug last injected in Victoria (61%), Australian Capital Territory (38%), New South Wales (37%) and Western Australia (33%). Methamphetamine was the most commonly reported drug last injected in South Australia (37%) and Queensland (29%), while pharmaceutical opioids were most commonly reported in the Northern Territory (49%) and methadone most commonly reported in Tasmania (33%).

Figure 2 Proportion of participants (%) reporting heroin, methamphetamine and pharmaceutical opioids as the drug last injected in 2009 by state and territory




Around half of participants reported daily or more frequent injecting in all of the past five years (Table 1). In 2009, daily injecting was more common among respondents that reported last injecting heroin (57%), pharmaceutical opioids (65%), buprenorphine (75%) and more than one drug (67%). Around one third of participants who reported last injecting methamphetamine or methadone injected daily, while a minority (23%) of those who reported last injecting anabolic steroids injected daily in the month prior to survey completion.

Prevalence of at least one public injection (injection in a street, car, beach, park or squat) in the month prior to survey completion remained stable at 43% to 46% over the period 2005 to 2009. Despite being unlawful in most jurisdictions, secondary exchange (onward supply) of unused needles and syringes appears to be relatively common with one in three participants reporting passing on or selling needle and syringes to others in the month prior to survey completion in 2009 (Table 4).

The proportion of participants reporting reuse of needles and syringes (including one's own) in the month preceding the survey was stable at 25% to 28% over the past five years (Figure 3).

The proportion of participants reporting re-use of someone else’s used needle and syringe in the previous month (receptive sharing) also remained relatively stable at between 13% and 16% during the period 2005 to 2009. Among those who reported receptive sharing of a needle and syringe, re-use after only one person was most commonly reported, typically a regular sex partner or close friend. Receptive sharing of ancillary equipment (water ampoule, drug mix, filter, spoon or tourniquet) was also stable in all of the past four survey years (there was a minor change to this question in 2006). One in three participants reported receptive sharing of an item of ancillary injecting equipment in the preceding month, with spoons, water ampoules and filters the most commonly identified shared items (Table 2).

Figure 3 Proportion of participants (%) reporting reuse and receptive sharing of a needle and syringe and receptive sharing of ancillary equipment in the month prior to the survey, 2005 - 2009



### Sexual behaviour

In each of the past five years, just over half of participants reported sex with a regular sex partner in the month prior to survey completion. Of these, a majority (71% to 74%) reported that they never used a condom. A smaller proportion of respondents (14% to 16%) reported sex with a non-regular sex partner although condom use was higher among this group, with a quarter to a third reporting never using a condom. The proportion of respondents reporting commercial sex work in the month prior to the survey remained low and stable at 5% to 6% over the past five years, while use of condoms at last commercial sex was high at between 83% and 95% in all years between 2005 and 2009 (Table 5).

### HIV antibody prevalence

HIV antibody prevalence has remained low at 1.5% or less nationally and less than 2.5% in all states and territories over the past five years (Table 7, Figure 4). No participants in Tasmania or the Australian Capital Territory tested positive to HIV antibodies between 2005 and 2009. Of the 31 HIV antibody positive participants the majority (74%) were from NSW (N=13) and Queensland (N= 10). HIV prevalence was consistently higher among homosexual male participants than among bisexual or heterosexual male participants or female participants in all survey years (Figure 5).

Figure 4 HIV antibody prevalence (%) by state and territory, 2005 - 2009






Figure 5 HIV antibody prevalence (%) by gender and sexual identity, 2005 - 2009



## HCV antibody prevalence

Nationally, HCV antibody prevalence was stable at 61% to 62% over the period 2005 to 2008. However a substantial decline in 2009, to 50% nationally, was observed in all states and territories with the exception of South Australia where a substantial decline was observed in 2008 (Figure 6). In the Australian Capital Territory, Northern Territory and Queensland, 2009 HCV antibody prevalence reflected a continuation of trends observed in 2007 and 2008.

Figure 6 HCV antibody prevalence (%) by state and territory, 2005 – 2009



Although this result may appear surprising, fluctuations of such magnitude in HCV antibody prevalence are not unprecedented in the ANSPS. Whereas national HCV antibody prevalence was stable between 2005 and 2008, this was not the case at the jurisdictional level, with fluctuations of 10% or more occurring in the majority of states and territories (Figure 6). Although there was some variation to the survey methodology in Queensland and South Australia in 2009 (see Methodological Notes page 169), there were no methodological changes in other jurisdictions that might account for the national decline observed in HCV prevalence. In addition, all of the participating NSP sites in 2009 were involved in the survey in 2008, and 84% of the 2009 sample was recruited from sites that had participated in each of the past five years. Further, as demonstrated by the Tables depicted later in this report, the 2009 sample was not significantly different from samples recruited in previous years in terms of demographic or key injecting and sexual risk behaviour variables assessed by the survey (see Tables 1 to 4). While we acknowledge that the 2009 sample may differ from earlier samples in terms of characteristics that the survey does not measure, as described in more detail below, the decline in HCV antibody prevalence occurred consistently across the entire sample.



HCV antibody prevalence significantly declined over the period 2005 to 2009 among both males and females ( $\chi^2$  trend  $p < 0.001$ ). As in previous years, HCV antibody prevalence was highest amongst participants aged over 30 years and those with a longer injecting history (Table 22 and Table 23).

Figures 7 and 8 illustrate the correlations between HCV antibody prevalence and age ( $r=0.17$ ,  $p < 0.001$  in 2009) and between HCV antibody prevalence and time since first injection ( $r=0.25$ ,  $p < 0.001$  in 2009). These figures also indicate that 2009 HCV antibody prevalence was consistently lower than prevalence observed in 2008, and declines were not confined to a specific group defined in terms of age or duration of injecting.

Figure 7 HCV antibody prevalence (%) by duration of injecting, 2008 and 2009





Figure 8 HCV antibody prevalence (%) by age, 2008 and 2009



In all years between 2005 and 2009, and among both males and females, HCV antibody prevalence was higher among participants reporting heroin or pharmaceutical opioids as the last drug injected than among those reporting methamphetamine (Figure 9). HCV antibody prevalence was also lower in 2009 than in any of the previous five years for both males and females among participants who reported last injecting heroin, methamphetamine or pharmaceutical opioids (Figure 9).

In each of the last five years, HCV antibody prevalence was higher among survey participants reporting imprisonment in the year prior to survey completion than among those not reporting recent imprisonment ( $p < 0.001$ , Figure 10).

Figure 9 HCV antibody prevalence (%) by drug last injected and gender, 2005 – 2009





Figure 10 HCV antibody prevalence (%) by recent imprisonment and gender, 2005 – 2009



## National

Table 1 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	49	44	52	53	51
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697
Response (%)	44%	38%	39%	39%	45%
Gender (%)					
Male	1149 (64)	1265 (65)	1241 (65)	1456 (64)	1756 (65)
Female	642 (36)	683 (35)	660 (35)	803 (35)	924 (34)
Transgender	8 (< 1)	10 (<1)	9 (<1)	6 (<1)	9 (<1)
Not reported	1 (< 1)	3 (<1)	2 (<1)	5 (<1)	8 (<1)
Sexual identity (%)					
Heterosexual	1464 (81)	1611 (82)	1570 (82)	1843 (81)	2236 (83)
Bisexual	150 (8)	176 (9)	177 (9)	219 (10)	236 (9)
Homosexual	99 (6)	109 (6)	116 (6)	115 (5)	89 (3)
Not reported	87 (5)	65 (3)	49 (3)	93 (4)	136 (5)
Age and duration of injection (years)					
<i>Median age</i>	34	34	35	36	36
<i>Age range</i>	15-66	13-68	14-69	16-70	15-66
<i>Age group (%)</i>					
<25 years	258 (14)	237 (12)	183 (10)	208 (9)	285 (11)
25+ years	1542 (86)	1717 (88)	1726 (90)	2056 (91)	2411 (89)
Not reported	0 (0)	7 (<1)	3 (<1)	6 (<1)	1 (<1)
<i>Median age 1<sup>st</sup> IDU</i>	18	18	18	18	18
<i>Age range</i>	9-55	10-52	10-56	10-60	10-58
<i>N° not reported</i>	67	71	51	46	67
<i>Median years IDU</i>	13	14	15	15	15
<i>Range</i>	<1-46	<1-45	<1-49	<1-48	<1-46
<i>Duration of drug injection (%)</i>					
<3 years	161 (9)	108 (6)	102 (5)	113 (5)	162 (6)
3+ years	1559 (87)	1779 (91)	1759 (92)	2110 (93)	2468 (92)
Not reported	80 (4)	74 (4)	51 (3)	47 (2)	67 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	1563 (87)	1695 (86)	1663 (87)	1934 (85)	2296 (85)
Yes	185 (10)	203 (10)	203 (11)	250 (11)	323 (12)
Not reported	51 (3)	63 (3)	46 (2)	86 (4)	78 (3)
Region/Country of birth					
Australia	1551 (86)	1668 (85)	1649 (86)	1918 (84)	2333 (87)
Other Oceania	54 (3)	62 (3)	46 (2)	83 (4)	85 (3)
Asia	14 (1)	17 (<1)	22 (1)	32 (1)	25 (1)
UK & Ireland	95 (5)	105 (5)	85 (4)	125 (6)	120 (4)
Other	72 (4)	73 (4)	72 (4)	68 (3)	89 (3)
Not reported	14 (1)	36 (2)	38 (2)	44 (2)	45 (2)
Main language spoke at home by parents					
English speaking	1534 (85)	1735 (88)	1778 (93)	2128 (94)	2548 (94)
Non-English speaking	266 (15)	121 (6)	102 (5)	109 (5)	113 (4)
Not reported	0 (0)	105 (5)	32 (2)	33 (1)	36 (1)
Imprisonment last year (%)					
No	1477 (82)	1622 (83)	1569 (82)	1812 (80)	2238 (83)
Yes	252 (14)	247 (13)	254 (13)	287 (13)	339 (13)
Not reported	71 (4)	92 (5)	89 (5)	171 (8)	120 (4)
Injected in prison last year (%)					
Yes	87 (35)	90 (36)	95 (37)	96 (33)	113 (33)
Frequency of injection last month (%)					
Not last month	160 (9)	182 (9)	155 (8)	230 (10)	270 (10)
Less than weekly	297 (17)	368 (19)	337 (18)	343 (15)	418 (15)
Weekly not daily	458 (25)	476 (24)	484 (25)	576 (25)	618 (23)
Daily or more	879 (49)	919 (47)	900 (47)	1099 (48)	1361 (50)
Not reported	6 (<1)	16 (<1)	36 (2)	22 (1)	30 (1)

## National

Table 2 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=1800	N=1961	N=1912	N=2270	N=2697
Anabolic steroids	29 (1)	36 (2)	20 (1)	35 (2)	43 (2)
Cocaine	53 (3)	44 (2)	33 (2)	53 (2)	66 (2)
Heroin	618 (34)	510 (26)	593 (31)	781 (34)	917 (34)
Methadone	166 (9)	180 (9)	187 (10)	192 (8)	232 (9)
Methamphetamine	573 (32)	737 (38)	574 (30)	645 (28)	657 (24)
Pharmaceutical Opioids	158 (9)	236 (12)	268 (14)	345 (15)	426 (16)
Subutex/Buprenorphine	56 (3)	101 (5)	99 (5)	104 (5)	134 (5)
More than one	40 (2)	36 (2)	53 (3)	53 (2)	86 (3)
Other	39 (2)	32 (2)	51 (3)	21 (1)	69 (3)
Not reported	68 (4)	49 (3)	34 (2)	41 (2)	67 (2)
N° Injected last month	N=1634	N=1763	N=1721	N=2018	N=2397
Places injected last month (%)*					
Own home	1319 (81)	1498 (90)	1488 (89)	1780 (89)	2065 (87)
Friend's home	618 (38)	703 (42)	714 (43)	825 (41)	973 (41)
Dealer's home	233 (14)	279 (17)	278 (17)	362 (18)	385 (16)
Street, park, beach	351 (21)	352 (21)	385 (23)	441 (22)	534 (22)
Car	487 (30)	548 (33)	561 (33)	606 (30)	724 (30)
Public toilet	344 (21)	363 (22)	389 (23)	451 (23)	544 (23)
Commercial injecting room	47 (3)	43 (3)	47 (3)	50 (3)	58 (2)
Squat	74 (5)	104 (6)	102 (6)	120 (6)	150 (6)
Use of sterile needles & syringes last month (%)					
All injections	1184 (72)	1262 (72)	1234 (72)	1429 (71)	1783 (74)
Most of the time	371 (23)	371 (21)	374 (22)	475 (24)	503 (21)
Half of the time	36 (2)	47 (3)	41 (2)	48 (2)	39 (2)
Some of the time	18 (1)	24 (1)	25 (1)	28 (1)	35 (1)
Not last month	4 (0)	17 (<1)	3 (<1)	13 (<1)	8 (<1)
Not reported	21 (1)	42 (2)	44 (3)	25 (1)	29 (1)
Re-used someone else's used needle & syringe last month (%)					
None	1345 (83)	1432 (81)	1381 (80)	1640 (81)	1963 (82)
Once	60 (4)	88 (5)	104 (6)	108 (5)	124 (5)
Twice	57 (4)	64 (4)	53 (3)	101 (5)	93 (4)
3-5 times	55 (3)	62 (4)	70 (4)	70 (3)	86 (4)
>5 times	37 (2)	47 (3)	36 (2)	55 (3)	73 (3)
Not reported	73 (4)	70 (4)	77 (4)	44 (2)	58 (2)
Number of people needle & syringe was re-used after last month (%)					
None	1277 (78)	1432 (81)	1381 (80)	1640 (81)	1963 (82)
One	147 (9)	129 (7)	125 (7)	169 (8)	185 (8)
Two	13 (1)	19 (1)	22 (1)	19 (<1)	26 (1)
Three to five	13 (1)	8 (<1)	14 (<1)	17 (<1)	15 (<1)
More than five	10 (1)	11 (<1)	8 (<1)	7 (<1)	10 (<1)
Don't know	67 (4)	46 (3)	43 (3)	71 (4)	58 (2)
Not reported	107 (7)	118 (7)	128 (7)	95 (5)	140 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	137 (8)	104 (6)	119 (7)	136 (7)	151 (6)
Casual sex partner	6 (<1)	14 (<1)	12 (<1)	12 (<1)	4 (<1)
Close friend	66 (4)	57 (3)	64 (4)	84 (4)	86 (4)
Acquaintance	31 (2)	26 (1)	23 (1)	29 (1)	32 (1)
Other	13 (1)	10 (<1)	16 (1)	21 (1)	29 (1)
Equipment used after someone else last month (%)*					
Spoon	365 (22)	351 (20)	379 (24)	436 (24)	541 (25)
Water	293 (18)	255 (15)	274 (17)	314 (17)	358 (16)
Filter	201 (12)	173 (10)	208 (13)	219 (12)	273 (12)
Drug mix	193 (12)	140 (8)	136 (9)	155 (8)	202 (9)
Tourniquet	192 (12)	166 (10)	168 (11)	195 (11)	196 (9)
None**	0 (0)	1064 (62)	1024 (65)	1181 (64)	1409 (64)
Injected by someone after that person injected themselves or others last month (%)					
No	1321 (81)	1451 (82)	1402 (81)	1673 (83)	1958 (82)
Yes	217 (13)	240 (14)	235 (14)	281 (14)	387 (16)
Not reported	96 (6)	72 (4)	84 (5)	64 (3)	52 (2)

\* More than one option could be selected

\*\* New variable in 2006

Table 3 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697
Any treatment/therapy for drug use (%)					
No	406 (23)	414 (21)	370 (19)	444 (20)	509 (19)
Yes	1374 (76)	1495 (76)	1504 (79)	1785 (79)	2144 (80)
Not reported	20 (1)	51 (3)	38 (2)	41 (2)	44 (2)
History of methadone maintenance treatment (%)					
Currently	600 (33)	575 (29)	605 (32)	696 (31)	823 (31)
Previously	426 (24)	519 (26)	539 (28)	587 (26)	645 (24)
Never	753 (42)	821 (42)	740 (39)	938 (41)	1167 (43)
Not reported	21 (1)	46 (2)	28 (1)	49 (2)	62 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	290 (13)	339 (13)
Previously	--	--	--	566 (25)	679 (25)
Never	--	--	--	1355 (60)	1621 (60)
Not reported	--	--	--	49 (2)	58 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	142 (6)	211 (8)
Previously	--	--	--	270 (12)	411 (15)
Never	--	--	--	1787 (79)	2003 (74)
Not reported	--	--	--	71 (3)	72 (3)

\* New variable in 2008

Table 4 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=1490#	N=2086#
Source of needles/syringes (%)*		
Chemist/Pharmacy	387 (26)	601 (29)
Needle Syringe Program	1285 (86)	1569 (75)
Dispensing/Vending Machine	180 (12)	222 (14)
Friend/Dealer	313 (21)	418 (20)
Other	64 (4)	69 (3)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	60 (16)	147 (24)
Needle Syringe Program	819 (64)	946 (60)
Dispensing/Vending Machine	29 (16)	29 (13)
Friend/Dealer	45 (14)	68 (16)
Other	15 (23)	19 (28)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=1721	N=2397
Secondary exchange	916 (53)	888 (37)

\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

## National

Table 5 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697
Sex with a regular partner last month (%)					
No	800 (44)	831 (42)	813 (43)	1015 (45)	1215 (45)
Yes	966 (54)	1074 (55)	1026 (54)	1190 (52)	1382 (51)
Not reported	34 (2)	56 (3)	73 (4)	65 (3)	100 (4)
Condom used with regular partner last month (%)					
N° surveyed	N=966	N=1074	N=1026	N=1190	N=1382
Never	686 (71)	750 (70)	756 (74)	828 (70)	999 (72)
Sometimes	133 (14)	150 (14)	131 (13)	144 (12)	179 (13)
Every time	103 (11)	96 (9)	103 (10)	154 (13)	135 (10)
Not reported	44 (5)	78 (7)	36 (4)	64 (5)	69 (5)
Sex with other partner/s last month (%)					
No	1461 (81)	1569 (80)	1562 (82)	1838 (81)	2186 (81)
Yes	296 (16)	296 (15)	279 (15)	345 (15)	378 (14)
Not reported	43 (2)	96 (5)	71 (4)	87 (4)	133 (5)
Condom used with other partner/s last month (%)					
N° surveyed	N=296	N=296	N=279	N=345	N=378
Never	74 (25)	77 (26)	91 (33)	85 (25)	129 (34)
Sometimes	76 (26)	74 (25)	69 (25)	101 (29)	96 (25)
Every time	135 (46)	127 (43)	105 (38)	143 (41)	148 (39)
Not reported	11 (4)	18 (6)	14 (5)	16 (5)	5 (1)
Sex work last month (%)					
No	1653 (92)	1736 (89)	1721 (90)	1991 (88)	2458 (91)
Yes	108 (6)	125 (6)	115 (6)	139 (6)	130 (5)
Not reported	39 (2)	100 (5)	76 (4)	140 (6)	109 (4)
Condom used at last sex work last month (%)*					
Yes	204 (95)	101 (86)	92 (87)	105 (83)	106 (84)

\* Percentages exclude missing data

Table 6 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=1800	N=1961	N=1912	N=2270	N=2697
Previous HIV test (%)					
Yes, last year	1035 (58)	1117 (57)	1077 (56)	1124 (50)	1360 (50)
> 1 year ago	564 (31)	618 (32)	617 (32)	818 (36)	922 (34)
Never tested	191 (11)	187 (10)	187 (10)	215 (9)	310 (11)
Not reported	10 (1)	39 (2)	31 (2)	113 (5)	105 (4)
Previous HCV test (%)					
Yes, last year	1089 (61)	1176 (60)	1147 (60)	1257 (55)	1549 (57)
> 1 year ago	521 (29)	579 (30)	596 (31)	769 (34)	855 (32)
Never tested	179 (10)	166 (8)	141 (7)	154 (7)	196 (7)
Not reported	11 (1)	40 (2)	28 (1)	90 (4)	97 (4)
Any treatment for HCV (%)					
Interferon	26 (3)	25 (3)	20 (2)	51 (4)	43 (3)
Interferon+Ribarvirin	13 (2)	25 (3)	23 (3)	56 (5)	83 (6)
Other	20 (2)	18 (2)	17 (2)	21 (2)	17 (1)
No treatment	759 (92)	791 (88)	747 (88)	1039 (86)	1174 (85)
Not reported	8 (1)	35 (4)	41 (5)	36 (3)	66 (5)
Current treatment for HCV					
Interferon/Interferon+Ribarvirin	11	11	6	18	21
Other	9	9	10	9	4

## HIV antibody prevalence

Table 7 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2005	1072	15 (1.4)	611	0 (0.0)	1692	15 (0.9)
2006	1223	26 (2.1)	661	2 (0.3)	1897	29 (1.5)
2007	1195	25 (2.1)	639	2 (0.3)	1845	28 (1.5)
2008	1396	29 (2.1)	764	3 (0.4)	2170	33 (1.5)
2009	1725	28 (1.6)	915	2 (0.2)	2657	31 (1.2)
$\chi^2$ trend p value		0.925		0.454		0.681

\* Total includes people whose gender was not reported or reported as transgender

Table 8 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)	N <sup>o</sup> tested	N <sup>o</sup> with HIV (%)
2005						
Heterosexual	939	4 (0.4)	439	0 (0.0)	1379	4 (0.3)
Bisexual	37	0 (0.0)	106	0 (0.0)	144	0 (0.0)
Homosexual	53	11 (20.8)	32	0 (0.0)	90	11 (12.2)
p value		<0.001		<0.001		<0.001
2006						
Heterosexual	1070	3 (0.3)	484	1 (0.2)	1557	4 (0.3)
Bisexual	55	4 (7.3)	110	1 (0.9)	171	6 (3.5)
Homosexual	59	19 (32.2)	46	0 (0.0)	107	19 (17.8)
p value		<0.001		0.428		<0.001
2007						
Heterosexual	1055	5 (0.5)	458	2 (0.4)	1514	7 (0.5)
Bisexual	47	2 (4.3)	119	0 (0.0)	170	3 (1.8)
Homosexual	69	18 (26.1)	42	0 (0.0)	114	18 (15.8)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	1228	3 (0.2)	537	1 (0.2)	1767	4 (0.2)
Bisexual	56	3 (5.4)	152	2 (1.3)	209	6 (2.9)
Homosexual	62	23 (37.1)	48	0 (0.0)	112	23 (20.6)
p value		<0.001		0.181		<0.001
2009						
Heterosexual	1510	7 (0.5)	682	2 (0.3)	2207	9 (0.4)
Bisexual	78	2 (2.5)	146	0 (0.0)	229	3 (1.3)
Homosexual	30	18 (37.5)	37	0 (0.0)	87	18 (20.7)
p value		<0.001		1.000		<0.001

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 9 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
< 20 years	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
20 – 24	109	1 (0.9)	90	0 (0.0)	199	1 (0.5)
25 – 29	177	0 (0.0)	137	0 (0.0)	315	0 (0.0)
30 + years	769	14 (1.8)	362	0 (0.0)	1,139	14 (1.2)
p value		0.300		---		0.200
2006						
< 20 years	19	0 (0.0)	24	0 (0.0)	43	0 (0.0)
20 – 24	101	2 (2.0)	81	0 (0.0)	182	2 (1.1)
25 – 29	230	0 (0.0)	124	0 (0.0)	357	1 (0.3)
30 + years	868	24 (2.8)	430	2 (0.5)	1308	26 (2.0)
p value		0.032		1.000		0.095
2007						
< 20 years	18	0 (0.0)	15	0 (0.0)	33	0 (0.0)
20 – 24	72	0 (0.0)	69	0 (0.0)	142	0 (0.0)
25 – 29	202	3 (1.5)	131	0 (0.0)	334	3 (0.9)
30 + years	901	22 (2.4)	423	2 (0.5)	1333	25 (1.9)
p value		0.649		1.000		0.281
2008						
< 20 years	21	0 (0.0)	16	0 (0.0)	37	0 (0.0)
20 – 24	86	0 (0.0)	73	0 (0.0)	159	0 (0.0)
25 – 29	187	1 (0.5)	142	2 (1.4)	331	4 (1.2)
30 + years	1097	28 (2.6)	532	1 (1.2)	1637	29 (1.8)
p value		0.191		0.175		0.361
2009						
< 20 years	39	0 (0.0)	30	0 (0.0)	70	0 (0.0)
20 – 24	118	1 (0.9)	88	0 (0.0)	207	1 (0.5)
25 – 29	226	0 (0.0)	177	0 (0.0)	404	0 (0.0)
30 + years	1342	27 (2.0)	619	1 (0.2)	1975	29 (1.5)
p value		0.102		1.000		0.031

\* Total includes people whose gender was not reported or reported as transgender



Table 10 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<3 years	54	2 (3.7)	29	0 (0.0)	84	2 (2.4)
3 to 5 years	100	2 (2.0)	74	0 (0.0)	175	2 (1.1)
6 to 10 years	97	0 (0.0)	106	0 (0.0)	204	0 (0.0)
10 + years	775	9 (1.2)	372	0 (0.0)	1,153	9 (0.8)
p value		0.200		---		0.200
2006						
<3 years	59	1 (1.7)	42	0 (0.0)	102	1 (1.0)
3 to 5 years	81	2 (2.5)	67	0 (0.0)	148	2 (1.4)
6 to 10 years	227	4 (1.8)	159	1 (.6)	390	6 (1.5)
10 + years	799	18 (2.3)	378	1 (.3)	1185	19 (1.6)
p value		0.936		0.658		1.000
2007						
<3 years	61	1 (1.6)	37	0 (0.0)	98	1 (1.0)
3 to 5 years	67	2 (3.0)	58	0 (0.0)	126	2 (1.6)
6 to 10 years	210	2 (1.0)	132	0 (0.0)	345	2 (0.6)
10 + years	826	19 (2.4)	394	2 (0.5)	1227	22 (1.8)
p value		0.537		1.000		0.411
2008						
<3 years	68	5 (7.4)	44	0 (0.0)	112	5 (4.5)
3 to 5 years	114	3 (2.6)	50	0 (0.0)	164	3 (1.8)
6 to 10 years	194	1 (0.5)	152	0 (0.0)	347	1 (0.3)
10 + years	986	19 (1.9)	508	3 (0.6)	1502	23 (1.5)
p value		0.014		1.000		0.016
2009						
<3 years	90	2 (2.2)	67	0 (0.0)	158	2 (1.3)
3 to 5 years	92	0 (0.0)	72	0 (0.0)	165	0 (0.0)
6 to 10 years	225	5 (2.2)	165	0 (0.0)	393	5 (1.3)
10 + years	1279	21 (1.6)	585	1 (0.2)	1875	23 (1.2)
p value		0.522		1.000		0.604

\* Total includes people whose gender was not reported or reported as transgender

Table 11 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	353	3 (0.8)	235	0 (0.0)	590	3 (0.5)
Methamphetamine	333	5 (1.5)	196	0 (0.0)	534	5 (0.9)
More than one	24	1 (4)	15	0 (0.0)	39	1 (2.5)
Other/Not reported	355	6 (1.7)	168	0 (0.0)	525	6 (1.1)
p value		0.362		---		0.300
2006						
Heroin	303	4 (1.3)	187	0 (0.0)	495	4 (0.8)
Methamphetamine	448	17 (3.8)	261	1 (0.4)	713	19 (2.7)
More than one	26	1 (3.9)	9	0 (0.0)	35	1 (2.9)
Other/Not reported	446	4 (0.9)	204	1 (0.5)	654	5 (0.8)
p value		0.012		1.000		0.012
2007						
Heroin	348	4 (1.2)	222	0 (0.0)	574	4 (0.7)
Methamphetamine	348	10 (2.9)	204	1 (0.5)	552	11 (2.0)
More than one	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Other/Not reported	468	11 (2.4)	195	1 (0.5)	670	13 (1.9)
p value		0.384		0.565		0.183
2008						
Heroin	494	3 (0.6)	253	1 (0.4)	749	4 (0.5)
Methamphetamine	362	17 (4.7)	238	1 (0.4)	604	19 (3.2)
More than one	39	1 (2.6)	12	1 (8.3)	51	2 (3.9)
Other/Not reported	501	8 (1.6)	261	0 (0.0)	766	8 (1.0)
p value		0.001		0.026		<0.001
2009						
Heroin	591	5 (0.9)	311	1 (0.3)	907	6 (0.7)
Methamphetamine	402	15 (3.7)	243	1 (0.4)	649	16 (2.5)
More than one	50	0 (0.0)	33	0 (0.0)	83	0 (0.0)
Other/Not reported	682	8 (1.2)	328	0 (0.0)	1017	9 (0.9)
p value		0.006		0.565		0.012

\* Total includes people whose gender was not reported or reported as transgender

Table 12 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Not last month	93	1 (1.1)	56	0 (0.0)	150	1 (0.7)
Less than weekly	166	5 (3.0)	101	0 (0.0)	270	5 (1.9)
Weekly not daily	294	7 (2.4)	142	0 (0.0)	439	7 (1.6)
Daily or more	517	2 (0.4)	308	0 (0.0)	827	2 (0.2)
p value		0.300		---		0.300
2006						
Not last month	109	1 (0.9)	66	1 (1.5)	178	2 (1.1)
Less than weekly	222	8 (3.6)	134	0 (0.0)	357	8 (2.2)
Weekly not daily	309	10 (3.2)	149	1 (0.7)	461	11 (2.4)
Daily or more	572	7 (1.2)	308	0 (0.0)	886	8 (0.9)
p value		0.062		0.138		0.103
2007						
Not last month	89	5 (5.6)	59	0 (0.0)	149	5 (3.4)
Less than weekly	220	5 (2.3)	111	1 (0.9)	332	6 (1.8)
Weekly not daily	293	6 (2.1)	165	0 (0.0)	462	7 (1.5)
Daily or more	572	8 (1.4)	292	1 (0.3)	869	9 (1.0)
p value		0.086		0.538		0.156
2008						
Not last month	136	4 (2.9)	83	1 (1.2)	220	5 (2.3)
Less than weekly	222	8 (3.6)	105	0 (0.0)	330	8 (2.4)
Weekly not daily	347	9 (2.6)	204	1 (0.5)	552	10 (1.8)
Daily or more	679	8 (1.2)	363	1 (0.3)	1047	10 (1.0)
p value		0.068		0.391		0.116
2009						
Not last month	169	4 (2.4)	96	0 (0.0)	266	4 (1.5)
Less than weekly	251	5 (2.0)	157	1 (0.6)	413	6 (1.5)
Weekly not daily	394	7 (1.8)	214	1 (0.5)	610	8 (1.3)
Daily or more	896	12 (1.3)	434	0 (0.0)	1339	13 (1.0)
p value		0.606		0.268		0.668

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 13 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used someone else's used needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No receptive sharing	800	13 (1.6)	456	0 (0.0)	1,262	13 (1.0)
Receptive sharing	130	1 (0.8)	68	0 (0.0)	200	1 (0.5)
p value		0.500		---		0.500
2006						
No receptive sharing	896	20 (2.2)	485	0 (0.0)	1387	20 (1.4)
Receptive sharing	161	4 (2.5)	86	0 (0.0)	249	5 (2.0)
p value		0.776		---		0.571
2007						
No receptive sharing	869	15 (1.7)	467	2 (0.4)	1343	18 (1.3)
Receptive sharing	162	4 (2.5)	79	0 (0.0)	244	4 (1.6)
p value		0.522		1.000		0.764
2008						
No receptive sharing	1024	23 (2.3)	544	2 (0.4)	1576	26 (1.7)
Receptive sharing	193	2 (1.0)	118	0 (0.0)	312	2 (0.6)
p value		0.408		1.000		0.300
2009						
No receptive sharing	1268	24 (1.9)	653	2 (0.3)	1936	27 (1.4)
Receptive sharing	238	0 (0.0)	133	0 (0.0)	372	0 (0.0)
p value		0.023		1.000		0.015

\* Total includes people whose gender was not reported or reported as transgender

Table 14 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No imprisonment	845	15 (1.8)	533	0 (0.0)	1386	15 (1.1)
Imprisonment	179	0 (0.0)	59	0 (0.0)	239	0 (0.0)
p value		0.070		---		0.100
2006						
No imprisonment	971	25 (2.6)	583	2 (0.3)	1566	28 (1.8)
Imprisonment	181	1 (0.6)	61	0 (0.0)	243	1 (0.4)
p value		0.106		1.000		0.165
2007						
No imprisonment	946	23 (2.4)	560	2 (0.4)	1514	25 (1.7)
Imprisonment	190	2 (1.0)	59	0 (0.0)	249	2 (0.8)
p value		0.412		1.000		0.413
2008						
No imprisonment	1079	26 (2.4)	648	0 (0.0)	1735	27 (1.6)
Imprisonment	208	2 (1.0)	65	2 (3.1)	274	4 (1.5)
p value		0.296		0.008		1.000
2009						
No imprisonment	1402	27 (1.9)	794	2 (0.3)	2213	30 (1.4)
Imprisonment	245	1 (0.4)	88	0 (0.0)	333	1 (0.3)
p value		0.108		1.000		0.172

\* Total includes people whose gender was not reported or reported as transgender

Table 15 HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005**						
No condom use	389	1 (0.3)	300	0 (0.0)	690	1 (0.1)
Condom use	177	4 (2.3)	88	0 (0.0)	267	4 (1.5)
p value		0.020		---		0.009
2006						
No condom use	533	6 (1.1)	339	1 (0.3)	880	8 (0.9)
Condom use	57	3 (5.3)	35	0 (0.0)	92	3 (3.3)
p value		0.047		1.000		0.077
2007						
No condom use	506	4 (0.8)	344	2 (0.6)	856	7 (0.8)
Condom use	66	1 (1.5)	31	0 (0.0)	98	1 (1.0)
p value		0.460		1.000		0.581
2008						
No condom use	547	4 (0.7)	380	0 (0.0)	930	4 (0.4)
Condom use	93	3 (3.2)	52	1 (1.9)	147	5 (3.4)
p value		0.067		0.120		0.004
2009						
No condom use	671	4 (0.6)	483	1 (0.2)	1162	5 (0.4)
Condom use	91	4 (4.4)	41	0 (0.0)	132	4 (3.0)
p value		0.009		1.000		0.009

\* Total includes people whose gender was not reported or reported as transgender

\*\*Question changed to "condom use with regular partner in last month" in 2005.

Table 16 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No sex work	1021	14 (1.4)	525	(0.0)	1553	14 (0.9)
Sex work	27	1 (3.7)	73	(0.0)	102	1 (1.0)
p value		0.300		---		0.900
2006						
No sex work	1123	24 (2.1)	548	2 (0.4)	1678	26 (1.6)
Sex work	34	2 (5.9)	81	0 (0.0)	121	3 (2.5)
p value		0.176		1.000		0.440
2007						
No sex work	1108	23 (2.1)	541	2 (0.4)	1656	25 (1.5)
Sex work	34	1 (2.9)	76	0 (0.0)	114	2 (1.8)
p value		0.519		1.000		0.691
2008						
No sex work	1264	27 (2.1)	633	3 (0.5)	1905	30 (1.6)
Sex work	39	2 (5.1)	91	0 (0.0)	131	3 (2.3)
p value		0.214		1.000		0.467
2009						
No sex work	1612	26 (1.6)	790	2 (0.3)	2425	29 (1.2)
Sex work	36	2 (5.6)	90	0 (0.0)	129	2 (1.6)
p value		0.122		1.000		0.668

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 17 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Non Indigenous	946	15 (1.6)	521	0 (0.0)	1,475	15 (1.0)
Indigenous	95	0 (0.0)	74	0 (0.0)	170	0 (0.0)
p value		0.200		---		0.200
2006						
Non Indigenous	1074	24 (2.2)	556	2 (0.4)	1639	27 (1.7)
Indigenous	109	2 (1.8)	89	0 (0.0)	199	2 (1.0)
p value		1.000		1.000		0.763
2007						
Non Indigenous	1045	21 (2.0)	548	2 (0.4)	1602	23 (1.4)
Indigenous	118	3 (2.5)	80	0 (0.0)	200	4 (2.0)
p value		0.728		1.000		0.532
2008						
Non Indigenous	1214	26 (2.1)	631	1 (0.2)	1853	28 (1.5)
Indigenous	130	2 (1.5)	105	2 (1.9)	237	4 (1.7)
p value		1.000		0.055		0.778
2009						
Non Indigenous	1503	26 (1.7)	752	2 (0.3)	2269	28 (1.2)
Indigenous	166	1 (0.6)	145	0 (0.0)	313	2 (0.6)
p value		0.511		1.000		0.571

\* Total includes people whose gender was not reported or reported as transgender

Table 18 HIV antibody prevalence by region/country of birth, gender and year of survey

	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Australia	911	13 (1.4)	541	0 (0.0)	1,459	13 (0.9)
Other Oceania	31	1 (3.2)	14	0 (0.0)	47	1 (2.1)
Asia	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
UK & Ireland	61	1 (1.6)	32	0 (0.0)	93	1 (1.1)
Other	52	0 (0.0)	15	0 (0.0)	67	0 (0.0)
p value		0.800		---		0.800
2006						
Australia	1026	22 (2.1)	577	2 (0.4)	1611	24 (1.5)
Other Oceania	38	1 (2.6)	23	0 (0.0)	62	2 (3.2)
Asia	11	0 (0.0)	4	0 (0.0)	15	0 (0.0)
UK & Ireland	73	2 (2.7)	30	0 (0.0)	104	2 (1.9)
Other	49	1 (2.0)	21	0 (0.0)	71	1 (1.4)
p value		0.824		1.000		0.535
2007						
Australia	1023	22 (2.2)	557	2 (0.4)	1590	25 (1.6)
Other Oceania	25	1 (4.0)	19	0 (0.0)	45	1 (2.2)
Asia	13	0 (0.0)	9	0 (0.0)	22	0 (0.0)
UK & Ireland	56	2 (3.6)	28	0 (0.0)	84	2 (2.4)
Other	51	0 (0.0)	19	0 (0.0)	70	0 (0.0)
p value		0.506		1.000		0.640
2008						
Australia	1181	24 (2.0)	650	3 (0.5)	1836	27 (1.5)
Other Oceania	34	3 (8.8)	27	0 (0.0)	63	4 (6.4)
Asia	21	1 (4.8)	7	0 (0.0)	28	1 (3.6)
UK & Ireland	68	0 (0.0)	43	0 (0.0)	113	0 (0.0)
Other	71	1 (1.4)	25	0 (0.0)	96	1 (1.0)
p value		0.063		1.000		0.033
2009						
Australia	1480	27 (1.8)	805	2 (0.3)	2298	30 (1.3)
Other Oceania	54	0 (0.0)	30	0 (0.0)	84	0 (0.0)
Asia	19	1 (5.3)	5	0 (0.0)	25	1 (4.0)
UK & Ireland	82	0 (0.0)	37	0 (0.0)	120	0 (0.0)
Other	57	0 (0.0)	30	0 (0.0)	89	0 (0.0)
p value		0.331		1.000		0.312

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 19 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	888	15 (1.7)	546	0 (0.0)	1,441	15 (1.0)
English speaking	184	0 (0.0)	65	0 (0.0)	251	0 (0.0)
Non-English speaking		0.100		---		0.100
p value						
2006						
English speaking	1063	24 (2.3)	610	2 (0.3)	1683	27 (1.6)
Non-English speaking	84	2 (2.4)	28	0 (0.0)	114	2 (1.8)
p value		0.715		1.000		0.706
2007						
English speaking	1100	24 (2.2)	609	2 (0.3)	1719	27 (1.6)
Non-English speaking	70	1 (1.4)	27	0 (0.0)	98	1 (1.0)
p value		1.000		1.000		1.000
2008						
English speaking	1299	28 (2.2)	728	3 (0.4)	2037	32 (1.6)
Non-English speaking	73	1 (1.4)	28	0 (0.0)	101	1 (1.0)
p value		1.000		1.000		1.000
2009						
English speaking	1628	27 (1.7)	869	2 (0.2)	2513	30 (1.2)
Non-English speaking	72	1 (1.4)	38	0 (0.0)	111	1 (0.9)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender



## HCV antibody prevalence

Table 20 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	1076	657 (61)	609	377 (62)	1694	1040 (61)
2006	1217	736 (60)	656	419 (64)	1886	1162 (62)
2007	1140	695 (61)	605	388 (64)	1756	1091 (62)
2008	1352	852 (63)	737	453 (61)	2099	1311 (62)
2009	1712	840 (49)	912	471 (52)	2641	1318 (50)
$\chi^2$ trend p value		<0.001		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 21 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	943	578 (61)	437	267 (61)	1381	845 (61)
Bisexual	37	20 (54)	106	64 (60)	144	85 (59)
Homosexual	54	31 (57)	32	24 (75)	91	59 (65)
p value		0.600		0.300		0.700
2006						
Heterosexual	1065	669 (63)	481	308 (64)	1549	979 (63)
Bisexual	55	25 (45)	109	76 (70)	170	102 (60)
Homosexual	59	26 (44)	45	23 (51)	106	51 (48)
p value		0.001		0.094		0.008
2007						
Heterosexual	1009	627 (62)	431	278 (65)	1441	906 (63)
Bisexual	45	25 (56)	116	77 (66)	165	105 (64)
Homosexual	63	30 (48)	41	21 (51)	107	53 (50)
p value		0.053		0.200		0.023
2008						
Heterosexual	1192	760 (64)	517	317 (61)	1711	1078 (63)
Bisexual	51	30 (59)	147	93 (63)	199	123 (62)
Homosexual	60	26 (43)	47	29 (62)	109	56 (51)
p value		0.006		0.901		0.054
2009						
Heterosexual	1506	751 (50)	681	335 (49)	2193	1090 (50)
Bisexual	79	36 (46)	146	97 (66)	228	133 (58)
Homosexual	48	13 (27)	37	15 (41)	87	28 (32)
p value		0.006		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 22 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	22	10 (45)	17	3 (18)	39	13 (33)
20 – 24	90	46 (51)	110	34 (31)	200	80 (40)
25 – 29	137	74 (54)	177	92 (52)	315	167 (53)
30 + years	772	528 (68)	360	247 (69)	1140	780 (68)
p value		<0.001		<0.001		<0.001
2006						
< 20 years	18	1 (6)	23	6 (26)	41	7 (17)
20 – 24	100	42 (42)	81	44 (54)	181	86 (48)
25 – 29	230	118 (51)	124	77 (62)	357	196 (55)
30 + years	864	571 (66)	426	290 (68)	1300	867 (67)
p value		<0.001		<0.001		<0.001
2007						
< 20 years	18	4 (22)	14	5 (36)	32	9 (28)
20 – 24	67	23 (34)	63	32 (51)	131	56 (43)
25 – 29	190	97 (51)	126	75 (60)	317	173 (55)
30 + years	863	569 (66)	401	276 (69)	1273	851 (67)
p value		<0.001		0.002		<0.001
2008						
< 20 years	21	6 (29)	16	7 (43)	37	13 (35)
20 – 24	84	25 (30)	73	34 (47)	157	59 (38)
25 – 29	176	93 (53)	140	81 (58)	318	175 (55)
30 + years	1066	725 (68)	507	331 (65)	1581	1061 (67)
p value		<0.001		0.005		<0.001
2009						
< 20 years	39	3 (8)	30	5 (17)	70	8 (11)
20 – 24	118	28 (24)	87	37 (43)	206	65 (32)
25 – 29	224	86 (38)	176	102 (58)	401	189 (47)
30 + years	1331	723 (54)	618	327 (53)	1963	1056 (54)
p value		<0.001		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 23 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	96	22 (23)	46	22 (48)	144	45 (31)
3 to 5 years	100	32 (32)	74	25 (34)	175	58 (33)
6 to 10 years	97	46 (47)	106	58 (55)	204	105 (51)
10 + years	736	529 (72)	353	253 (72)	1094	785 (72)
p value		<0.001		<0.001		<0.001
2006						
<3 years	58	9 (16)	41	9 (22)	100	18 (18)
3 to 5 years	79	25 (32)	67	19 (28)	146	44 (30)
6 to 10 years	227	111 (49)	158	102 (65)	389	214 (55)
10 + years	797	558 (70)	375	280 (75)	1180	844 (72)
p value		<0.001		<0.001		<0.001
2007						
<3 years	59	8 (14)	37	11 (30)	96	19 (20)
3 to 5 years	67	22 (33)	55	29 (53)	123	52 (42)
6 to 10 years	197	85 (43)	124	68 (55)	324	154 (48)
10 + years	786	558 (71)	372	267 (72)	1165	831 (71)
p value		<0.001		<0.001		<0.001
2008						
<3 years	67	13 (19)	43	17 (40)	110	30 (27)
3 to 5 years	112	32 (29)	50	19 (38)	162	51 (31)
6 to 10 years	181	90 (50)	150	79 (53)	332	169 (51)
10 + years	960	699 (73)	485	336 (69)	1453	1040 (72)
p value		<0.001		<0.001		<0.001
2009						
<3 years	90	6 (7)	66	15 (23)	157	21 (13)
3 to 5 years	92	24 (26)	72	20 (28)	165	44 (27)
6 to 10 years	222	81 (36)	164	81 (49)	389	164 (42)
10 + years	1269	716 (56)	584	345 (59)	1864	1065 (57)
p value		<0.001		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

## National

Table 24 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	30	14 (47)	563	389 (69)	593	403 (68)
Methamphetamine	58	9 (16)	482	241 (50)	540	250 (46)
More than one	1	1 (100)	39	32 (82)	40	33 (83)
Other/Not reported	55	19 (35)	477	343 (72)	532	362 (68)
p value		0.003		<0.001		<0.001
2006						
Heroin	12	3 (25)	464	349 (75)	493	364 (74)
Methamphetamine	53	4 (8)	635	305 (48)	710	319 (45)
More than one	0	0 (0)	33	23 (70)	34	24 (71)
Other/Not reported	35	11 (31)	583	425 (73)	649	455 (70)
p value		0.010		<0.001		<0.001
2007						
Heroin	21	6 (29)	517	359 (69)	545	371 (68)
Methamphetamine	52	10 (19)	460	244 (53)	524	265 (51)
More than one	2	0 (0)	37	19 (51)	48	22 (46)
Other/Not reported	21	3 (14)	598	415 (69)	639	433 (68)
p value		0.706		<0.001		<0.001
2008						
Heroin	22	9 (41)	688	507 (74)	721	524 (73)
Methamphetamine	43	8 (19)	538	256 (48)	587	265 (45)
More than one	2	2 (100)	43	35 (81)	46	37 (80)
Other/Not reported	43	11 (26)	678	462 (68)	745	485 (65)
p value		0.034		<0.001		<0.001
2009						
Heroin	32	9 (28)	862	512 (59)	902	524 (58)
Methamphetamine	51	4 (8)	585	221 (38)	648	230 (35)
More than one	3	1 (33)	77	46 (60)	83	48 (58)
Other/Not reported	71	7 (10)	894	494 (55)	1008	516 (51)
p value		0.026		<0.001		<0.001

\* Total includes people who did not report duration of drug injection

Table 25 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	77	20 (26)	626	384 (61)	732	421 (58)
Daily or more	48	23 (48)	734	491 (67)	824	542 (66)
p value		0.010		0.030		0.001
2006						
Less than daily	51	4 (8)	740	463 (63)	812	476 (59)
Daily or more	39	11 (28)	801	526 (66)	881	566 (64)
p value		0.611		<0.001		<0.001
2007						
Less than daily	54	8 (15)	687	443 (64)	753	463 (61)
Daily or more	36	8 (22)	768	499 (65)	826	525 (64)
p value		0.408		0.869		0.405
2008						
Less than daily	53	10 (19)	792	490 (62)	855	505 (59)
Daily or more	36	15 (42)	951	650 (68)	1010	679 (67)
p value		0.030		0.005		<0.001
2009						
Less than daily	63	6 (10)	940	484 (51)	1018	496 (49)
Daily or more	69	13 (19)	1232	655 (53)	1329	683 (51)
p value		0.144		0.461		0.211

\* Total includes people who did not report duration of drug injection

Table 26 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	94	32 (34)	1111	700 (63)	1265	769 (61)
Receptive sharing	16	7 (44)	173	124 (72)	198	137 (69)
p value		0.500		0.030		0.020
2006						
No receptive sharing	77	13 (17)	1262	791 (63)	1378	824 (60)
Receptive sharing	10	1 (10)	220	156 (71)	248	171 (69)
p value		1.000		0.019		0.007
2007						
No receptive sharing	73	12 (16)	1176	754 (64)	1271	785 (62)
Receptive sharing	13	4 (31)	215	145 (67)	235	156 (66)
p value		0.405		0.394		0.187
2008						
No receptive sharing	71	17 (24)	1428	918 (64)	1529	952 (62)
Receptive sharing	16	8 (50)	278	196 (71)	296	206 (70)
p value		0.063		0.046		0.018
2009						
No receptive sharing	109	11 (10)	1784	922 (52)	1924	948 (49)
Receptive sharing	19	7 (37)	340	194 (57)	369	205 (56)
p value		0.006		0.075		0.031

\* Total includes people who did not report duration of drug injection

## National

Table 27 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	124	33 (27)	1205	743 (62)	1386	805 (58)
Imprisoned	13	9 (69)	210	162 (77)	241	187 (78)
p value		<0.001		0.002		<0.001
2006						
Not imprisoned	90	16 (18)	1412	860 (61)	1558	906 (58)
Imprisoned	7	2 (29)	224	176 (79)	240	184 (77)
p value		0.611		<0.001		<0.001
2007						
Not imprisoned	88	16 (18)	1315	816 (62)	1439	855 (59)
Imprisoned	3	2 (67)	226	170 (75)	238	181 (76)
p value		0.099		<0.001		<0.001
2008						
Not imprisoned	96	24 (25)	1555	959 (62)	1680	998 (59)
Imprisoned	7	4 (57)	250	196 (78)	264	204 (77)
p value		0.085		<0.001		<0.001
2009						
Not imprisoned	140	14 (10)	2006	1006 (50)	2200	1038 (47)
Imprisoned	12	6 (50)	311	206 (66)	331	216 (65)
p value		0.001		<0.001		<0.001

\* Total includes people who did not report duration of drug injection

Table 28 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	140	43 (31)	1345	856 (64)	1555	941 (61)
Sex work	2	2 (100)	93	69 (74)	102	76 (75)
p value		0.040		0.040		0.005
2006						
No sex work	90	17 (19)	1515	964 (64)	1699	1017 (61)
Sex work	5	1 (20)	114	75 (66)	121	77 (64)
p value		1.000		0.687		0.629
2007						
No sex work	82	16 (20)	1452	938 (65)	1573	983 (62)
Sex work	7	2 (29)	98	63 (64)	110	68 (62)
p value		0.626		1.000		0.919
2008						
No sex work	99	26 (26)	1715	1104 (64)	1850	1149 (62)
Sex work	4	3 (75)	117	80 (68)	123	83 (67)
p value		0.067		0.424		0.250
2009						
No sex work	153	19 (12)	2200	1149 (52)	2409	1189 (49)
Sex work	3	2 (67)	120	75 (63)	129	79 (61)
p value		0.048		0.031		0.009

\* Total includes people who did not report duration of drug injection

Table 29 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	950	576 (61)	521	313 (60)	1479	894 (60)
Indigenous	95	63 (66)	72	56 (78)	168	120 (71)
p value		0.300		0.003		0.006
2006						
Non Indigenous	1069	639 (60)	553	339 (61)	1631	981 (60)
Indigenous	108	69 (64)	87	68 (78)	196	138 (70)
p value		0.471		0.003		0.003
2007						
Non Indigenous	998	599 (60)	523	333 (64)	1530	939 (61)
Indigenous	112	80 (71)	73	48 (66)	187	129 (69)
p value		0.019		0.795		0.046
2008						
Non Indigenous	1177	732 (62)	614	372 (61)	1799	1108 (62)
Indigenous	125	82 (66)	98	67 (68)	225	151 (67)
p value		0.497		0.148		0.109
2009						
Non Indigenous	1490	721 (48)	749	388 (52)	2253	1115 (49)
Indigenous	166	87 (52)	145	76 (52)	313	163 (52)
p value		0.328		0.928		0.399

\* Total includes people whose gender was not reported or reported as transgender

Table 30 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	914	551 (60)	539	331 (61)	1460	887 (61)
Other Oceania	31	14 (45)	14	9 (64)	47	24 (51)
Asia	10	4 (40)	4	1 (25)	14	5 (36)
UK & Ireland	61	46 (75)	32	22 (69)	93	68 (73)
Other	53	37 (70)	15	10 (67)	68	47 (69)
p value		0.010		0.500		0.010
2006						
Australia	1021	613 (60)	573	366 (64)	1602	984 (61)
Other Oceania	38	20 (53)	23	17 (74)	62	37 (60)
Asia	11	6 (55)	4	2 (50)	15	8 (53)
UK & Ireland	73	49 (67)	30	19 (63)	104	68 (65)
Other	48	28 (58)	20	9 (45)	69	37 (54)
p value		0.651		0.336		0.559
2007						
Australia	975	592 (61)	526	334 (64)	1511	934 (62)
Other Oceania	24	16 (67)	17	9 (53)	42	25 (60)
Asia	12	9 (75)	8	6 (75)	20	15 (75)
UK & Ireland	53	33 (62)	28	20 (71)	81	53 (65)
Other	50	31 (62)	19	14 (74)	69	45 (65)
p value		0.880		0.631		0.715
2008						
Australia	1145	721 (63)	626	378 (60)	1776	1103 (62)
Other Oceania	34	14 (41)	26	13 (50)	62	27 (44)
Asia	19	17 (89)	6	3 (50)	25	20 (80)
UK & Ireland	66	40 (61)	43	31 (72)	111	72 (65)
Other	68	46 (68)	25	18 (72)	93	64 (69)
p value		0.008		0.259		0.006
2009						
Australia	1467	728 (50)	802	411 (51)	2282	1144 (50)
Other Oceania	54	23 (43)	30	17 (57)	84	40 (48)
Asia	19	9 (47)	5	2 (40)	25	11 (44)
UK & Ireland	82	42 (51)	37	21 (57)	120	64 (53)
Other	57	24 (42)	30	15 (50)	89	40 (45)
p value		0.672		0.904		0.734

\* Total includes people whose gender was not reported or reported as transgender



Table 31 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	892	546 (61)	544	333 (61)	1443	884 (61)
Non-English speaking	184	111 (60)	65	44 (68)	251	156 (62)
p value		0.800		0.300		0.800
2006						
English speaking	1058	643 (61)	607	391 (64)	1675	1039 (62)
Non-English speaking	83	45 (54)	27	14 (52)	112	60 (54)
p value		0.246		0.219		0.088
2007						
English speaking	1048	642 (61)	576	369 (64)	1634	1018 (62)
Non-English speaking	68	41 (60)	26	17 (65)	95	59 (62)
p value		0.898		1.000		1.000
2008						
English speaking	1262	788 (62)	704	433 (62)	1976	1227 (62)
Non-English speaking	68	51 (75)	26	14 (54)	94	65 (69)
p value		0.039		0.422		0.191
2009						
English speaking	1615	790 (49)	866	449 (52)	2497	1246 (50)
Non-English speaking	72	39 (54)	38	17 (45)	111	56 (50)
p value		0.401		0.411		0.923

\* Total includes people whose gender was not reported or reported as transgender

## Australian Capital Territory

Table 32 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	1	1	1	1	1
N° surveyed	N=39	N=52	N=22	N=31	N=63
Response (%)	70	---	---	---	67
Gender (%)					
Male	30 (77)	31 (60)	12 (55)	22 (71)	39 (62)
Female	9 (23)	20 (39)	10 (45)	9 (29)	24 (38)
Transgender	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	33 (85)	44 (85)	19 (86)	22 (71)	52 (83)
Bisexual	2 (5)	7 (13)	1 (5)	3 (10)	7 (11)
Homosexual	1 (3)	1 (2)	2 (9)	3 (10)	1 (2)
Not reported	3 (8)	0 (0)	0 (0)	3 (10)	3 (5)
Age and duration of injection (years)					
<i>Median age</i>	36	33	29.5	36	32
Age range	15-57	15-60	17-61	22-56	16-60
<i>Age group (%)</i>					
<25 years	6 (15)	7 (13)	5 (23)	3 (10)	15 (23)
25+ years	33 (85)	44 (85)	17 (77)	28 (90)	48 (76)
Not reported	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	17	17	16	18	17
Age range	11-28	12-39	12-33	11-40	12-42
Not reported	9	2	1	0 (0)	1
<i>Median years IDU</i>	18	13	11	16	13
Range	<1-32	<1-45	2-47	2-38	1-36
<i>Duration of drug injection (%)</i>					
<3 years	1 (3)	2 (4)	1 (5)	1 (3)	7 (11)
3+ years	38 (97)	48 (92)	20 (91)	30 (97)	55 (87)
Not reported	0 (0)	2 (4)	1 (5)	0 (0)	1 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	31 (79)	49 (94)	21 (95)	25 (81)	56 (89)
Yes	7 (18)	3 (6)	0 (0)	4 (13)	5 (8)
Not reported	1 (3)	0 (0)	1 (5)	2 (6)	2 (3)
Region/Country of birth (%)					
Australia	32 (82)	43 (83)	18 (82)	25 (81)	50 (79)
Other Oceania	1 (3)	2 (4)	0 (0)	0 (0)	2 (3)
Asia	1 (3)	1 (2)	1 (5)	2 (6)	1 (2)
UK & Ireland	2 (5)	1 (2)	2 (9)	1 (3)	8 (13)
Other	3 (8)	4 (8)	1 (5)	2 (6)	2 (3)
Not reported	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)
Main language spoken at home by parents (%)					
English speaking	30 (77)	42 (81)	20 (91)	30 (97)	61 (97)
Non-English speaking	9 (23)	7 (13)	2 (9)	1 (3)	2 (3)
Not reported	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
Imprisonment last year (%)					
No	33 (85)	44 (85)	19 (86)	26 (84)	51 (81)
Yes	4 (10)	7 (13)	2 (9)	2 (6)	9 (14)
Not reported	2 (5)	1 (2)	1 (5)	3 (10)	3 (5)
Injected in prison (%)	N=4	N=7	N=2	N=2	N=9
Yes	2 (50)	4 (57)	1 (50)	0 (0)	1 (11)
Frequency of injection last month (%)					
Not last month	8 (21)	7 (13)	3 (14)	0 (0)	4 (6)
Less than weekly	4 (10)	13 (25)	1 (5)	3 (10)	10 (16)
Weekly not daily	15 (38)	19 (37)	9 (41)	15 (48)	12 (19)
Daily or more	12 (31)	13 (25)	8 (36)	13 (42)	37 (59)
Not reported	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)

Table 33 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=39	N=52	N=22	N=31	N=63
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Heroin	14 (36)	20 (38)	9 (41)	14 (45)	24 (38)
Methadone	3 (8)	6 (12)	0 (0)	2 (6)	2 (3)
Methamphetamine	10 (26)	21 (40)	9 (41)	9 (29)	15 (24)
Pharm. Opioids	2 (5)	1 (2)	1 (5)	2 (6)	6 (10)
Subutex/Buprenorphine	0 (0)	3 (6)	2 (9)	3 (10)	6 (10)
More than one	2 (5)	0 (0)	1 (5)	0 (0)	2 (3)
Other drug	0 (0)	1 (2)	0 (0)	0 (0)	4 (6)
Not reported	8 (20)	0 (0)	0 (0)	1 (3)	2 (3)
N <sup>o</sup> Injected last month	N=31	N=45	N=18	N=31	N=59
Places injected last month (%)*					
Own home	20 (65)	35 (81)	16 (94)	27 (87)	50 (86)
Friend's home	11 (35)	20 (47)	11 (65)	11 (35)	30 (52)
Dealer's home	6 (19)	14 (33)	8 (47)	5 (16)	13 (22)
Street, park, beach	9 (29)	11 (26)	8 (47)	12 (39)	16 (28)
Car	11 (35)	20 (47)	8 (47)	12 (39)	18 (31)
Public toilet	11 (35)	16 (37)	9 (53)	12 (39)	17 (29)
Commercial injecting room	2 (6)	1 (2)	1 (6)	2 (6)	1 (2)
Squat	6 (19)	8 (19)	2 (12)	3 (10)	1 (2)
Use of new sterile needles & syringes last month (%)					
All injections	19 (61)	32 (71)	9 (50)	24 (77)	43 (73)
Most of the time	11 (35)	12 (27)	6 (33)	6 (19)	15 (25)
Half of the time	0 (0)	1 (2)	1 (6)	1 (3)	1 (2)
Some of the time	1 (3)	0 (0)	1 (6)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	1 (6)	0 (0)	0 (0)
<b>Re-used another's used needle &amp; syringe last month (%)</b>					
None	25 (81)	35 (78)	9 (50)	25 (81)	51 (86)
Once	1 (3)	3 (7)	3 (17)	2 (6)	1 (2)
Twice	0 (0)	0 (0)	1 (6)	2 (6)	1 (2)
3-5 times	0 (0)	3 (7)	2 (11)	1 (3)	4 (7)
>5 times	0 (0)	3 (7)	2 (11)	1 (3)	1 (2)
Not reported	5 (16)	1 (2)	1 (6)	0 (0)	1 (2)
Number of people needle & syringe was re-used after last month (%)					
None	21 (68)	35 (78)	9 (50)	25 (81)	51 (86)
One	4 (13)	3 (7)	2 (11)	3 (10)	4 (7)
Two	0 (0)	2 (4)	3 (17)	0 (0)	0 (0)
Three to five	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)
More than five	0 (0)	1 (2)	0 (0)	0 (0)	2 (3)
Don't know	2 (6)	1 (2)	2 (11)	1 (3)	0 (0)
Not reported	4 (13)	2 (4)	2 (11)	2 (6)	1 (2)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	3 (10)	4 (9)	2 (11)	2 (6)	4 (7)
Casual sex partner	0 (0)	1 (2)	0 (0)	1 (3)	0 (0)
Close friend	2 (6)	3 (7)	3 (17)	0 (0)	2 (3)
Acquaintance	1 (3)	3 (7)	2 (11)	0 (0)	1 (2)
Other	0 (0)	0 (0)	1 (6)	1 (3)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	10 (32)	17 (40)	6 (35)	11 (37)	20 (38)
Water	9 (29)	12 (28)	9 (53)	8 (27)	14 (26)
Filter	5 (16)	7 (16)	4 (24)	6 (20)	4 (8)
Drug mix	7 (23)	7 (16)	4 (24)	7 (23)	7 (13)
Tourniquet	2 (6)	9 (21)	4 (24)	1 (3)	9 (17)
None**	0 (0)	21 (49)	5 (30)	19 (63)	28 (53)
Injected by someone after that person injected themselves or others last month (%)					
No	21 (68)	37 (82)	10 (56)	28 (90)	49 (83)
Yes	4 (13)	7 (16)	6 (33)	3 (10)	10 (17)
Not reported	6 (19)	1 (2)	2 (11)	0 (0)	0 (0)

\* More than one option could be selected

\*\* New variable in 2006

Table 34 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=39	N=52	N=22	N=31	N=63
Any treatment/therapy for drug use (%)					
No	13 (33)	7 (13)	5 (23)	3 (10)	10 (16)
Yes	25 (64)	45 (87)	17 (77)	27 (87)	53 (84)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)
History of methadone maintenance treatment (%)					
Currently	14 (36)	20 (38)	5 (23)	11 (35)	23 (37)
Previously	9 (23)	11 (21)	9 (41)	10 (32)	18 (29)
Never	15 (38)	21 (40)	8 (36)	9 (29)	22 (35)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	0 (0)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	6 (19)	4 (6)
Previously	--	--	--	5 (16)	11 (17)
Never	--	--	--	19 (61)	46 (73)
Not reported	--	--	--	1 (3)	2 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	3 (10)	5 (8)
Previously	--	--	--	5 (16)	4 (6)
Never	--	--	--	22 (71)	51 (81)
Not reported	--	--	--	1 (3)	3 (5)

\* New variable in 2008

Table 35 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=21#	N=54#
Source of needles/syringes (%)*		
Chemist/Pharmacy	12 (57)	30 (56)
Needle Syringe Program	19 (90)	34 (63)
Dispensing/Vending Machine	8 (38)	15 (28)
Friend/Dealer	6 (29)	21 (39)
Other	1 (5)	1 (2)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	1 (8)	7 (23)
Needle Syringe Program	7 (37)	9 (26)
Dispensing/Vending Machine	0 (0)	1 (7)
Friend/Dealer	0 (0)	3 (14)
Other	0 (0)	1 (100)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=18	N=59
Secondary exchange	14 (78)	20 (34)

\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

Table 36 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=39	N=52	N=22	N=31	N=63
Sex with a regular partner last month (%) **					
No	19 (49)	30 (58)	11 (50)	22 (71)	34 (54)
Yes	19 (49)	22 (42)	9 (41)	8 (26)	28 (44)
Not reported	1 (3)	0 (0)	2 (9)	1 (3)	1 (2)
Condom used with regular partner last month (%)**					
N° surveyed	N=19	N=22	N=9	N=8	N=28
Never	14 (74)	15 (68)	7 (78)	3 (38)	20 (71)
Sometimes	2 (11)	1 (5)	2 (22)	2 (25)	4 (14)
Every time	1 (5)	5 (23)	0 (0)	2 (25)	3 (11)
Not reported	2 (11)	1 (5)	0 (0)	1 (12)	1 (4)
Sex with other partner/s last month (%)**					
No	2 (40)	40 (77)	14 (64)	26 (84)	59 (94)
Yes	3 (60)	10 (19)	7 (32)	3 (10)	2 (3)
Not reported	0 (0)	2 (4)	1 (5)	2 (6)	2 (3)
Condom used with other partner/s last month (%)**					
N° surveyed	N=5	N=10	N=7	N=3	N=2
Never	6 (15)	4 (40)	3 (43)	2 (67)	1 (50)
Sometimes	3 (8)	1 (10)	2 (29)	1 (33)	0 (0)
Every time	1 (3)	4 (40)	2 (29)	0 (0)	1 (50)
Not reported	29 (74)	1 (10)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	38 (97)	47 (90)	20 (91)	29 (94)	60 (95)
Yes	1 (3)	3 (6)	1 (5)	2 (6)	0 (0)
Not reported	0 (0)	2 (4)	1 (5)	0 (0)	3 (5)
Condom used at last sex work last month (%)*					
Yes	1 (100)	2 (67)	1 (100)	0 (0)	0 (0)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 37 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=39	N=52	N=22	N=31	N=63
Previous HIV test (%)					
Last year	20 (51)	39 (75)	13 (59)	8 (26)	30 (48)
> 1 year ago	14 (36)	12 (23)	9 (41)	21 (68)	25 (40)
Never tested	4 (10)	1 (2)	0 (0)	1 (3)	5 (8)
Not reported	1 (3)	0 (0)	0 (0)	1 (3)	3 (5)
Previous HCV test (%)					
Last year	24 (62)	38 (73)	12 (55)	11 (35)	34 (54)
> 1 year ago	11 (28)	12	10 (45)	18 (58)	24 (38)
Never tested	2 (5)	1	0 (0)	1 (3)	4 (6)
Not reported	2 (5)	1	0 (0)	1 (3)	1 (2)
Any treatment for HCV (%)	N=21	N=34	N=12	N=18	N=31
Interferon	0 (0)	1 (3)	1 (8)	0 (0)	1 (3)
Interferon+Ribavirin	1 (5)	1 (3)	0 (0)	2 (11)	1 (3)
Other	17 (81)	0 (0)	0 (0)	1 (6)	0 (0)
No treatment	2 (10)	31 (91)	11 (92)	15 (83)	29 (94)
Not reported	1 (5)	1 (3)	0 (0)	0 (0)	0 (0)
Current treatment for HCV	N=1	N=1	N=0	N=0	N=0
Interferon/Interferon+Ribavirin	1	0	0	0	0
Other	0	1	0	0	0

ACT

## HIV antibody prevalence

Table 38 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	23	0 (0.0)	7	0 (0.0)	30	0 (0.0)
2006	30	0 (0.0)	18	0 (0.0)	49	0 (0.0)
2007	10	0 (0.0)	8	0 (0.0)	18	0 (0.0)
2008	18	0 (0.0)	8	0 (0.0)	26	0 (0.0)
2009	36	0 (0.0)	22	0 (0.0)	58	0 (0.0)
$\chi^2$ trend p value		---		---		---

\* Total includes people whose gender was not reported or reported as transgender

## HCV antibody prevalence

Table 39 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	24	16 (67)	7	7 (100)	31	23 (74)
2006	29	23 (79)	16	10 (63)	46	33 (72)
2007	10	10 (100)	8	6 (75)	18	16 (89)
2008	18	12 (67)	8	6 (75)	26	18 (69)
2009	36	21 (58)	22	13 (59)	58	34 (59)
$\chi^2$ trend p value		0.191		0.179		0.081

\* Total includes people whose gender was not reported or reported as transgender

Table 40 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	20	14 (70)	6	6 (100)	26	20 (77)
Bisexual	1	0 (0)	1	1 (100)	2	1 (50)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		0.300		---		0.600
2006						
Heterosexual	28	22 (79)	10	7 (70)	38	29 (76)
Bisexual	0	0 (0)	6	3 (50)	7	3 (43)
Homosexual	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		0.607		0.223
2007						
Heterosexual	9	9 (100)	7	5 (71)	16	14 (88)
Bisexual	0	0 (0)	1	0 (0)	2	0 (0)
Homosexual	1	1 (100)		1 (100)		1 (100)
p value		---		1.000		1.000
2008						
Heterosexual	13	8 (62)	6	4 (67)	19	12 (63)
Bisexual	2	1 (50)	0	0 (0)	2	1 (50)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.779
2009						
Heterosexual	32	19 (59)	18	10 (56)	50	29 (58)
Bisexual	3	1 (33)	2	1 (50)	5	2 (40)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.565		1.000		0.643

\* Total includes people whose gender was not reported or reported as transgender

Table 41 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	1	0 (0)	0	0 (0)	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	2	2 (100)	3	3 (100)	5	5 (100)
30 + years	19	14 (74)	3	3 (100)	22	17 (77)
p value		0.500		0.060		0.600
2006						
< 20 years	0	0 (0)	1	0 (0)	1	0 (0)
20 – 24	3	1 (33)	2	1 (50)	5	2 (40)
25 – 29	6	5 (83)	5	3 (60)	11	8 (73)
30 + years	19	16 (85)	8	6 (75)	28	22 (79)
p value		0.144		0.685		0.107
2007						
< 20 years	1	1 (100)	1	1 (100)	2	2 (100)
20 – 24	0	0 (0)	3	3 (100)	3	3 (100)
25 – 29	4	4 (100)	2	1 (50)	6	5 (83)
30 + years	5	5 (100)	2	1 (50)	7	6 (86)
p value		---		0.571		1.000
2008						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	1	0 (0)	1	1 (100)	2	1 (50)
25 – 29	1	0 (0)	2	2 (100)	3	2 (67)
30 + years	16	12 (75)	5	3 (60)	21	15 (71)
p value		0.098		1.000		0.777
2009						
< 20 years	2	0 (0)	3	2 (67)	5	2 (40)
20 – 24	6	3 (50)	2	2 (100)	8	5 (63)
25 – 29	6	4 (67)	3	1 (33)	9	5 (56)
30 + years	22	14 (64)	14	8 (57)	36	22 (61)
p value		0.411		0.684		0.891

\* Total includes people whose gender was not reported or reported as transgender

Table 42 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	8	1 (13)	0	0 (0)	8	1 (13)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	0	0 (0)	1	1 (100)	1	1 (100)
10 + years	16	15 (94)	6	6(100)	22	21 (95)
p value		---		---		---
2006						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	1	1 (100)	2	1 (50)
6 to 10 years	9	7 (78)	6	3 (50)	15	10 (67)
10 + years	17	14 (82)	8	6 (75)	26	20 (70)
p value		0.329		0.519		0.263
2007						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 5 years	0	0 (0)	2	2 (100)	2	2 (100)
6 to 10 years	3	3 (100)	2	2 (100)	5	5 (100)
10 + years	6	6 (100)	3	1 (33)	9	7 (78)
p value		---		0.238		0.669
2008						
<3 years	1	0 (0)	0	0 (0)	1	0 (0)
3 to 5 years	1	0 (0)	0	0 (0)	1	0 (0)
6 to 10 years	3	2 (67)	1	1 (100)	4	3 (75)
10 + years	13	10 (77)	7	5 (71)	20	15 (75)
p value		0.214		1.000		0.155
2009						
<3 years	3	0 (0)	3	2 (67)	6	2 (33)
3 to 5 years	2	2 (100)	0	0 (0)	2	2 (100)
6 to 10 years	10	7 (70)	3	2 (67)	13	9 (69)
10 + years	20	11 (55)	16	9 (56)	36	20 (56)
p value		0.108		1.000		0.360

\* Total includes people whose gender was not reported or reported as transgender



Table 43 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	2	0 (0)	8	7 (88)	10	7 (70)
Methamphetamine	0	0 (0)	14	14 (100)	14	14 (100)
More than one	0	0 (0)	2	2 (100)	2	2 (100)
Other/Not reported	8	1 (13)	5	5 (100)	13	6 (46)
p value		1.000		0.517		0.005
2006						
Heroin	0	0 (0)	16	13 (81)	17	14 (82)
Methamphetamine	1	0 (0)	18	10 (56)	20	11 (55)
More than one	0	0 (0)	0	0 (0)	0	0 (0)
Other/Not reported	0	0 (0)	9	8 (89)	9	8 (9)
p value		---		0.164		0.116
2007						
Heroin	0	0 (0)	7	5 (71)	7	5 (71)
Methamphetamine	1	1 (100)	6	6 (100)	8	8 (100)
More than one	0	0 (0)	0	0 (0)	0	0 (0)
Other/Not reported	0	0 (0)	3	3 (100)	3	3 (100)
p value		---		0.650		0.294
2008						
Heroin	0	0 (0)	12	10 (83)	12	10 (83)
Methamphetamine	1	0 (0)	7	4 (57)	8	4 (50)
More than one	0	0 (0)	0	0 (0)	0	0 (0)
Other/Not reported	0	0 (0)	6	4 (67)	6	4 (67)
p value				0.522		0.260
2009						
Heroin	2	2 (100)	22	13 (59)	24	15 (63)
Methamphetamine	0	0 (0)	15	6 (40)	15	6 (40)
More than one	0	0 (0)	1	1 (100)	1	1 (100)
Other/Not reported	4	0 (0)	13	11 (84)	18	12 (67)
p value		0.067		0.070		0.326

\* Total includes people who did not report duration of drug injection

Table 44 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	8	1 (13)	14	13 (93)	22	14 (64)
Daily or more	0	0 (0)	9	9 (100)	9	9 (100)
p value		---		0.400		0.040
2006						
Less than daily	0	0 (0)	28	22 (79)	30	24 (80)
Daily or more	1	0 (0)	9	4 (44)	10	4 (40)
p value		---		0.091		0.041
2007						
Less than daily	1	1 (100)	7	6 (86)	8	7 (88)
Daily or more	0	0 (0)	6	5 (83)	7	6 (86)
p value		---		1.000		1.000
2008						
Less than daily	0	0 (0)	14	10 (71)	14	10 (71)
Daily or more	1	0 (0)	11	8 (73)	12	8 (67)
p value		---		1.000		1.000
2009						
Less than daily	1	0 (0)	19	7 (37)	20	7 (35)
Daily or more	5	2 (40)	28	21 (75)	34	24 (71)
p value		1.000		0.015		0.021

\* Total includes people who did not report duration of drug injection

Table 45 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	0	0 (0)	18	17 (94)	18	17 (94)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
p value		---		0.800		0.800
2006						
No receptive sharing	0	0 (0)	31	23 (74)	32	24 (75)
Receptive sharing	1	0 (0)	6	3 (50)	7	3 (43)
p value		---		0.335		0.172
2007						
No receptive sharing	1	1 (100)	7	5 (71)	8	6 (75)
Receptive sharing	0	0 (0)	5	5 (100)	6	6 (100)
p value		---		0.470		0.473
2008						
No receptive sharing	1	0 (0)	20	13 (65)	21	13 (62)
Receptive sharing	0	0 (0)	5	5 (100)	5	5 (100)
p value		---		0.274		0.281
2009						
No receptive sharing	5	1 (20)	41	23 (56)	46	24 (52)
Receptive sharing	0	0 (0)	6	5 (83)	7	6 (86)
p value		0.123		1.000		1.000

\* Total includes people who did not report duration of drug injection

Table 46 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	6	1 (17)	21	20 (95)	27	21 (78)
Imprisoned	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.700		0.800		0.400
2006						
Not imprisoned	1	0 (0)	37	26 (70)	39	27 (69)
Imprisoned	0	0 (0)	6	5 (83)	6	5 (83)
p value		---		0.659		0.656
2007						
Not imprisoned	1	1 (100)	14	12 (86)	16	14 (88)
Imprisoned	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2008						
Not imprisoned	1	0 (0)	20	15 (75)	21	15 (71)
Imprisoned	0	0 (0)	2	1 (50)	2	1 (50)
p value		---		0.481		0.526
2009						
Not imprisoned	5	2 (40)	44	27 (61)	49	29 (59)
Imprisoned	1	0 (0)	5	3 (60)	7	4 (57)
p value		1.000		1.000		1.000

\* Total includes people who did not report duration of drug injection

Table 47 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	8	1 (13)	23	22 (96)	31	23 (74)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2006						
No sex work	1	0 (0)	39	31 (79)	41	32 (78)
Sex work	0	0 (0)	3	0 (0)	3	3 (100)
p value		---		0.014		0.017
2007						
No sex work	1	1 (100)	15	13 (87)	17	15 (88)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
No sex work	1	0 (0)	23	16 (70)	24	16 (67)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
No sex work	6	2 (33)	48	30 (63)	55	33 (60)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---

\* Total includes people who did not report duration of drug injection

Table 48 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	18	13 (72)	6	6 (100)	24	19 (79)
Indigenous	5	3 (60)	1	1 (100)	6	4 (67)
p value		0.3		0.003		0.006
2006						
Non Indigenous	27	21 (78)	15	9 (60)	43	30 (70)
Indigenous	2	2 (100)	1	1 (100)	3	3 (100)
p value		1.000		1.000		0.548
2007						
Non Indigenous	10	10 (100)	7	6 (86)	17	16 (94)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
Non Indigenous	13	8 (62)	7	5 (71)	20	13 (65)
Indigenous	4	3 (75)	0	0 (0)	4	3 (75)
p value		1.000		---		1.000
2009						
Non Indigenous	35	21 (60)	17	10 (59)	52	31 (60)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.417		0.566		0.303

\* Total includes people whose gender was not reported or reported as transgender

Table 49 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	20	14 (70)	6	6 (100)	26	20 (77)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	0	0 (0)	1	1 (100)	1	1 (100)
Other	3	2 (67)	0	0 (0)	3	2 (67)
p value		0.3		---		0.3
2006						
Australia	27	21 (78)	13	10 (77)	40	31 (78)
Other Oceania	1	1 (100)	1	0 (0)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	1	0 (0)	1	1 (100)
Other	0	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		0.036		0.020
2007						
Australia	10	10 (100)	6	5 (83)	16	15 (94)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	0	0 (0)	1	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		0.464		0.216
2008						
Australia	16	11 (69)	6	4 (67)	22	15 (68)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	1	1 (100)	0	0 (0)	1	1 (100)
Other	0	0 (0)	1	1(100)	1	1 (100)
p value		0.569		1.000		0.704
2009						
Australia	27	18 (67)	18	12 (67)	45	30 (67)
Other Oceania	2	2 (100)	0	0 (0)	2	2 (100)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	5	1 (20)	3	1 (33)	8	2 (25)
Other	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.055		0.352		0.015

\* Total includes people whose gender was not reported or reported as transgender

Table 50 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	17	13 (76)	7	7 (100)	24	20 (83)
Non-English speaking	7	3 (43)	0	0 (0)	7	3 (43)
p value		0.1		---		0.03
2006						
English speaking	23	20 (87)	15	10 (67)	38	30 (79)
Non-English speaking	3	1 (33)	1	0 (0)	5	1 (20)
p value		0.085		0.375		0.017
2007						
English speaking	10	10 (100)	8	6 (75)	18	16 (89)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
English speaking	18	12 (67)	7	5 (71)	25	17 (68)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	35	21 (60)	21	13 (62)	56	34 (61)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		0.417		0.409		0.167

\* Total includes people whose gender was not reported or reported as transgender

## New South Wales

Table 51 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	20	19	22	22	20
N° surveyed	N=729	N=683	N=701	N=899	N=830
Response (%)	44	41	37	36	39
Gender (%)					
Male	464 (64)	434 (64)	450 (64)	582 (65)	500 (60)
Female	259 (36)	242 (35)	247 (35)	310 (34)	322 (39)
Transgender	6 (1)	6 (<1)	3 (<1)	4 (<1)	7 (<1)
Not reported	---	1 (<1)	1 (<1)	3 (<1)	1 (<1)
Sexual identity (%)					
Heterosexual	590 (81)	553 (81)	575 (82)	715 (80)	669 (81)
Bisexual	58 (8)	65 (10)	64 (9)	93 (10)	77 (9)
Homosexual	48 (7)	45 (7)	45 (6)	56 (6)	40 (5)
Not reported	33 (5)	20 (3)	17 (2)	35 (4)	44 (5)
Age and duration of injection (years)					
Median age	34	36	37	37	38
Age range	17-66	15-65	16-69	17-70	18-64
Age group (%)					
<25 years	89 (12)	61 (9)	59 (8)	81 (9)	66 (8)
25+ years	640 (88)	619 (91)	642 (92)	815 (91)	764 (92)
Not reported	---	3 (<1)	---	3 (<1)	0 (0)
Median age 1 <sup>st</sup> IDU	18	18	18	18	18
Age range	9-55	10-52	10-56	10-60	10-57
N° not reported	26	3	21	18	17
Median years IDU	13	15	16	17	17
Range	<1-46	<1-43	<1-49	<1-48	<1-45
Duration of drug injection (%)					
<3 years	60 (8)	31 (5)	23 (3)	46 (5)	47 (6)
<3+ years	642 (88)	625 (92)	657 (94)	835 (93)	766 (92)
Not reported	27 (4)	27 (4)	21 (3)	18 (2)	17 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	590 (81)	571 (84)	575 (82)	736 (82)	682 (82)
Yes	115 (16)	87 (13)	105 (15)	131 (15)	122 (15)
Not reported	24 (3)	25 (4)	21 (3)	32 (4)	26 (3)
Region/Country of birth (%)					
Australia	628 (86)	575 (84)	592 (84)	781 (87)	726 (87)
Other Oceania	25 (3)	29 (4)	18 (3)	31 (3)	18 (2)
Asia	4 (1)	5 (<1)	10 (1)	8 (1)	4 (<1)
UK & Ireland	31 (4)	35 (5)	26 (4)	38 (4)	37 (4)
Other	33 (5)	28 (4)	38 (5)	28 (3)	28 (3)
Not reported	8 (1)	11 (2)	17 (2)	13 (1)	17 (2)
Main language spoken at home by parents (%)					
English speaking	629 (86)	593 (87)	648 (92)	844 (94)	787 (95)
Non-English speaking	100 (14)	60 (9)	37 (5)	40 (4)	33 (4)
Not reported	0	30 (4)	16 (2)	15 (2)	10 (1)
Imprisonment last year (%)*					
No	568 (78)	556 (81)	566 (81)	687 (76)	684 (82)
Yes	130 (18)	94 (14)	103 (15)	137 (15)	103 (12)
Not reported	31 (4)	33 (5)	32 (5)	75 (8)	43 (5)
Injected in prison (%)	N=130	N=94	N=103	N=137	N=103
Yes	38 (29)	40 (43)	37 (36)	46 (34)	30 (29)
Frequency of injection last month (%)					
Not last month	71 (10)	88 (13)	81 (12)	126 (14)	129 (16)
Less than weekly	121 (17)	131 (19)	136 (19)	146 (16)	150 (18)
Weekly not daily	176 (24)	169 (25)	167 (24)	229 (25)	200 (24)
Daily or more	357 (49)	285 (42)	298 (43)	392 (44)	337 (41)
Not reported	4 (1)	10 (1)	19 (3)	6 (1)	14 (2)

Table 52 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=729	N=683	N=701	N=899	N=830
Anabolic steroids	20 (3)	16 (2)	12 (2)	20 (2)	30 (4)
Cocaine	45 (6)	36 (5)	30 (4)	45 (5)	51 (6)
Heroin	296 (41)	231 (34)	254 (36)	346 (39)	306 (37)
Methadone	105 (14)	96 (14)	88 (13)	107 (12)	116 (14)
Methamphetamine	183 (25)	197 (29)	185 (26)	230 (26)	181 (22)
Pharm. Opioids	24 (3)	49 (7)	57 (8)	80 (9)	80 (10)
Subutex/Buprenorphine	2 (<1)	16 (2)	20 (3)	27 (3)	16 (2)
More than one	11 (2)	9 (<1)	26 (4)	21 (2)	23 (3)
Other	5 (<1)	4 (<1)	18 (3)	8 (1)	22 (3)
Not reported	25 (3)	20 (3)	11 (2)	15 (2)	21 (3)
N° Injected last month	N=654	N=585	N=601	N=767	N=687
Places injected last month (%)*					
Own home	520 (80)	506 (90)	517 (88)	673 (89)	610 (90)
Friend's home	228 (35)	219 (39)	226 (39)	316 (42)	244 (36)
Dealer's home	100 (15)	84 (15)	101 (17)	120 (16)	94 (14)
Street, park, beach	160 (24)	126 (22)	143 (24)	165 (22)	130 (19)
Car	157 (24)	144 (26)	159 (27)	181 (24)	158 (23)
Public toilet	134 (20)	110 (20)	137 (23)	163 (22)	126 (19)
Commercial injecting room	42 (6)	38 (7)	39 (7)	40 (5)	42 (6)
Squat	24 (4)	41 (7)	39 (7)	50 (7)	32 (5)
MSIC	42 (6)	59 (11)	62 (11)	64 (8)	60 (9)
Use of new sterile needles & syringes last month (%)					
All injections	472 (72)	407 (70)	431 (72)	544 (71)	500 (73)
Most of the time	146 (22)	129 (22)	130 (22)	174 (23)	157 (23)
Half of the time	15 (2)	12 (2)	17 (3)	22 (3)	10 (1)
Some of the time	6 (1)	10 (2)	9 (2)	11 (1)	9 (1)
Not last month	1 (<1)	11 (2)	---	7 (1)	2 (<1)
Not reported	14 (2)	16 (3)	14 (2)	9 (1)	9 (1)
Re-used another's used needle & syringe last month (%)					
None	532 (82)	477 (82)	485 (81)	604 (79)	560 (82)
Once	26 (4)	31 (5)	42 (7)	50 (7)	44 (6)
Twice	24 (4)	20 (3)	19 (3)	42 (5)	33 (5)
3-5 times	26 (4)	17 (3)	17 (3)	26 (3)	18 (3)
>5 times	16 (2)	14 (2)	6 (1)	22 (3)	17 (2)
Not reported	28 (4)	26 (4)	32 (5)	23 (3)	15 (2)
Number of people needle & syringe was re-used after last month (%)					
None	504 (77)	477 (82)	485 (81)	604 (79)	560 (82)
One	65 (10)	43 (7)	42 (7)	66 (9)	53 (8)
Two	5 (1)	7 (1)	7 (1)	11 (1)	6 (1)
Three to five	5 (1)	2 (<1)	5 (<1)	10 (1)	3 (<1)
More than five	3 (<1)	2 (<1)	2 (<1)	3 (<1)	2 (<1)
Don't know	28 (4)	16 (3)	12 (2)	30 (4)	18 (3)
Not reported	44 (7)	38 (7)	48 (8)	43 (6)	45 (7)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	60 (9)	30 (5)	36 (6)	56 (7)	39 (6)
Casual sex partner	3 (<1)	5 (<1)	2 (<1)	7 (1)	3 (<1)
Close friend	29 (4)	15 (3)	27 (4)	39 (5)	16 (2)
Acquaintance	10 (2)	12 (2)	12 (2)	12 (2)	13 (2)
Other	4 (1)	4 (<1)	4 (<1)	8 (1)	11 (2)
Equipment used after someone else last month (%)*					
Spoon	152 (23)	114 (20)	134 (25)	160 (23)	127 (20)
Water	107 (16)	68 (12)	101 (19)	114 (16)	81 (13)
Filter	66 (10)	36 (6)	62 (11)	78 (11)	52 (8)
Drug mix	67 (10)	45 (8)	45 (8)	50 (7)	52 (8)
Tourniquet	71 (11)	47 (8)	58 (11)	74 (11)	57 (9)
None**	---	358 (62)	353 (65)	457 (66)	420 (68)
Injected by someone after that person injected themselves or others last month (%)					
No	528 (81)	497 (85)	494 (82)	631 (82)	592 (86)
Yes	87 (13)	60 (10)	77 (13)	110 (14)	76 (11)
Not reported	41 (6)	28 (5)	30 (5)	26 (3)	19 (3)

\* More than one option could be selected

\*\* New variable in 2006



Table 53 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=729	N=683	N=701	N=899	N=830
Any treatment/therapy for drug use (%)					
No	123 (17)	97 (14)	106 (15)	128 (14)	112 (13)
Yes	599 (82)	565 (82)	578 (82)	754 (84)	704 (85)
Not reported	7 (1)	21 (3)	17 (2)	17 (2)	14 (2)
History of methadone maintenance treatment (%)					
Currently	320 (44)	298 (44)	286 (41)	379 (42)	396 (48)
Previously	153 (21)	169 (25)	182 (26)	219 (24)	177 (21)
Never	250 (34)	201 (29)	218 (31)	281 (31)	236 (28)
Not reported	6 (1)	15 (2)	15 (2)	20 (2)	21 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	120 (13)	91 (11)
Previously	--	--	--	193 (21)	213 (26)
Never	--	--	--	564 (63)	500 (60)
Not reported	--	--	--	22 (2)	26 (3)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	26 (3)	37 (4)
Previously	--	--	--	59 (7)	76 (9)
Never	--	--	--	782 (87)	687 (87)
Not reported	--	--	--	32 (4)	1 (1)

\* New variable in 2008

Table 54 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=535#	N=687#
Source of needles/syringes (%)*		
Chemist/Pharmacy	136 (25)	139 (23)
Needle Syringe Program	456 (85)	474 (80)
Dispensing/Vending Machine	129 (24)	129 (22)
Friend/Dealer	86 (16)	79 (13)
Other	30 (6)	22 (4)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	21 (15)	27 (19)
Needle Syringe Program	284 (62)	287 (61)
Dispensing/Vending Machine	23 (18)	23 (18)
Friend/Dealer	11 (13)	11 (14)
Other	7 (23)	7 (32)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=601	N=687
Secondary exchange	299 (50)	245 (36)

\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

## New South Wales

Table 55 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=729	N=683	N=701	N=899	N=830
Sex with a regular partner last month (%)**					
No	314 (43)	288 (42)	300 (43)	392 (44)	369 (44)
Yes	397 (54)	376 (55)	375 (54)	481 (54)	439 (53)
Not reported	18 (2)	19 (3)	26 (4)	26 (3)	22 (3)
Condom used with regular partner last month (%)**					
N° surveyed	N=397	N=376	N=375	N=481	N=439
Never	277 (70)	259 (69)	275 (73)	330 (69)	378 (86)
Sometimes	59 (15)	51 (14)	38 (10)	61 (13)	43 (10)
Every time	46 (12)	28 (7)	49 (13)	69 (14)	2 (<1)
Not reported	15 (4)	38 (10)	13 (3)	21 (4)	16 (4)
Sex with other partner/s last month (%)**					
No	583 (80)	525 (77)	570 (81)	705 (78)	665 (80)
Yes	125 (17)	124 (18)	100 (14)	165 (18)	126 (15)
Not reported	21 (3)	34 (5)	31 (4)	29 (3)	39 (5)
Condom used with other partner/s last month (%)**					
N° surveyed	N=125	N=124	N=100	N=165	N=126
Never	31 (25)	26 (21)	28 (28)	38 (23)	47 (37)
Sometimes	34 (27)	38 (31)	17 (17)	39 (24)	22 (17)
Every time	56 (45)	53 (43)	47 (47)	79 (48)	55 (44)
Not reported	4 (3)	7 (6)	8 (8)	9 (5)	2 (2)
Sex work last month (%)					
No	660 (91)	586 (86)	618 (88)	771 (86)	740 (89)
Yes	52 (7)	59 (9)	50 (7)	78 (9)	57 (7)
Not reported	17 (2)	38 (6)	33 (5)	50 (6)	33 (4)
Condom used at last sex work last month (%)*					
Yes	72 (94)	49 (88)	47 (98)	57 (84)	52 (91)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 56 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=729	N=683	N=701	N=899	N=830
Previous HIV test (%)					
Yes, last year	436 (60)	409 (60)	392 (56)	443 (49)	423 (51)
> 1 year ago	226 (31)	199 (29)	228 (33)	334 (37)	304 (37)
Never tested	64 (9)	60 (9)	65 (9)	73 (8)	69 (8)
Not reported	3 (0)	15 (2)	16 (2)	49 (5)	34 (4)
Previous HCV test (%)					
Yes, last year	452 (62)	420 (61)	420 (60)	494 (55)	497 (60)
> 1 year ago	211 (29)	203 (30)	215 (31)	327 (36)	265 (32)
Never tested	64 (9)	47 (7)	52 (7)	45 (5)	39 (5)
Not reported	2 (0)	13 (2)	14 (2)	33 (4)	29 (3)
Any treatment for HCV (%)	N=372	N=363	N=344	N=546	N=508
Interferon	16 (4)	8 (2)	2 (<1)	24 (4)	13 (3)
Interferon+Ribarvarin	3 (1)	9 (2)	10 (3)	29 (5)	37 (7)
Other	4 (1)	8 (2)	4 (1)	5 (1)	3 (<1)
No treatment	346 (93)	327 (90)	312 (91)	470 (86)	432 (85)
Not reported	3 (1)	11 (3)	16 (5)	18 (3)	23 (5)
Current treatment for HCV	N=3	N=7	N=3	N=13	N=6
Interferon/Interferon+Ribarvirin	3	3	2	9	5
Other	0	4	1	4	1

## HIV antibody prevalence

Table 57 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	436	6 (1.4)	243	0 (0.0)	685	6 (0.9)
2006	424	12 (2.8)	232	1 (0.4)	663	14 (2.1)
2007	439	12 (2.7)	240	2 (0.8)	683	15 (2.2)
2008	563	15 (2.7)	297	3 (1.0)	867	19 (2.2)
2009	488	12 (2.5)	320	0 (0.0)	816	13 (1.6)
$\chi^2$ trend p value		0.386		0.773		0.357

\* Total includes people whose gender was not reported or reported as transgender

Table 58 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heterosexual	386	1 (0.3)	171	0 (0.0)	557	1 (0.2)
Bisexual	10	0 (0.0)	44	0 (0.0)	55	0 (0.0)
Homosexual	24	5 (20.8)	16	0 (0.0)	44	5 (11.4)
p value		<0.001		---		<0.001
2006						
Heterosexual	366	2 (0.6)	170	1 (0.6)	537	3 (0.6)
Bisexual	23	3 (13.0)	38	0 (0)	64	4 (6.3)
Homosexual	27	7 (25.9)	16	0 (0)	44	7 (15.9)
p value		<0.001		1.000		<0.001
2007						
Heterosexual	383	4 (1.0)	174	2 (1.2)	558	6 (1.1)
Bisexual	21	0 (0.0)	42	0 (0.0)	64	1 (1.6)
Homosexual	25	8 (32.0)	19	0 (0.0)	44	8 (18.2)
p value		<0.001		1.000		<0.001
2008						
Heterosexual	488	2 (0.4)	202	1 (0.5)	691	3 (0.4)
Bisexual	25	0 (0.0)	63	2 (3.2)	89	3 (3.4)
Homosexual	31	13 (41.9)	21	0 (0.0)	54	13 (24.1)
p value		<0.001		0.207		<0.001
2009						
Heterosexual	424	2 (0.5)	232	0 (0.0)	658	2 (0.3)
Bisexual	21	0 (0.0)	53	0 (0.0)	76	1 (1.3)
Homosexual	22	10 (45.5)	15	0 (0.0)	39	10 (25.6)
p value		<0.001		---		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 59 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
< 20 years	6	0 (0.0)	5	0 (0.0)	11	0 (0.0)
20 – 24	36	1 (2.8)	34	0 (0.0)	70	1 (1.4)
25 – 29	63	0 (0.0)	57	0 (0.0)	121	0 (0.0)
30 + years	331	5 (1.5)	147	0 (0.0)	483	5 (1.0)
p value		0.700		---		0.700
2006						
< 20 years	3	0 (0)	6	0 (0)	9	0 (0.0)
20 – 24	31	1 (3.2)	19	0 (0)	50	1 (2.0)
25 – 29	67	0 (0)	42	0 (0)	111	1 (0.9)
30 + years	322	11 (3.4)	163	1 (0.6)	490	12 (2.7)
p value		0.353		1.000		0.576
2007						
< 20 years	3	0 (0.0)	5	0 (0.0)	8	0 (0.0)
20 – 24	25	0 (0.0)	23	0 (0.0)	48	0 (0.0)
25 – 29	59	3 (5.1)	40	0 (0.0)	100	3 (3.0)
30 + years	352	9 (2.6)	172	2 (1.2)	527	12 (2.3)
p value		0.518		1.000		0.684
2008						
< 20 years	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
20 – 24	40	0 (0.0)	29	0 (0.0)	69	0 (0.0)
25 – 29	66	1 (1.5)	45	2 (4.4)	113	4 (3.5)
30 + years	449	14 (3.1)	218	1 (0.5)	672	15 (2.2)
p value		0.718		0.135		0.455
2009						
< 20 years	4	0 (0.0)	6	0 (0.0)	10	0 (0.0)
20 – 24	22	0 (0.0)	32	0 (0.0)	54	0 (0.0)
25 – 29	54	0 (0.0)	56	0 (0.0)	110	0 (0.0)
30 + years	408	12 (2.9)	226	0 (0.0)	642	13 (2.0)
p value		0.679		---		0.393

\* Total includes people whose gender was not reported or reported as transgender

Table 60 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<3 years	19	0 (0.0)	10	0 (0.0)	30	0 (0.0)
3 to 5 years	35	2 (5.7)	18	0 (0.0)	53	2 (3.8)
6 to 10 years	42	0 (0.0)	49	0 (0.0)	92	0 (0.0)
10 + years	324	2 (0.6)	157	0 (0.0)	485	2 (0.4)
p value		0.030		---		0.020
2006						
<3 years	19	1 (5.3)	11	0 (0.0)	30	1 (3.3)
3 to 5 years	27	1 (3.7)	18	0 (0.0)	45	1 (2.2)
6 to 10 years	67	2 (3.0)	47	1 (2.1)	118	4 (3.4)
10 + years	292	8 (2.7)	149	0 (0.0)	444	8 (1.8)
p value		0.576		0.338		0.437
2007						
<3 years	11	0 (0.0)	11	0 (0.0)	22	0 (0.0)
3 to 5 years	31	1 (3.2)	19	0 (0.0)	51	1 (1.0)
6 to 10 years	61	0 (0.0)	42	0 (0.0)	104	0 (0.0)
10 + years	326	11 (3.4)	158	2 (1.3)	486	14 (2.9)
p value		0.520		1.000		0.312
2008						
<3 years	33	3 (9.1)	15	0 (0.0)	48	3 (6.3)
3 to 5 years	44	2 (4.6)	15	0 (0.0)	59	2 (3.4)
6 to 10 years	70	0 (0.0)	49	0 (0.0)	120	0 (0.0)
10 + years	400	10 (2.5)	217	3 (1.4)	622	14 (2.3)
p value		0.049		1.000		0.047
2009						
<3 years	30	2 (6.7)	16	0 (0.0)	46	2 (4.4)
3 to 5 years	13	0 (0.0)	16	0 (0.0)	29	0 (0.0)
6 to 10 years	53	2 (3.8)	52	0 (0.0)	106	2 (1.9)
10 + years	382	8 (2.1)	229	0 (0.0)	618	9 (1.5)
p value		0.210		---		0.357

\* Total includes people whose gender was not reported or reported as transgender

Table 61 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	183	2 (1.1)	109	0 (0.0)	286	2 (0.7)
Methamphetamine	101	3 (3.0)	65	0 (0.0)	170	3 (1.8)
More than one	7	0 (0.0)	23	0 (0.0)	11	0 (0.0)
Other/Not reported	146	1 (0.7)	46	0 (0.0)	219	1 (0.5)
p value		0.392		---		0.600
2006						
Heroin	133	2 (1.5)	88	0 (0.0)	223	2 (0.9)
Methamphetamine	124	8 (6.5)	64	0 (0.0)	192	9 (4.7)
More than one	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
Other/Not reported	162	2 (1.2)	76	1 (1.3)	239	3 (1.3)
p value		.057		0.621		0.055
2007						
Heroin	153	4 (2.6)	91	0 (0.0)	246	4 (1.6)
Methamphetamine	109	4 (3.7)	71	1 (1.4)	180	5 (2.8)
More than one	13	0 (0.0)	5	0 (0.0)	18	0 (0.0)
Other/Not reported	164	4 (2.4)	73	1 (1.4)	239	6 (2.5)
p value		0.871		0.543		0.762
2008						
Heroin	218	1 (0.5)	116	1 (0.9)	335	2 (0.6)
Methamphetamine	138	11 (8.0)	75	1 (1.3)	217	13 (6.0)
More than one	15	0 (0.0)	6	1 (16.7)	21	1 (4.8)
Other/Not reported	192	3 (1.6)	100	0 (0.0)	294	3 (1.0)
p value		0.001		0.043		<0.001
2009						
Heroin	180	2 (1.1)	119	0 (0.0)	302	2 (0.7)
Methamphetamine	98	7 (7.1)	79	0 (0.0)	178	7 (3.9)
More than one	9	0 (0.0)	12	0 (0.0)	22	0 (0.0)
Other/Not reported	201	3 (1.5)	110	0 (0.0)	314	4 (1.3)
p value		0.028		---		0.069

\* Total includes people whose gender was not reported or reported as transgender

Table 62 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Not last month	208	0 (0.0)	127	0 (0.0)	336	0 (0.0)
Less than weekly	116	3 (2.6)	53	0 (0.0)	171	3 (1.8)
Weekly not daily	68	3 (4.4)	38	0 (0.0)	108	3 (2.8)
Daily or more	43	0 (0.0)	22	0 (0.0)	66	0 (0.0)
p value		0.030		---		0.020
2006						
Not last month	49	1 (2.0)	36	1 (2.8)	86	2 (2.3)
Less than weekly	77	2 (2.6)	50	0 (0.0)	127	2 (1.6)
Weekly not daily	119	6 (5.0)	45	0 (0.0)	166	6 (3.6)
Daily or more	172	3 (1.7)	99	0 (0.0)	275	4 (1.5)
p value		0.433		0.157		0.483
2007						
Not last month	47	2 (4.3)	32	0 (0.0)	80	2 (2.5)
Less than weekly	87	1 (1.2)	47	1 (2.1)	134	2 (1.5)
Weekly not daily	99	3 (3.0)	59	0 (0.0)	161	4 (2.5)
Daily or more	196	6 (3.1)	96	1 (1.0)	292	7 (2.4)
p value		0.713		0.625		0.927
2008						
Not last month	77	3 (3.9)	45	1 (2.2)	123	4 (3.3)
Less than weekly	96	5 (5.2)	41	0 (0.0)	140	5 (3.6)
Weekly not daily	148	3 (2.0)	73	1 (1.4)	222	4 (1.8)
Daily or more	239	4 (1.7)	135	1 (0.7)	376	6 (1.6)
p value		0.252		0.842		0.396
2009						
Not last month	78	3 (3.9)	48	0 (0.0)	127	3 (2.4)
Less than weekly	80	3 (3.8)	65	0 (0.0)	147	3 (2.0)
Weekly not daily	114	2 (1.8)	81	0 (0.0)	196	2 (1.0)
Daily or more	207	4 (1.9)	121	0 (0.0)	332	5 (1.5)
p value		0.615		---		0.759

\* Total includes people whose gender was not reported or reported as transgender

Table 63 HIV antibody prevalence by re-use of someone else's used needle &amp; syringe last month, gender and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No receptive sharing	321	6 (1.9)	176	0 (0.0)	501	6 (1.2)
Receptive sharing	54	0 (0.0)	34	0 (0.0)	89	0 (0.0)
p value		0.300		---		0.300
2006						
No receptive sharing	294	9 (3.1)	166	0 (0)	464	9 (1.9)
Receptive sharing	56	2 (3.6)	22	0 (0)	79	3 (3.8)
p value		0.691		---		0.396
2007						
No receptive sharing	306	6 (2.0)	165	2 (1.2)	474	9 (1.9)
Receptive sharing	56	4 (7.1)	26	0 (0.0)	82	4 (4.9)
p value		0.053		1.000		0.110
2008						
No receptive sharing	388	11 (2.8)	190	2 (1.1)	584	14 (2.4)
Receptive sharing	79	1 (1.3)	52	0 (0.0)	131	1 (0.8)
p value		0.700		1.000		0.328
2009						
No receptive sharing	337	9 (2.7)	210	0 (0.0)	554	10 (1.8)
Receptive sharing	56	0 (0.0)	53	0 (0.0)	109	0 (0.0)
p value		0.370		---		0.381

\* Total includes people whose gender was not reported or reported as transgender

Table 64 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No imprisonment	327	6 (1.8)	201	0 (0.0)	533	6 (1.1)
Imprisonment	90	0 (0.0)	34	0 (0.0)	125	0 (0.0)
p value		0.200		---		0.200
2006						
No imprisonment	331	12 (3.6)	200	1 (0.5)	538	14 (2.6)
Imprisonment	66	0 (0.0)	27	0 (0.0)	93	0 (0.0)
p value		0.230		1.000		0.242
2007						
No imprisonment	342	10 (2.9)	205	2 (1.0)	550	12 (2.2)
Imprisonment	76	2 (2.6)	26	0 (0.0)	102	2 (2.0)
p value		1.000		1.000		1.000
2008						
No imprisonment	416	14 (3.4)	240	0 (0.0)	662	15 (2.3)
Imprisonment	98	1 (1.0)	32	2 (6.3)	131	3 (2.3)
p value		0.323		0.013		1.000
2009						
No imprisonment	394	12 (3.1)	273	0 (0.0)	675	13 (1.9)
Imprisonment	70	0 (0.0)	32	0 (0.0)	102	0 (0.0)
p value		0.228		---		0.236

\* Total includes people whose gender was not reported or reported as transgender



Table 65 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005**						
No condom use	164	0 (0.0)	113	0 (0.0)	277	0 (0.0)
Condom use	84	2 (2.4)	39	0 (0.0)	125	2 (1.6)
p value		0.050		---		0.040
2006						
No condom use	190	2 (1.1)	113	0 (0.0)	306	3 (1.0)
Condom use	15	1 (6.7)	12	0 (0.0)	27	1 (3.7)
p value		0.205		---		0.288
2007						
No condom use	181	2 (1.1)	119	2 (1.7)	303	5 (1.7)
Condom use	29	1 (3.5)	19	0 (0.0)	48	1 (2.1)
p value		0.361		1.000		0.589
2008						
No condom use	226	1 (0.4)	150	0 (0.0)	378	1 (0.3)
Condom use	43	1 (2.3)	22	1 (4.6)	67	3 (1.5)
p value		0.295		0.128		0.012
2009						
No condom use	197	1 (0.5)	175	0 (0.0)	374	1 (0.3)
Condom use	31	2 (6.5)	10	0 (0.0)	41	2 (4.9)
p value		0.049		---		0.027

\* Total includes people whose gender was not reported or reported as transgender

\*\* Question changed to "condom use with regular partner in last month" in 2005.

Table 66 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No sex work	415	5 (1.2)	202	0 (0.0)	621	5 (0.8)
Sex work	12	1 (8.3)	35	0 (0.0)	49	1 (2.0)
p value		--		---		0.400
2006						
No sex work	383	10 (2.6)	182	1 (0.6)	568	11 (1.9)
Sex work	18	2 (11.1)	36	0 (0.0)	58	3 (5.0)
p value		0.096		1.000		0.132
2007						
No sex work	407	11 (2.7)	190	2 (1.1)	600	13 (2.2)
Sex work	9	1 (11.1)	40	0 (0.0)	50	2 (4.0)
p value		0.234		1.000		0.323
2008						
No sex work	511	13 (2.5)	229	3 (1.3)	745	16 (2.2)
Sex work	23	2 (8.7)	49	0 (0.0)	73	3 (4.1)
p value		0.133		1.000		0.236
2009						
No sex work	462	10 (2.2)	261	0 (0.0)	729	11 (1.5)
Sex work	7	2 (28.6)	48	0 (0.0)	57	2 (3.5)
p value		0.012		---		0.243

\* Total includes people whose gender was not reported or reported as transgender

Table 67 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Non Indigenous	369	6 (1.6)	185	0 (0.0)	559	6 (1.1)
Indigenous	54	0 (0.0)	48	0 (0.0)	103	0 (0.0)
p value		0.400		---		0.300
2006						
Non Indigenous	372	12 (3.2)	176	1 (0.6)	554	14 (2.5)
Indigenous	39	0 (0.0)	47	0 (0.0)	86	0 (0.0)
p value		0.615		1.000		0.235
2007						
Non Indigenous	366	10 (2.8)	190	2 (1.1)	559	12 (2.2)
Indigenous	56	1 (1.8)	47	0 (0.0)	104	2 (1.9)
p value		1.000		1.000		1.000
2008						
Non Indigenous	469	13 (2.8)	234	1 (0.4)	709	15 (2.1)
Indigenous	71	1 (1.4)	54	2 (3.7)	126	3 (2.4)
p value		1.000		0.091		0.744
2009						
Non Indigenous	422	11 (2.6)	245	0 (0.0)	672	11 (1.6)
Indigenous	48	1 (2.1)	70	0 (0.0)	120	2 (1.7)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 68 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Australia	368	5 (1.4)	216	0 (0.0)	588	5 (0.9)
Other Oceania	13	1 (7.7)	8	0 (0.0)	23	1 (4.4)
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
UK & Ireland	21	0 (0.0)	10	0 (0.0)	31	0 (0.0)
Other	26	0 (0.0)	6	0 (0.0)	32	0 (0.0)
p value		0.300		---		0.400
2006						
Australia	347	11 (3.2)	208	1 (0.5)	559	12 (2.2)
Other Oceania	17	0 (0.0)	11	0 (0.0)	29	1 (3.5)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	7	0 (0.0)	35	0 (0.0)
Other	23	1 (4.4)	3	0 (0.0)	26	1 (3.9)
p value		0.793		1.000		0.503
2007						
Australia	365	11 (3.0)	208	2 (1.0)	576	14 (2.4)
Other Oceania	9	1 (11.1)	8	0 (0.0)	18	1 (5.6)
Asia	5	0 (0.0)	5	0 (0.0)	10	0 (0.0)
UK & Ireland	19	0 (0.0)	7	0 (0.0)	26	0 (0.0)
Other	28	0 (0.0)	9	0 (0.0)	37	0 (0.0)
p value		0.461		1.000		0.643
2008						
Australia	485	12 (2.5)	266	3 (1.1)	755	15 (2.0)
Other Oceania	14	2 (14.3)	10	0 (0.0)	26	3 (11.2)
Asia	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
UK & Ireland	25	0 (0.0)	9	0 (0.0)	35	0 (0.0)
Other	27	1 (3.7)	7	0 (0.0)	34	1 (2.9)
p value		0.135		1.000		0.063
2009						
Australia	417	12 (2.9)	292	0 (0.0)	714	13 (1.8)
Other Oceania	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Asia	3	0 (0.0)	1	0 (0.0)	4	0 (0.0)
UK & Ireland	28	0 (0.0)	8	0 (0.0)	37	0 (0.0)
Other	17	0 (0.0)	9	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 69 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
English speaking	366	6 (1.6)	218	0 (0.0)	589	6 (1.0)
Non-English speaking	70	0 (0.0)	25	0 (0.0)	96	0 (0.0)
p value		0.300		---		0.300
2006						
English speaking	361	11 (3.1)	214	1 (0.5)	581	13 (2.2)
Non-English speaking	42	1 (2.4)	12	0 (0.0)	54	1 (1.9)
p value		1.000		1.000		1.000
2007						
English speaking	403	12 (3.0)	225	2 (0.9)	632	15 (2.4)
Non-English speaking	23	0 (0.0)	14	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000
2008						
English speaking	525	15 (2.9)	284	3 (1.1)	816	19 (2.3)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		1.000		1.000		1.000
2009						
English speaking	461	12 (2.6)	307	0 (0.0)	776	13 (1.7)
Non-English speaking	21	0 (0.0)	11	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender

## HCV antibody prevalence

Table 70 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	439	302 (69)	243	168 (69)	688	474 (69)
2006	424	292 (69)	232	173 (75)	663	468 (71)
2007	428	289 (68)	231	169 (73)	663	460 (69)
2008	539	379 (70)	281	208 (74)	827	591 (71)
2009	485	272 (56)	320	193 (60)	813	468 (58)
$\chi^2$ trend p value		<0.001		0.019		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 71 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	389	270 (69)	171	112 (66)	560	382 (68)
Bisexual	10	7 (70)	44	34 (77)	55	42 (76)
Homosexual	24	15 (63)	16	13 (81)	44	31 (70)
p value		0.800		0.200		0.500
2006						
Heterosexual	366	263 (72)	170	130 (76)	537	393 (73)
Bisexual	23	14 (61)	38	27 (71)	64	41 (64)
Homosexual	27	11 (41)	16	9 (56)	44	21 (48)
p value		0.003		0.191		0.001
2007						
Heterosexual	374	264 (71)	166	121 (73)	541	386 (71)
Bisexual	20	11 (55)	41	34 (83)	62	45 (73)
Homosexual	24	8 (33)	19	9 (47)	43	17 (40)
p value		<0.001		0.020		<0.001
2008						
Heterosexual	468	337 (72)	191	144 (75)	660	481 (73)
Bisexual	24	17 (71)	59	45 (76)	84	62 (74)
Homosexual	29	12 (41)	20	13 (65)	51	26 (51)
p value		0.003		0.564		0.005
2009						
Heterosexual	421	238 (57)	232	134 (58)	655	373 (57)
Bisexual	21	13 (62)	53	41 (77)	76	54 (71)
Homosexual	22	5 (23)	15	7 (47)	39	12 (31)
p value		0.004		0.012		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 72 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	6	1 (17)	5	2 (40)	11	3 (27)
20 – 24	36	12 (33)	34	24 (71)	70	36 (51)
25 – 29	63	39 (62)	57	34 (60)	121	74 (61)
30 + years	334	250 (75)	147	108 (73)	486	361 (74)
p value		<0.001		0.100		<0.001
2006						
< 20 years	3	1 (33)	6	4 (67)	9	5 (56)
20 – 24	31	16 (52)	19	14 (74)	50	30 (60)
25 – 29	67	39 (58)	42	30 (71)	111	69 (62)
30 + years	322	236 (73)	163	123 (75)	490	362 (74)
p value		0.004		0.868		0.015
2007						
< 20 years	3	0 (0)	5	3 (60)	8	3 (38)
20 – 24	22	6 (27)	22	13 (50)	44	19 (43)
25 – 29	56	27 (48)	39	25 (64)	96	53 (55)
30 + years	347	256 (74)	165	128 (78)	515	385 (75)
p value		<0.001		0.090		<0.001
2008						
< 20 years	5	2 (40)	5	3 (60)	10	5 (50)
20 – 24	38	13 (34)	29	19 (66)	67	32 (48)
25 – 29	60	37 (62)	44	29 (66)	106	67 (63)
30 + years	433	326 (75)	203	157 (77)	641	486 (76)
p value		<0.001		0.179		<0.001
2009						
< 20 years	6	2 (33)	10	2 (20)	30	1 (3)
20 – 24	32	15 (47)	54	17 (31)	13	1 (8)
25 – 29	56	38 (68)	109	66 (61)	52	19 (37)
30 + years	226	138 (61)	640	383 (60)	380	249 (66)
p value		0.127		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 73 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	33	10 (30)	19	12 (63)	53	22 (42)
3 to 5 years	35	13 (37)	18	7 (39)	53	20 (38)
6 to 10 years	42	22 (52)	49	33 (67)	92	56 (61)
10 + years	313	245 (78)	148	110 (74)	465	358 (77)
p value		<0.001		0.0200		<0.001
2006						
<3 years	19	2 (11)	11	3 (27)	30	5 (17)
3 to 5 years	27	11 (41)	18	7 (39)	45	18 (40)
6 to 10 years	67	38 (57)	47	37 (79)	118	76 (64)
10 + years	292	231 (79)	149	121 (81)	444	354 (80)
p value		<<0.001		<<0.001		<<0.001
2007						
<3 years	11	1 (9)	11	4 (36)	22	5 (23)
3 to 5 years	31	11 (35)	18	15 (83)	50	27 (54)
6 to 10 years	57	24 (42)	40	24 (60)	98	48 (49)
10 + years	319	247 (77)	153	119 (78)	474	367 (77)
p value		<0.001		0.004		<0.001
2008						
<3 years	33	8 (24)	14	7 (50)	47	15 (32)
3 to 5 years	42	17 (40)	15	10 (67)	57	27 (47)
6 to 10 years	64	38 (59)	48	30 (63)	113	68 (60)
10 + years	386	309 (80)	203	161 (79)	594	473 (80)
p value		<0.001		0.011		<0.001
2009						
<3 years	30	1 (3)	16	6 (38)	46	7 (15)
3 to 5 years	13	1 (8)	16	9 (56)	29	10 (34)
6 to 10 years	52	19 (37)	52	28 (54)	105	48 (46)
10 + years	380	249 (66)	229	147 (64)	616	398 (65)
p value		<0.001		0.118		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 74 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	14	5 (36)	272	202 (74)	286	207 (72)
Methamphetamine	13	5 (38)	158	93 (59)	171	98 (57)
More than one	0	0 (0)	11	10 (91)	11	10 (91)
Other/Not reported	25	11 (44)	196	148 (76)	221	159 (72)
p value		0.934		0.001		0.001
2006						
Heroin	133	100 (75)	88	71 (81)	223	172 (77)
Methamphetamine	124	72 (58)	64	39 (61)	192	112 (58)
More than one	5	5 (100)	4	4 (100)	9	9 (100)
Other/Not reported	162	115 (71)	76	59 (78)	239	175 (73)
p value		0.009		0.027		<<0.001
2007						
Heroin	10	2 (20)	229	163 (71)	241	167 (69)
Methamphetamine	6	3 (50)	162	110 (68)	172	116 (67)
More than one	0	0 (0)	11	7 (64)	18	10 (56)
Other/Not reported	6	0 (0)	220	162 (74)	323	167 (72)
p value		0.119		0.594		0.430
2008						
Heroin	10	3 (30)	305	240 (79)	319	245 (77)
Methamphetamine	11	3 (27)	195	123 (63)	209	126 (60)
More than one	0	0 (0)	18	17 (94)	18	17 (94)
Other/Not reported	26	9 (35)	246	188 (76)	281	203 (72)
p value		1.000		<0.001		<0.001
2009						
Heroin	10	3 (30)	289	187 (65)	301	190 (63)
Methamphetamine	10	3 (30)	164	85 (52)	177	90 (51)
More than one	0	0 (0)	22	14 (64)	22	14 (64)
Other/Not reported	26	7 (15)	275	170 (62)	313	174 (56)
p value		0.023		0.057		0.047

\* Total includes people who did not report duration of drug injection



Table 75 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	30	10 (33)	304	207 (68)	347	225 (65)
Daily or more	20	11 (55)	305	226 (74)	337	247 (73)
p value		0.100		0.100		0.020
2006						
Less than daily	16	0 (0)	269	199 (74)	293	201 (69)
Daily or more	11	3 (27)	251	183 (73)	275	197 (72)
p value		0.056		0.843		0.464
2007						
Less than daily	11	2 (18)	272	202 (74)	287	208 (72)
Daily or more	10	3 (30)	265	180 (68)	282	189 (67)
p value		0.635		0.107		0.171
2008						
Less than daily	23	3 (13)	318	224 (70)	344	229 (67)
Daily or more	15	8 (53)	332	263 (79)	357	277 (78)
p value		0.012		0.011		0.001
2009						
Less than daily	17	3 (18)	321	196 (61)	342	200 (58)
Daily or more	20	2 (10)	305	184 (60)	330	190 (58)
p value		0.644		0.870		0.815

\* Total includes people who did not report duration of drug injection

Table 76 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	33	12 (36)	452	316 (70)	503	342 (68)
Receptive sharing	9	6 (67)	77	63 (82)	89	71 (80)
p value		0.100		0.030		0.030
2006						
No receptive sharing	24	3 (13)	429	313 (73)	464	320 (69)
Receptive sharing	2	0 (0)	69	53 (77)	79	61 (77)
p value		1.000		0.559		0.146
2007						
No receptive sharing	14	4 (29)	439	309 (70)	460	320 (70)
Receptive sharing	5	1 (20)	72	53 (74)	79	56 (71)
p value		1.000		0.675		0.895
2008						
No receptive sharing	30	7 (23)	515	379 (74)	558	394 (71)
Receptive sharing	6	4 (67)	114	89 (78)	120	93 (78)
p value		0.057		0.345		0.146
2009						
No receptive sharing	34	3 (9)	510	307 (60)	551	314 (57)
Receptive sharing	3	2 (67)	105	66 (63)	109	68 (62)
p value		0.042		0.742		0.341

\* Total includes people who did not report duration of drug injection

Table 77 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	44	15 (34)	473	323 (68)	535	350 (65)
Imprisoned	6	5 (83)	113	93 (82)	126	104 (83)
p value		0.020		0.003		<0.001
2006						
Not imprisoned	26	4 (15)	492	347 (71)	538	361 (67)
Imprisoned	3	1 (33)	86	76 (88)	93	80 (86)
p value		0.446		<<0.001		<<0.001
2007						
Not imprisoned	20	5 (25)	499	350 (70)	533	363 (68)
Imprisoned	0	0 (0)	95	72 (76)	99	76 (77)
p value		---		0.323		0.096
2008						
Not imprisoned	39	11 (28)	582	412 (71)	632	428 (68)
Imprisoned	4	2 (50)	118	100 (85)	125	104 (83)
p value		0.572		0.001		<0.001
2009						
Not imprisoned	41	4 (10)	615	360 (59)	673	369 (55)
Imprisoned	3	2 (67)	98	70 (71)	101	72 (71)
p value		0.045		0.020		0.002

\* Total includes people who did not report duration of drug injection

Table 78 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	52	21 (40)	549	387 (70)	624	424 (68)
Sex work	1	1 (100)	46	37 (80)	49	40 (82)
p value		0.200		0.200		0.0500
2006						
No sex work	26	4 (15)	520	388 (75)	568	404 (71)
Sex work	2	1 (50)	54	37 (69)	58	39 (67)
p value		0.331		0.331		0.546
2007						
No sex work	19	5 (26)	548	393 (72)	581	408 (70)
Sex work	1	0 (0)	45	32 (71)	49	33 (67)
p value		1.000		1.000		0.746
2008						
No sex work	41	12 (29)	659	483 (73)	714	502 (70)
Sex work	3	2 (67)	64	50 (78)	68	52 (76)
p value		0.234		0.459		0.330
2009						
No sex work	45	6 (13)	666	399 (60)	726	410 (56)
Sex work	1	1 (100)	55	40 (73)	57	41 (72)
p value		0.152		0.084		0.036

\* Total includes people who did not report duration of drug injection

Table 79 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non-Indigenous	372	258 (69)	185	124 (67)	562	385 (69)
Indigenous	54	38 (70)	48	39 (81)	103	78 (76)
p value		0.800		0.060		0.100
2006						
Non-Indigenous	372	257 (69)	176	125 (71)	554	384 (69)
Indigenous	39	27 (69)	47	42 (89)	86	69 (80)
p value		1.000		0.008		0.041
2007						
Non-Indigenous	358	239 (67)	184	135 (73)	545	376 (69)
Indigenous	54	42 (78)	44	31 (70)	99	73 (74)
p value		0.118		0.708		0.405
2008						
Non-Indigenous	449	314 (70)	225	163 (72)	680	480 (71)
Indigenous	67	50 (75)	48	40 (83)	116	91 (78)
p value		0.475		0.146		0.094
2009						
Non-Indigenous	419	231 (55)	245	152 (62)	669	385 (58)
Indigenous	48	27 (56)	70	37 (53)	120	64 (53)
p value		1.000		0.269		0.484

\* Total includes people whose gender was not reported or reported as transgender

Table 80 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	371	252 (68)	216	148 (69)	591	403 (68)
Other Oceania	13	8 (62)	8	7 (88)	23	16 (70)
Asia	4	2 (50)	---	---	4	2 (50)
UK & Ireland	21	18 (86)	10	7 (70)	31	25 (81)
Other	26	19 (73)	6	3 (50)	32	22 (69)
p value		0.400		0.500		0.600
2006						
Australia	347	241 (69)	208	155 (75)	559	397 (71)
Other Oceania	17	12 (71)	11	9 (82)	29	21 (72)
Asia	3	3 (100)	1	0 (0)	4	3 (75)
UK & Ireland	28	19 (68)	7	4 (57)	35	23 (66)
Other	23	13 (57)	3	3 (100)	26	16 (62)
p value		0.616		0.292		0.792
2007						
Australia	356	237 (67)	200	145 (73)	559	384 (69)
Other Oceania	9	7 (78)	7	5 (71)	17	12 (71)
Asia	5	3 (60)	5	3 (60)	10	6 (60)
UK & Ireland	17	14 (82)	7	7 (100)	24	21 (88)
Other	28	21 (75)	9	7 (78)	37	28 (76)
p value		0.568		0.516		0.273
2008						
Australia	464	324 (70)	251	187 (75)	719	514 (71)
Other Oceania	14	10 (71)	9	5 (56)	25	15 (60)
Asia	5	5 (100)	1	0 (0)	6	5 (83)
UK & Ireland	24	17 (71)	9	7 (78)	34	25 (74)
Other	25	18 (72)	7	5 (71)	32	23 (72)
p value		0.796		0.356		0.761
2009						
Australia	414	234 (57)	292	171 (59)	711	406 (57)
Other Oceania	11	8 (73)	7	5 (71)	18	13 (72)
Asia	3	1 (33)	1	1 (100)	4	2 (50)
UK & Ireland	28	16 (57)	8	6 (75)	37	23 (62)
Other	17	9 (53)	9	8 (89)	28	18 (64)
p value		0.771		0.280		0.649

\* Total includes people whose gender was not reported or reported as transgender

Table 81 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	369	253 (69)	218	151 (69)	592	407 (69)
Non-English speaking	70	49 (70)	25	17 (68)	96	67 (70)
p value		0.800		0.900		0.800
2006						
English speaking	361	253 (70)	214	159 (74)	581	414 (71)
Non-English speaking	42	25 (60)	12	8 (67)	54	33 (61)
p value		0.163		0.517		0.122
2007						
English speaking	392	266 (68)	216	158 (73)	612	426 (70)
Non-English speaking	23	16 (70)	14	10 (71)	37	26 (70)
p value		1.000		1.000		1.000
2008						
English speaking	503	352 (70)	268	197 (74)	778	553 (71)
Non-English speaking	27	21 (78)	8	7 (88)	35	28 (80)
p value		0.517		0.685		0.339
2009						
English speaking	458	258 (56)	307	183 (60)	773	444 (57)
Non-English speaking	21	10 (48)	11	8 (73)	32	18 (56)
p value		0.823		0.536		1.000

\* Total includes people whose gender was not reported or reported as transgender

## Northern Territory

Table 82 Number (percentage) of respondents by graphic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	3	2	3	3	3
N° surveyed	N=29	N=20	N=31	N=75	N=77
Response (%)	39	---	31	43	29
Gender (%)					
Male	19 (66)	9 (45)	22 (71)	48 (64)	52 (68)
Female	10 (34)	11 (55)	9 (29)	27 (36)	25 (32)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	26 (90)	13 (65)	28 (90)	62 (83)	66 (86)
Bisexual	2 (7)	4 (20)	1 (3)	4 (5)	5 (6)
Homosexual	1 (3)	3 (15)	2 (6)	5 (7)	2 (3)
Not reported	0 (0)	0 (0)	0 (0)	4 (5)	4 (5)
Age and duration of injection (years)					
<i>Median age</i>	35	33	38	39	40
<i>Age range</i>	19-56	24-52	25-59	17-66	22-60
<i>Age group (%)</i>					
<25 years	4 (14)	1 (5)	0 (0)	3 (4)	4 (5)
25+ years	25 (86)	19 (95)	31 (100)	72 (96)	73 (95)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	20	19.5	17	18	18
<i>Age range</i>	11-41	14-30	12-42	13-58	12-42
Not reported	2	0	1	2	4
<i>Median years IDU</i>	15	11.5	18	16	18
<i>Range</i>	1-36	5-36	3-36	<1-35	1-37
<i>Duration of drug injection (%)</i>					
<3 years	2 (7)	0 (0)	0 (0)	1 (1)	4 (5)
3+ years	26 (90)	20 (100)	30 (97)	72 (96)	69 (90)
Not reported	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)
Aboriginal and Torres Strait Islander origin (%)					
No	27 (93)	17 (85)	0 (0)	61 (81)	65 (84)
Yes	1 (3)	3 (15)	30 (97)	13 (17)	10 (13)
Not reported	1 (3)	0 (0)	1 (3)	1 (1)	2 (3)
Region/Country of birth (%)					
Australia	28 (97)	19 (95)	28 (90)	65 (87)	65 (84)
Other Oceania	0 (0)	1 (5)	1 (3)	2 (3)	2 (3)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	2 (3)
UK & Ireland	0 (0)	0 (0)	1 (3)	3 (4)	2 (3)
Other	0 (0)	0 (0)	0 (0)	2 (3)	4 (5)
Not reported	1 (3)	0 (0)	1 (3)	3 (4)	2 (3)
Main language spoken at home by parents (%)					
English speaking	25 (86)	18 (90)	29 (94)	75 (100)	70 (91)
Non-English speaking	4 (14)	0 (0)	1 (3)	0 (0)	6 (7)
Not reported	0 (0)	2 (10)	1 (3)	0 (0)	1 (1)
Imprisonment last year (%)					
No	26 (90)	19 (95)	29 (94)	69 (92)	72 (94)
Yes	2 (7)	1 (5)	1 (3)	3 (4)	2 (3)
Not reported	1 (3)	0 (0)	1 (3)	3 (4)	3 (4)
Injected in prison (%)	N=2	N=1	N=1	N=3	N=2
Yes	1 (50)	0 (0)	1 (100)	0 (0)	1 (50)
Frequency of injection last month (%)					
Not last month	0 (0)	0 (0)	2 (6)	4 (5)	7 (9)
Less than weekly	5 (17)	5 (25)	3 (10)	8 (11)	13 (17)
Weekly not daily	2 (7)	4 (20)	6 (19)	11 (15)	15 (19)
Daily or more	22 (76)	11 (55)	20 (65)	52 (69)	42 (55)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 83 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=29	N=20	N=31	N=75	N=77
Anabolic steroids	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Heroin	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)
Methadone	4 (14)	0 (0)	5 (16)	4 (5)	7 (9)
Methamphetamine	8 (28)	7 (35)	5 (16)	13 (17)	20 (26)
Pharm. Opioids	14 (48)	12 (60)	16 (52)	47 (63)	38 (49)
Subutex/Buprenorphine	1 (3)	0 (0)	4 (13)	1 (1)	1 (1)
More than one	0 (0)	1 (5)	0 (0)	2 (3)	1 (1)
Other	1 (3)	0 (0)	0 (0)	4 (5)	2 (3)
Not reported	1 (3)	0 (0)	1 (3)	2 (3)	4 (5)
N° Injected last month	N=29	N=17	N=29	N=71	N=70
Places injected last month (%)*					
Own home	24 (83)	16 (94)	26 (93)	67 (94)	62 (89)
Friend's home	9 (31)	9 (53)	8 (29)	27 (38)	34 (49)
Dealer's home	2 (7)	4 (24)	1 (4)	9 (13)	13 (19)
Street, park, beach	2 (7)	3 (18)	1 (4)	7 (10)	11 (16)
Car	3 (10)	4 (24)	3 (11)	8 (11)	18 (26)
Public toilet	1 (3)	2 (12)	6 (21)	9 (13)	9 (13)
Commercial injecting room	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Squat	2 (7)	0 (0)	0 (0)	1 (1)	3 (4)
Use of new sterile needles & syringes last month (%)					
All injections	26 (90)	15 (75)	26 (90)	61 (86)	59 (84)
Most of the time	1 (3)	4 (20)	2 (7)	9 (13)	9 (13)
Half of the time	2 (7)	0 (0)	1 (3)	0 (0)	1 (1)
Some of the time	0 (0)	0 (0)	0 (0)	1 (1)	1 (1)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)
Re-used another's used needle & syringe last month (%)					
None	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)
Once	0 (0)	0 (0)	0 (0)	1 (1)	5 (7)
Twice	0 (0)	0 (0)	0 (0)	2 (3)	0 (0)
3-5 times	1 (3)	0 (0)	1 (3)	3 (4)	1 (1)
>5 times	0 (0)	1 (5)	0 (0)	0 (0)	1 (1)
Not reported	1 (3)	1 (5)	2 (7)	0 (0)	1 (1)
Number of people needle & syringe was re-used after last month (%)					
None	27 (93)	18 (90)	26 (90)	65 (92)	62 (89)
One	0 (0)	0 (0)	0 (0)	2 (3)	2 (3)
Two	1 (3)	0 (0)	0 (0)	1 (1)	0 (0)
Three to five	0 (0)	1 (5)	0 (0)	1 (1)	0 (0)
More than five	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Don't know	0 (0)	0 (0)	0 (0)	1 (1)	2 (3)
Not reported	1 (3)	1 (5)	3 (10)	0 (0)	4 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	0 (0)	1 (5)	0 (0)	3 (4)	1 (1)
Casual sex partner	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Close friend	1 (3)	0 (0)	0 (0)	2 (3)	0 (0)
Acquaintance	1 (3)	1 (5)	0 (0)	2 (3)	0 (0)
Other	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Equipment used after someone else last month (%)*					
Spoon	8 (28)	3 (16)	4 (17)	18 (26)	12 (18)
Water	4 (14)	0 (0)	1 (4)	5 (7)	4 (6)
Filter	3 (10)	2 (11)	1 (4)	6 (9)	8 (12)
Drug mix	5 (17)	1 (5)	1 (4)	5 (7)	4 (6)
Tourniquet	7 (24)	1 (5)	1 (4)	14 (21)	10 (15)
None**	0 (0)	14 (74)	16 (67)	38 (56)	47 (71)
Injected by someone after that person injected themselves or others last month (%)					
No	26 (90)	18 (90)	22 (76)	59 (83)	58 (83)
Yes	2 (7)	0 (0)	4 (14)	11 (15)	11 (16)
Not reported	1 (3)	2 (10)	3 (10)	1 (1)	1 (1)

\* More than one option could be selected

\*\* New variable in 2006

Table 84 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=29	N=20	N=31	N=75	N=77
Any treatment/therapy for drug use (%)					
No	13 (45)	12 (60)	13 (42)	22 (29)	21 (27)
Yes	16 (55)	8 (40)	17 (55)	53 (71)	55 (71)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	1 (1)
History of methadone maintenance treatment					
Currently	4 (14)	1 (5)	4 (13)	12 (16)	12 (16)
Previously	10 (34)	2 (10)	10 (32)	18 (24)	14 (18)
Never	15 (52)	17 (85)	16 (52)	45 (60)	49 (64)
Not reported	0 (0)	0 (0)	1 (3)	0 (0)	2 (3)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	13 (17)	3 (4)
Previously	--	--	--	20 (27)	18 (23)
Never	--	--	--	42 (56)	55 (71)
Not reported	--	--	--	0 (0)	1 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	5 (7)	3 (9)
Previously	--	--	--	15 (20)	6 (8)
Never	--	--	--	54 (72)	67 (87)
Not reported	--	--	--	1 (1)	1 (1)

\* New variable in 2008

Table 85 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N <sup>o</sup> surveyed	N=23#	N=60#
Source of needles/syringes (%)*		
Chemist/Pharmacy	0 (0)	7 (12)
Needle Syringe Program	20 (87)	46 (77)
Dispensing/Vending Machine	0 (0)	1 (2)
Friend/Dealer	8 (35)	21 (35)
Other	0 (0)	0 (0)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	0 (0)	2 (29)
Needle Syringe Program	15 (75)	35 (76)
Dispensing/Vending Machine	0 (0)	1 (100)
Friend/Dealer	3 (38)	9 (43)
Other	0 (0)	0 (0)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N <sup>o</sup> Injected last month	N=29	N=70
Secondary exchange	17 (59)	22 (31)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.



Table 86 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=29	N=20	N=31	N=75	N=77
Sex with a regular partner last month (%) **					
No	16 (55)	8 (40)	16 (52)	42 (56)	47 (61)
Yes	12 (41)	12 (60)	13 (42)	33 (44)	26 (34)
Not reported	1 (3)	0 (0)	2 (6)	0 (0)	4 (5)
Condom used with regular partner last month (%)**					
N <sup>o</sup> surveyed	N=12	N=12	N=13	N=33	N=26
Never	8 (67)	9 (75)	10 (77)	24 (73)	19 (73)
Sometimes	1 (8)	0 (0)	0 (0)	0 (0)	1 (4)
Every time	1 (8)	1 (8)	3 (23)	8 (24)	3 (12)
Not reported	2 (17)	2 (17)	0 (0)	1 (3)	3 (12)
Sex with other partner/s last month (%)**					
No	25 (86)	16 (80)	24 (77)	66 (88)	65 (84)
Yes	4 (14)	4 (20)	6 (19)	7 (9)	6 (8)
Not reported	0 (0)	0 (0)	1 (3)	2 (3)	6 (8)
Condom used with other partner/s last month (%)**					
N <sup>o</sup> surveyed	N=4	N=4	N=6	N=7	N=6
Never	3 (75)	1 (25)	2 (33)	2 (29)	2 (33)
Sometimes	0 (0)	1 (25)	0 (0)	3 (43)	1 (17)
Every time	1 (25)	2 (50)	4 (67)	2 (29)	3 (50)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sex work last month (%)					
No	28 (97)	15 (75)	28 (90)	69 (92)	71 (92)
Yes	0 (0)	4 (20)	1 (3)	4 (5)	3 (4)
Not reported	1 (3)	1 (5)	2 (6)	2 (3)	3 (4)
Condom used at last sex work last month (%)**					
Yes	0 (0)	4 (100)	1 (100)	4 (100)	3 (100)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 87 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=29	N=20	N=31	N=75	N=77
Previous HIV test (%)					
Yes, last year	15 (52)	15 (75)	16 (52)	36 (48)	32 (42)
> 1 year ago	12 (41)	4 (20)	12 (39)	25 (33)	33 (43)
Never tested	2 (7)	0 (0)	2 (6)	9 (12)	9 (12)
Not reported	0 (0)	1 (5)	1 (3)	5 (7)	3 (4)
Previous HCV test (%)					
Yes, last year	14 (48)	15 (75)	19 (61)	38 (51)	40 (52)
> 1 year ago	14 (48)	5 (25)	10 (32)	27 (36)	32 (42)
Never tested	1 (3)	0 (0)	1 (3)	5 (7)	3 (4)
Not reported	0 (0)	0 (0)	1 (3)	5 (7)	2 (3)
Any treatment for HCV (%)	N=13	N=4	N=17	N=36	N=32
Interferon	0 (0)	0 (0)	0 (0)	2 (6)	0 (0)
Interferon+Ribarvarin	0 (0)	0 (0)	0 (0)	1 (3)	2 (6)
Other	1 (8)	0 (0)	2 (12)	2 (6)	0 (0)
No treatment	12 (92)	3 (75)	12 (71)	31 (86)	30 (94)
Not reported	0 (0)	1 (25)	3 (18)	0 (0)	0 (0)
Current treatment for HCV	N = 0	N=0	N=1	N=2	N=0
Interferon/Interferon+Ribarvirin	0 (0)	0 (0)	1	1	0
Other	0 (0)	0 (0)	0 (0)	1	0

## HIV antibody prevalence

Table 88 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
2006	9	0 (0.0)	11	0 (0.0)	20	0 (0.0)
2007	20	0 (0.0)	9	0 (0.0)	29	0 (0.0)
2008	46	1 (2.2)	27	0 (0.0)	73	1 (1.4)
2009	51	0 (0.0)	25	0 (0.0)	76	0 (0.0)
$\chi^2$ trend p value		0.860		---		0.823

\* Total includes people whose gender was not reported or reported as transgender

## HCV antibody prevalence

Table 89 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	15	6 (40)	9	6 (67)	24	12 (50)
2006	7	4 (57)	10	1 (10)	17	5 (29)
2007	20	13 (65)	9	5 (56)	29	18 (62)
2008	46	23 (50)	26	15 (58)	72	38 (53)
2009	50	20 (40)	25	9 (36)	75	29 (39)
$\chi^2$ trend p value		0.495		0.753		0.480

\* Total includes people whose gender was not reported or reported as transgender

Table 90 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	14	6 (43)	8	5 (63)	22	11 (50)
Bisexual	0	0 (0)	1	1 (100)	1	1 (100)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.400		0.500		0.600
2006						
Heterosexual	6	4 (67)	5	0 (0)	11	4 (36)
Bisexual	0	0 (0)	4	0 (0)	4	0 (0)
Homosexual	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.429		0.100		0.413
2007						
Heterosexual	18	13 (72)	9	5 (56)	27	18 (67)
Bisexual	0	0 (0)	0	0 (0)	0	0 (0)
Homosexual	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.316		---		0.357
2008						
Heterosexual	40	22 (55)	19	11 (58)	59	33 (56)
Bisexual	1	0 (0)	3	2 (67)	4	2 (50)
Homosexual	2	0 (0)	3	2 (67)	5	2 (40)
p value		0.108		1.000		0.867
2009						
Heterosexual	46	19 (41)	18	7 (39)	64	26 (41)
Bisexual	2	1 (50)	3	1 (33)	5	2 (40)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.826

\* Total includes people whose gender was not reported or reported as transgender

Table 91 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	0	0 (0)	2	2 (100)	2	2 (100)
25 – 29	1	0 (0)	0	0 (0)	1	0 (0)
30 + years	14	6 (43)	7	4 (57)	21	10 (48)
p value		0.400		0.300		0.200
2006						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	0	0 (0)	0	0 (0)	0	0 (0)
25 – 29	2	1 (50)	4	0 (0)	6	1 (17)
30 + years	5	3 (60)	6	1 (17)	11	4 (36)
p value		1.000		1.000		0.600
2007						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	0	0 (0)	0	0 (0)	0	0 (0)
25 – 29	3	1 (33)	3	2 (67)	6	3 (50)
30 + years	17	12 (71)	6	3 (50)	23	15 (65)
p value		0.270		1.000		0.646
2008						
< 20 years	1	0 (0)	1	0 (0)	2	0 (0)
20 – 24	0	0 (0)	1	1 (100)	1	1 (100)
25 – 29	5	2 (40)	1	0 (0)	6	2 (33)
30 + years	40	21 (53)	23	14 (61)	63	35 (56)
p value		0.665		0.381		0.190
2009						
< 20 years	2	0 (0)	2	1 (50)	4	1 (25)
20 – 24	0	0 (0)		0 (0)	0	0 (0)
25 – 29	3	0 (0)	6	2 (33)	9	2 (22)
30 + years	45	20 (44)	17	6 (35)	62	26 (42)
p value		0.203		1.000		0.560

\* Total includes people whose gender was not reported or reported as transgender

Table 92 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	2	0 (0)	1	0 (0)	3	0 (0)
3 to 5 years	2	1 (50)	0	0 (0)	2	1 (50)
6 to 10 years	0	0 (0)	2	1 (50)	2	1 (50)
10 + years	10	5 (50)	6	5 (83)	16	10 (63)
p value		0.300		0.200		0.400
2006						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	0	0 (0)	0	0 (0)	0	0 (0)
6 to 10 years	1	1 (100)	4	0 (0)	5	1 (20)
10 + years	6	3 (50)	6	1 (17)	12	4 (33)
p value		1.000		1.000		1.000
2007						
<3 years	0	0 (0)	0	0 (0)	0	0 (0)
3 to 5 years	1	1 (100)	2	1 (50)	3	2 (67)
6 to 10 years	2	0 (0)	1	1 (100)	3	1 (33)
10 + years	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.123		1.000		0.792
2008						
<3 years	0	0 (0)	1	0 (0)	1	0 (0)
3 to 5 years	3	1 (33)	0	0 (0)	3	1 (33)
6 to 10 years	7	0 (0)	5	4 (80)	12	4 (33)
10 + years	34	22 (65)	20	11 (55)	54	33 (61)
p value		0.002		0.337		0.183
2009						
<3 years	2	0 (0)	2	1 (50)	4	1 (25)
3 to 5 years	1	1 (100)	1	0 (0)	2	1 (50)
6 to 10 years	3	0 (0)	4	1 (25)	7	1 (14)
10 + years	42	19 (45)	16	7 (44)	58	26 (45)
p value		0.147		0.882		0.479

\* Total includes people whose gender was not reported or reported as transgender

Table 93 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	No tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	1	0 (0)	5	3 (60)	6	3 (50)
More than one	0	0 (0)	0	0 (0)	0	0 (0)
Other/Not reported	2	0 (0)	16	9 (56)	18	9 (50)
p value		0.080		0.060		0.030
2006						
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	0	0 (0)	6	1 (17)	6	1 (17)
More than one	0	0 (0)	1	1 (100)	1	1 (100)
Other/Not reported	0	0 (0)	10	3 (30)	10	3 (30)
p value		---		0.360		0.360
2007						
Heroin	0	0 (0)	0	0 (0)	0	0 (0)
Methamphetamine	0	0 (0)	4	1 (25)	5	2 (40)
More than one	0	0 (0)	0	0 (0)	0	0 (0)
Other/Not reported	0	0 (0)	24	16 (67)	24	16 (67)
p value		---		0.269		0.339
2008						
Heroin	0	0 (0)	11	2 (18)	12	2 (17)
Methamphetamine	1	0 (0)	2	1 (50)	2	1 (50)
More than one	0	0 (0)	2	1 (50)	2	1 (50)
Other/Not reported	0	0 (0)	54	34 (63)	56	34 (61)
p value		---		0.016		0.015
2009						
Heroin	0	0 (0)	2	0 (0)	2	0 (0)
Methamphetamine	2	0 (0)	17	3 (18)	19	3 (16)
More than one	0	0 (0)	0	0 (0)	1	0 (0)
Other/Not reported	2	1 (50)	48	25 (52)	53	26 (49)
p value		1.000		0.019		0.016

\* Total includes people who did not report duration of drug injection

## Northern Territory

Table 94 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	0	0 (0)	5	3 (60)	5	3 (60)
Daily or more	3	0 (0)	15	9 (60)	19	9 (47)
p value		---		0.900		0.600
2006						
Less than daily	0	0 (0)	8	1 (13)	8	1 (13)
Daily or more	0	0 (0)	9	4 (44)	9	4 (44)
p value		---		0.294		0.294
2007						
Less than daily	0	0 (0)	9	5 (56)	9	5 (56)
Daily or more	0	0 (0)	17	11 (65)	18	12 (63)
p value		---		0.692		0.683
2008						
Less than daily	1	0 (0)	17	7 (41)	18	7 (39)
Daily or more	0	0 (0)	49	30 (61)	51	30 (59)
p value		---		0.169		0.176
2009						
Less than daily	1	0 (0)	26	14 (54)	28	14 (50)
Daily or more	2	1 (50)	38	14 (37)	41	15 (37)
p value		1.000		0.207		0.325

\* Total includes people who did not report duration of drug injection

Table 95 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's</b> used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	3	0 (0)	18	10 (56)	22	10 (45)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
p value		-		0.400		0.300
2006						
No receptive sharing	0	0 (0)	15	5 (33)	15	5 (33)
Receptive sharing	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		1.000		1.000
2007						
No receptive sharing	0	0 (0)	23	14 (61)	24	15 (63)
Receptive sharing	0	0 (0)	1	1 (100)	1	1 (100)
p value		---		1.000		1.000
2008						
No receptive sharing	0	0 (0)	61	33 (54)	63	33 (52)
Receptive sharing	1	1 (100)	5	4 (80)	6	4 (67)
p value		---		0.375		0.679
2009						
No receptive sharing	3	1 (33)	57	23 (40)	61	24 (39)
Receptive sharing	0	0 (0)	6	4 (67)	7	4 (57)
p value		--		0.388		0.435

\* Total includes people who did not report duration of drug injection

Table 96 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No imprisonment	3	0(0)	18	10 (56)	22	10 (45)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value				0.400		0.300
2006						
No imprisonment	0	0 (0)	16	5 (31)	16	5 (31)
Imprisonment	0	0 (0)	1	1 (100)	1	1 (100)
p value		---		1.000		1.000
2007						
No imprisonment	0	0 (0)	27	17 (63)	27	17 (63)
Imprisonment	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
No imprisonment	1	0 (0)	65	35 (54)	66	35 (53)
Imprisonment	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No imprisonment	4	1 (25)	62	24 (39)	70	25 (36)
Imprisonment	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.161		0.137

\* Total includes people who did not report duration of drug injection

Table 97 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	3	0 (0)	19	11 (58)	23	11 (48)
Sex work	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2006						
No sex work	0	0 (0)	13	4 (31)	13	4 (31)
Sex work	0	0 (0)	4	1 (25)	4	1 (25)
p value		---		1.000		1.000
2007						
No sex work	0	0 (0)	25	17 (68)	26	18 (69)
Sex work	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.346		0.333
2008						
No sex work	1	0 (0)	65	35 (54)	66	35 (53)
Sex work	0	0 (0)	2	2 (100)	3	2 (67)
p value		---		0.498		1.000
2009						
No sex work	4	1 (25)	61	26 (43)	69	27 (39)
Sex work	0	0 (0)	3	0 (0)	3	0 (0)
p value		---		0.265		0.287

\* Total includes people who did not report duration of drug injection

Table 98 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	14	6 (43)	9	6 (67)	23	12 (52)
Indigenous	1	0 (0)	0	0 (0)	1	0 (0)
p value		0.400		---		0.400
2006						
Non Indigenous	7	4 (57)	7	1 (14)	14	5 (36)
Indigenous	0	0 (0)	3	0 (0)	3	0 (0)
p value		---		1.000		0.515
2007						
Non Indigenous	19	13 (68)	9	5 (56)	28	18 (64)
Indigenous	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2008						
Non Indigenous	39	21 (54)	20	12 (60)	59	33 (56)
Indigenous	7	2 (29)	6	3 (50)	13	5 (38)
p value		0.414		1.000		0.359
2009						
Non Indigenous	40	17 (43)	23	9 (39)	63	26 (41)
Indigenous	8	1 (13)	2	0 (0)	10	1 (10)
p value		0.229		0.520		0.080

\* Total includes people whose gender was not reported or reported as transgender



Table 99 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	15	6 (40)	9	6 (67)	15	6 (67)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2006						
Australia	6	3 (50)	10	1 (10)	16	4 (25)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	0	0 (0)	0	0 (0)	0	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		1.000		---		0.294
2007						
Australia	17	12 (71)	9	5 (56)	26	17 (65)
Other Oceania	1	1 (100)	0	0 (0)	1	1 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	0 (0)	0	0 (0)	1	0 (0)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.544		---		0.595
2008						
Australia	39	20 (51)	23	13 (57)	62	33 (53)
Other Oceania	2	1 (50)	0	0 (0)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	3	1 (33)	1	0 (0)	4	1 (25)
p value		1.000		0.697		0.747
2009						
Australia	40	14 (35)	23	8 (35)	63	22 (35)
Other Oceania	1	1 (100)	1	1 (100)	2	2 (100)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	2	1 (50)	0	0 (0)	2	1 (50)
Other	4	3 (75)	0	0 (0)	4	3 (75)
p value		0.283		0.600		0.109

\* Total includes people whose gender was not reported or reported as transgender

Table 100 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	12	6 (50)	9	6 (67)	21	12 (57)
Non-English speaking	3	0 (0)	0	0 (0)	3	0 (0)
p value		0.100		----		0.060
2006						
English speaking	6	4 (67)	9	1 (11)	15	5 (33)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2007						
English speaking	18	12 (67)	9	5 (56)	27	17 (63)
Non-English speaking	1	1 (100)	0	0 (0)	1	1 (100)
p value		1.000		---		1.000
2008						
English speaking	46	23 (50)	26	15 (58)	72	38 (53)
Non-English speaking	0	0 (0)	0	0 (0)	0	0 (0)
p value		---		---		---
2009						
English speaking	44	16 (36)	24	9 (38)	68	25 (37)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		0.363		1.000		0.667

\* Total includes people whose gender was not reported or reported as transgender

## Queensland

Table 101 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	7	7	7	8	8
N <sup>o</sup> surveyed	N=291	N=501	N=417	N=508	N=801
Response (%)	35	34	36	37	59
Gender (%)					
Male	198 (68)	353 (70)	282 (68)	341 (67)	585 (73)
Female	91 (31)	145 (29)	131 (31)	165 (32)	211 (26)
Transgender	1 (0)	2 (<1)	3 (<1)	1 (<1)	1 (<1)
Not reported	1 (0)	1 (<1)	1 (<1)	1 (<1)	4 (<1)
Sexual identity (%)					
Heterosexual	236 (81)	411 (82)	350 (84)	436 (86)	868 (86)
Bisexual	23 (8)	37 (7)	32 (8)	40 (8)	63 (8)
Homosexual	19 (7)	39 (8)	25 (6)	21 (4)	10 (1)
Not reported	13 (4)	14 (3)	10 (2)	11 (2)	42 (5)
Age and duration of injection (years)					
<i>Median age</i>	32	33	35	34	34
Age range	16-63	13-57	17-60	16-60	15-66
<i>Age group (%)</i>					
<25 years	43 (15)	75 (15)	49 (12)	68 (13)	117 (15)
25+ years	248 (85)	425 (85)	367 (88)	438 (86)	684 (85)
Not reported	0 (0)	1 (<1)	1 (<1)	2 (<1)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	18	18	18	18	18
Age range	11-50	10-52	11-44	10-57	10-58
Not reported	9	1	12	7	19
<i>Median years IDU</i>	13	13	14	14	14
Range	<1-37	<1-43	<1-38	<1-40	<1-46
Duration of drug injection					
<3 years	18 (6)	39 (8)	32 (8)	29 (6)	58 (7)
3+ years	258 (89)	442 (88)	373 (89)	471 (93)	724 (90)
Not reported	15 (5)	20 (4)	12 (3)	8 (2)	19 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	273 (94)	438 (87)	375 (90)	459 (90)	675 (84)
Yes	14 (5)	49 (10)	38 (10)	32 (6)	105 (13)
Not reported	4 (1)	14 (3)	4 (<1)	17 (3)	21 (3)
Region/Country of birth (%)					
Australia	259 (89)	436 (87)	374 (90)	431 (85)	698 (87)
Other Oceania	11 (4)	21 (4)	15 (4)	25 (5)	40 (5)
Asia	2 (1)	4 (<1)	1 (<1)	5 (1)	5 (<1)
UK & Ireland	13 (4)	18 (4)	14 (3)	22 (4)	24 (3)
Other	5 (2)	12 (2)	10 (2)	14 (3)	21 (3)
Not reported	1 (<1)	10 (2)	3 (<1)	11 (2)	13 (2)
Main language spoken at home by parents (%)					
English speaking	259 (89)	465 (93)	395 (95)	489 (96)	768 (96)
Non-English speaking	32 (11)	17 (3)	17 (4)	13 (3)	24 (3)
Not reported	0 (0)	19 (4)	5 (1)	6 (1)	9 (1)
Imprisonment last year (%)					
No	250 (86)	412 (82)	363 (87)	418 (82)	656 (82)
Yes	34 (12)	67 (13)	43 (10)	56 (11)	111 (14)
Not reported	7 (2)	22 (4)	11 (3)	34 (7)	34 (4)
Injected in prison (%)	N=34	N=67	N=43	N=56	N=111
Yes	14 (41)	27 (40)	22 (51)	20 (36)	51 (46)
Frequency of injection last month (%)					
Not last month	35 (12)	61 (12)	32 (8)	50 (10)	74 (9)
Less than weekly	45 (15)	100 (20)	70 (17)	80 (16)	123 (15)
Weekly not daily	89 (31)	96 (19)	119 (29)	137 (27)	173 (22)
Daily or more	120 (41)	243 (49)	188 (45)	234 (46)	426 (53)
Not reported	2 (1)	1 (<1)	8 (2)	7 (1)	5 (<1)

Table 102 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=291	N=501	N=417	N=508	N=801
Anabolic steroids	6 (2)	13 (3)	5 (1)	11 (2)	9 (1)
Cocaine	1 (<1)	2 (<1)	1 (<1)	2 (<1)	7 (<1)
Heroin	85 (29)	115 (23)	106 (25)	124 (24)	218 (27)
Methadone	10 (3)	24 (5)	19 (5)	32 (6)	38 (5)
Methamphetamine	116 (40)	197 (39)	145 (35)	171 (34)	232 (29)
Pharm. Opioids	43 (14)	94 (19)	96 (23)	120 (24)	177 (22)
Subutex/Buprenorphine	10 (3)	30 (6)	28 (7)	26 (5)	53 (7)
More than one	8 (3)	4 (<1)	2 (<1)	11 (2)	30 (4)
Other	2 (<1)	2 (<1)	6 (1)	6 (1)	20 (2)
Not reported	9 (3)	15 (3)	9 (2)	5 (1)	17 (2)
N° Injected last month	N=254	N=439	N=377	N=451	N=722
Places injected last month (%)*					
Own home	202 (80)	355 (85)	328 (88)	410 (91)	591 (83)
Friend's home	97 (38)	165 (40)	159 (43)	172 (38)	309 (43)
Dealer's home	38 (15)	65 (16)	53 (14)	66 (15)	131 (18)
Street, park, beach	57 (22)	88 (21)	65 (17)	73 (16)	186 (26)
Car	77 (30)	126 (30)	134 (36)	137 (31)	218 (31)
Public toilet	66 (26)	94 (23)	73 (20)	71 (16)	184 (26)
Commercial injecting room	2 (1)	1 (<1)	3 (<1)	2 (<1)	7 (1)
Squat	25 (10)	35 (8)	17 (5)	13 (3)	62 (9)
Use of new sterile needles & syringes last month (%)					
All injections	187 (74)	332 (76)	282 (75)	329 (73)	532 (74)
Most of the time	55 (22)	85 (19)	71 (19)	107 (24)	151 (21)
Half of the time	5 (2)	9 (2)	9 (2)	7 (2)	10 (1)
Some of the time	4 (2)	2 (<1)	2 (<1)	2 (<1)	14 (2)
Not last month	1 (<1)	1 (<1)	3 (<1)	2 (<1)	5 (<1)
Not reported	2 (1)	10 (2)	10 (3)	4 (1)	10 (1)
Re-used another's used needle & syringe last month (%)					
None	206 (82)	349 (80)	316 (84)	388 (86)	579 (80)
Once	10 (4)	29 (7)	16 (4)	24 (5)	37 (5)
Twice	9 (4)	18 (4)	12 (3)	14 (3)	23 (5)
3-5 times	11 (4)	16 (4)	16 (4)	7 (2)	32 (4)
>5 times	8 (3)	9 (2)	9 (2)	13 (3)	31 (4)
Not reported	8 (3)	18 (4)	8 (2)	5 (1)	20 (3)
Number of people needle & syringe was re-used after last month (%)					
None	196 (77)	349 (80)	316 (84)	388 (86)	579 (80)
One	22 (9)	33 (8)	28 (7)	35 (8)	63 (9)
Two	1 (<1)	3 (<1)	5 (1)	0 (0)	11 (2)
Three to five	5 (2)	2 (<1)	2 (<1)	3 (1)	7 (1)
More than five	1 (<1)	2 (<1)	1 (<1)	3 (1)	5 (<1)
Don't know	14 (6)	12 (3)	8 (2)	9 (2)	16 (2)
Not reported	15 (6)	38 (9)	17 (5)	13 (3)	41 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	21 (8)	29 (7)	26 (7)	26 (6)	52 (7)
Casual sex partner	0 (0)	4 (<1)	2 (<1)	1 (<1)	1 (<1)
Close friend	8 (3)	12 (3)	13 (3)	13 (3)	43 (6)
Acquaintance	6 (2)	1 (<1)	0 (0)	7 (2)	8 (1)
Other	3 (1)	2 (<1)	5 (1)	3 (1)	6 (<1)
Equipment used after someone else last month (%)*					
Spoon	68 (27)	83 (20)	80 (23)	85 (21)	187 (28)
Water	45 (18)	67 (16)	50 (15)	61 (15)	132 (20)
Filter	38 (15)	51 (12)	53 (15)	48 (12)	100 (15)
Drug mix	32 (13)	35 (8)	33 (10)	32 (8)	65 (10)
Tourniquet	26 (10)	41 (10)	27 (8)	39 (9)	56 (9)
None**	---	268 (63)	239 (69)	280 (68)	389 (59)
Injected by someone after that person injected themselves or others last month (%)					
No	212 (83)	358 (82)	314 (83)	381 (84)	575 (80)
Yes	31 (12)	65 (15)	52 (14)	62 (14)	133 (18)
Not reported	11 (4)	16 (4)	11 (3)	8 (2)	14 (2)

\* More than one option could be selected

\*\* New variable in 2006

Table 103 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use		2005	2006	2007	2008
N° surveyed	N=291	N=501	N=417	N=508	N=801
Any treatment/therapy for drug use (%)					
No	73 (25)	115 (23)	86 (21)	124 (24)	182 (23)
Yes	215 (74)	374 (75)	323 (77)	374 (74)	606 (76)
Not reported	3 (1)	12 (2)	8 (2)	10 (2)	13 (2)
History of methadone maintenance treatment (%)					
Currently	62 (21)	91 (18)	94 (23)	92 (18)	143 (18)
Previously	87 (30)	140 (28)	132 (32)	129 (25)	189 (24)
Never	137 (47)	253 (51)	189 (45)	272 (54)	453 (57)
Not reported	5 (2)	17 (3)	2 (<1)	15 (3)	16 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	60 (12)	115 (14)
Previously	--	--	--	125 (25)	173 (22)
Never	--	--	--	309 (61)	497 (62)
Not reported	--	--	--	14 (3)	16 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	43 (8)	70 (9)
Previously	--	--	--	75 (15)	153 (19)
Never	--	--	--	376 (74)	560 (70)
Not reported	--	--	--	14 (3)	18 (2)

\* New variable in 2008

Table 104 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=325#	N=639#
Source of needles/syringes (%)*		
Chemist/Pharmacy	96 (30)	234 (37)
Needle Syringe Program	276 (85)	461 (72)
Dispensing/Vending	37 (11)	71 (11)
Friend/Dealer	62 (19)	133 (21)
Other	16 (5)	18 (3)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	16 (17)	64 (27)
Needle Syringe Program	172 (62)	256 (56)
Dispensing/Vending Machine	5 (14)	4 (6)
Friend/Dealer	7 (11)	20 (15)
Other	5 (31)	3 (17)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=377	N=722
Secondary exchange	219 (58)	271 (38)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

## Queensland

Table 105 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	209
N <sup>o</sup> surveyed	N=291	N=501	N=417	N=508	N=801
Sex with a regular partner last month (%) **					
No	135 (46)	200 (40)	178 (43)	228 (45)	358 (45)
Yes	154 (53)	284 (57)	224 (54)	261 (51)	414 (52)
Not reported	2 (1)	17 (3)	15 (4)	19 (4)	29 (4)
Condom used with regular partner last month (%)**					
N <sup>o</sup> surveyed	N=154	N=284	N=224	N=261	N=414
Never	110 (71)	191 (67)	165 (74)	191 (73)	293 (71)
Sometimes	18 (12)	49 (17)	31 (14)	25 (10)	58 (14)
Every time	21 (14)	29 (10)	21 (9)	27 (10)	41 (10)
Not reported	5 (3)	15 (5)	7 (3)	18 (7)	22 (5)
Sex with other partner/s last month (%)**					
No	246 (85)	410 (82)	347 (83)	417 (82)	653 (82)
Yes	38 (13)	68 (14)	61 (15)	68 (13)	117 (15)
Not reported	7 (2)	23 (5)	9 (2)	23 (5)	31 (4)
Condom used with other partner/s last month (%)**					
N <sup>o</sup> surveyed	N=38	N=68	N=61	N=68	N=117
Never	9 (24)	17 (25)	20 (33)	21 (31)	40 (34)
Sometimes	9 (24)	15 (22)	22 (36)	16 (24)	40 (34)
Every time	18 (47)	32 (47)	16 (26)	28 (41)	36 (31)
Not reported	2 (5)	4 (6)	3 (5)	3 (4)	1 (<1)
Sex work last month (%)					
No	275 (95)	458 (91)	387 (93)	455 (90)	740 (92)
Yes	9 (3)	20 (4)	20 (5)	14 (3)	30 (4)
Not reported	7 (2)	23 (5)	10 (2)	39 (8)	31 (4)
Condom used at last sex work last month (%)**					
Yes	32 (94)	17 (85)	11 (65)	12 (86)	18 (69)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 106 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=291	N=501	N=417	N=508	N=801
Previous HIV test (%)					
Yes, last year	179 (62)	297 (59)	239 (57)	258 (51)	410 (51)
> 1 year ago	83 (29)	159 (32)	135 (32)	176 (35)	239 (30)
Never tested	29 (10)	37 (7)	40 (10)	49 (10)	126 (16)
Not reported	0 (0)	8 (2)	3 (<1)	25 (5)	26 (3)
Previous HCV test (%)					
Yes, last year	185 (64)	297 (59)	258 (62)	289 (57)	446 (56)
> 1 year ago	77 (26)	154 (31)	123 (30)	160 (32)	249 (31)
Never tested	28 (10)	38 (8)	32 (8)	36 (7)	85 (11)
Not reported	1 (<1)	12 (2)	4 (1)	23 (5)	21 (9)
Any treatment for HCV (%)	N=129	N=207	N=188	N=238	N=351
Interferon	2 (2)	4 (2)	4 (2)	7 (3)	7 (2)
Interferon+Ribarvarin	5 (4)	8 (4)	8 (4)	11 (5)	18 (5)
Other	7 (5)	3 (1)	5 (3)	2 (1)	6 (2)
No treatment	112 (87)	187 (90)	163 (87)	211 (89)	300 (85)
Not reported	3 (2)	5 (2)	8 (4)	7 (3)	20 (6)
Current treatment for HCV	N=6	N=5	N=4	N=1	N=8
Interferon/Interferon+Ribarvirin	3	3	4	1	6
Other	3	2	0	0	2

## HIV antibody prevalence

Table 107 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	188	4 (2.1)	88	0 (0.0)	278	4 (1.4)
2006	350	11 (3.1)	142	1 (0.7)	495	12 (2.4)
2007	279	10 (3.6)	130	0 (0.0)	413	10 (2.4)
2008	335	9 (2.7)	161	0 (0.0)	498	9 (1.8)
2009	581	10 (1.7)	209	0 (0.0)	795	10 (1.3)
$\chi^2$ trend p value		0.298		0.326		0.291

\* Total includes people whose gender was not reported or reported as transgender

Table 108 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heterosexual	159	1 (0.6)	67	0 (0.0)	227	1 (0.4)
Bisexual	8	0 (0.0)	14	0 (0.0)	22	0 (0.0)
Homosexual	12	3 (25.0)	5	0 (0.0)	17	3 (17.7)
p value		<0.001		---		<0.001
2006						
Heterosexual	303	0 (0.0)	104	0 (0.0)	408	0 (0.0)
Bisexual	11	0 (0.0)	22	1 (4.5)	34	1 (2.9)
Homosexual	26	11 (42.3)	12	0 (0.0)	39	11 (28.2)
p value		<0.001		0.246		<0.001
2007						
Heterosexual	249	1 (0.4)	98	0 (0.0)	347	1 (0.3)
Bisexual	7	1 (14.3)	22	0 (0.0)	31	1 (3.2)
Homosexual	18	8 (44.4)	6	0 (0.0)	25	8 (32.0)
p value		<0.001		---		<0.001
2008						
Heterosexual	302	0 (0.0)	127	0 (0.0)	430	0 (0.0)
Bisexual	10	2 (20)	27	0 (0.0)	37	2 (5.4)
Homosexual	17	7 (41)	4	0 (0.0)	21	7 (33)
p value		<0.001		---		<0.001
2009						
Heterosexual	519	1 (0.2)	162	0 (0.0)	682	1 (0.2)
Bisexual	24	2 (8.3)	37	0 (0.0)	62	2 (3.2)
Homosexual	9	6 (67.0)	1	0 (0.0)	10	6 (60.0)
p value		<0.001		---		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 109 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
< 20 years	3	0 (0.0)	4	0 (0.0)	7	0 (0.0)
20 – 24	26	0 (0.0)	10	0 (0.0)	36	0 (0.0)
25 – 29	41	0 (0.0)	22	0 (0.0)	63	0 (0.0)
30 + years	118	4 (3.4)	52	0 (0.0)	172	4 (2.3)
p value		0.500		---		0.500
2006						
< 20 years	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
20 – 24	35	1 (2.9)	22	0 (0.0)	57	1 (1.8)
25 – 29	68	0 (0.0)	27	0 (0.0)	96	0 (0.0)
30 + years	235	10 (4.3)	87	1 (1)	324	11 (3.4)
p value		0.356		1.000		0.267
2007						
< 20 years	6	0 (0.0)	1	0 (0.0)	7	0 (0.0)
20 – 24	2	0 (0.0)	14	0 (0.0)	42	0 (0.0)
25 – 29	48	0 (0.0)	19	0 (0.0)	67	0 (0.0)
30 + years	196	10 (5.1)	96	0 (0.0)	296	10 (3.4)
p value		0.397		---		0.365
2008						
< 20 years	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
20 – 24	27	0 (0.0)	21	0 (0.0)	48	0 (0.0)
25 – 29	55	0 (0.0)	29	0 (0.0)	84	0 (0.0)
30 + years	241	9 (3.7)	105	0 (0.0)	348	9 (2.6)
p value		0.507		---		0.452
2009						
< 20 years	20	0 (0.0)	10	0 (0.0)	31	0 (0.0)
20 – 24	55	0 (0.0)	29	0 (0.0)	85	0 (0.0)
25 – 29	90	0 (0.0)	40	0 (0.0)	130	0 (0.0)
30 + years	416	10 (2.4)	130	0 (0.0)	549	10 (1.8)
p value		0.426		---		0.354

\* Total includes people whose gender was not reported or reported as transgender



Table 110 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<3 years	13	1 (7.7)	3	0 (0.0)	16	1 (6.3)
3 to 5 years	25	0 (0.0)	18	0 (0.0)	43	0 (0.0)
6 to 10 years	16	0 (0.0)	11	0 (0.0)	27	0 (0.0)
10 + years	124	3 (2.4)	51	0 (0.0)	177	3 (1.7)
p value		0.400		---		0.300
2006						
<3 years	25	0 (0.0)	14	0 (0.0)	39	0 (0.0)
3 to 5 years	30	1 (3.3)	16	0 (0.0)	46	1 (2.2)
6 to 10 years	58	2 (3.5)	36	0 (0.0)	94	2 (2.1)
10 + years	219	7 (3.2)	74	1 (1)	296	8 (2.7)
p value		1.000		1.000		0.953
2007						
<3 years	23	1 (4.4)	9	0 (0.0)	32	1 (3.1)
3 to 5 years	15	0 (0.0)	10	0 (0.0)	25	0 (0.0)
6 to 10 years	62	1 (1.6)	24	0 (0.0)	86	1 (1.2)
10 + years	169	7 (4.1)	85	0 (0.0)	258	7 (2.7)
p value		0.791		---		0.799
2008						
<3 years	19	1 (5.3)	10	0 (0.0)	29	1 (3.5)
3 to 5 years	40	1 (2.5)	16	0 (0.0)	56	1 (1.8)
6 to 10 years	55	0 (0.0)	45	0 (0.0)	100	0 (0.0)
10 + years	215	7 (3.3)	88	0 (0.0)	305	7 (2.3)
p value		0.363		---		0.287
2009						
<3 years	36	0 (0.0)	20	0 (0.0)	57	0 (0.0)
3 to 5 years	46	0 (0.0)	19	0 (0.0)	66	0 (0.0)
6 to 10 years	82	1 (1.2)	48	0 (0.0)	131	1 (0.8)
10 + years	404	9 (2.2)	116	0 (0.0)	522	9 (1.7)
p value		0.930		---		0.741

\* Total includes people whose gender was not reported or reported as transgender

Table 111 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with	N° tested	N° with	N° tested	N° with
2005						
Heroin	50	0 (0.0)	38	0 (0.0)	79	0 (0.0)
Methamphetamine	74	1 (1.4)	30	0 (0.0)	114	1 (0.8)
More than one	6	1 (16.7)	1	0 (0.0)	8	1 (12.5)
Other/Not reported	58	2 (3.5)	13	0 (0.0)	77	2 (2.6)
p value		0.070		---		0.050
2006						
Heroin	71	1 (1.4)	41	0 (0.0)	113	1 (0.9)
Methamphetamine	139	7 (5.0)	56	1 (1.8)	195	8 (4.1)
More than one	4	1 (25.0)	0	0 (0.0)	4	1 (25.0)
Other/Not reported	136	2 (1.5)	45	0 (0.0)	183	2 (1.1)
p value		0.043		1.000		0.022
2007						
Heroin	64	0 (0.0)	41	0 (0.0)	106	0 (0.0)
Methamphetamine	97	4 (4.1)	46	0 (0.0)	143	4 (2.8)
More than one	4	0 (0.0)	2	0 (0.0)	6	0 (0.0)
Other/Not reported	114	6 (5.3)	41	0 (0.0)	158	6 (3.8)
p value		0.297		---		0.204
2008						
Heroin	83	1 (1.2)	41	0 (0.0)	124	1 (0.8)
Methamphetamine	107	4 (3.7)	56	0 (0.0)	163	4 (2.5)
More than one	7	1 (14.3)	3	0 (0.0)	10	1 (10.0)
Other/Not reported	138	3 (2.2)	61	0 (0.0)	201	3 (1.5)
p value		0.186		---		0.184
2009						
Heroin	158	1 (0.6)	57	0 (0.0)	216	1 (0.5)
Methamphetamine	169	7 (4.1)	60	0 (0.0)	231	7 (3.0)
More than one	21	0 (0.0)	9	0 (0.0)	30	0 (0.0)
Other/Not reported	233	2 (0.9)	83	0 (0.0)	318	2 (0.6)
p value		0.081		---		0.077

\* Total includes people whose gender was not reported or reported as transgender

Table 112 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Not last month	74	0 (0.0)	40	0 (0.0)	114	0 (0.0)
Less than weekly	61	2 (3.3)	21	0 (0.0)	83	2 (2.4)
Weekly not daily	30	2 (6.7)	13	0 (0.0)	44	2 (4.6)
Daily or more	22	0 (0.0)	13	0 (0.0)	35	0 (0.0)
p value		0.100		---		0.100
2006						
Not last month	39	0 (0.0)	20	0 (0.0)	60	0 (0.0)
Less than weekly	71	6 (8.5)	27	0 (0.0)	99	6 (6.1)
Weekly not daily	70	2 (2.9)	24	1 (4.2)	94	3 (3.2)
Daily or more	169	3 (1.8)	71	0 (0.0)	241	3 (1.3)
p value		0.042		0.310		0.040
2007						
Not last month	24	2 (8.3)	8	0 (0.0)	32	2 (6.3)
Less than weekly	52	4 (7.7)	17	0 (0.0)	70	4 (5.7)
Weekly not daily	73	3 (4.1)	42	0 (0.0)	116	3 (2.6)
Daily or more	123	0 (0.0)	62	0 (0.0)	187	0 (0.0)
p value		0.005		---		0.003
2008						
Not last month	31	0 (0.0)	17	0 (0.0)	48	0 (0.0)
Less than weekly	53	2 (3.8)	25	0 (0.0)	78	2 (2.6)
Weekly not daily	92	5 (5.4)	44	0 (0.0)	136	5 (3.7)
Daily or more	154	2 (1.3)	73	0 (0.0)	229	2 (0.9)
p value		0.197		---		0.190
2009						
Not last month	56	1 (1.8)	18	0 (0.0)	74	1 (1.4)
Less than weekly	82	1 (1.2)	40	0 (0.0)	123	1 (0.8)
Weekly not daily	136	5 (3.7)	36	0 (0.0)	173	5 (2.9)
Daily or more	305	3 (1.0)	112	0 (0.0)	420	3 (0.7)
p value		0.229		---		0.158

\* Total includes people whose gender was not reported or reported as transgender

Table 113 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No receptive sharing	136	4 (2.9)	57	0 (0.0)	194	4 (2.1)
Receptive sharing	25	0 (0.0)	11	0 (0.0)	37	0 (0.0)
p value		0.400		---		0.400
2006						
No receptive sharing	254	9 (3.5)	90	0 (0.0)	345	9 (2.6)
Receptive sharing	44	1 (2.3)	27	0 (0.0)	71	1 (1.4)
p value		1.000		---		1.000
2007						
No receptive sharing	207	7 (3.4)	104	0 (0.0)	314	7 (2.2)
Receptive sharing	34	0 (0.0)	16	0 (0.0)	51	0 (0.0)
p value		0.598		---		0.600
2008						
No receptive sharing	255	8 (3.1)	123	0 (0.0)	380	8 (2.1)
Receptive sharing	40	1 (2.5)	18	0 (0.0)	58	1 (1.7)
p value		1.000		---		1.000
2009						
No receptive sharing	418	9 (2.2)	152	0 (0.0)	574	9 (1.6)
Receptive sharing	94	0 (0.0)	28	0 (0.0)	123	0 (0.0)
p value		0.377		---		0.373

\* Total includes people whose gender was not reported or reported as transgender

Table 114 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No imprisonment	155	4 (2.6)	80	0 (0.0)	237	4 (1.7)
Imprisonment	29	0 (0.0)	5	0 (0.0)	34	0 (0.0)
p value		0.400		---		0.500
2006						
No imprisonment	273	10 (3.7)	130	1 (0.8)	406	11 (2.7)
Imprisonment	57	1 (1.8)	10	0 (0.0)	67	1 (1.5)
p value		0.697		1.000		1.000
2007						
No imprisonment	238	10 (4.2)	118	0 (0.0)	359	10 (2.8)
Imprisonment	32	0 (0.0)	11	0 (0.0)	43	0 (0.0)
p value		0.613		---		0.609
2008						
No imprisonment	276	7 (2.5)	134	0 (0.0)	411	7 (1.7)
Imprisonment	36	1 (2.8)	47	0 (0.0)	53	1 (1.9)
p value		1.000		---		1.000
2009						
No imprisonment	465	10 (2.2)	182	0 (0.0)	652	10 (1.5)
Imprisonment	86	0 (0.0)	24	0 (0.0)	110	0 (0.0)
p value		0.375		---		0.372

\* Total includes people whose gender was not reported or reported as transgender

Table 115 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005**						
No condom use	69	1 (1.5)	40	0 (0.0)	110	1 (0.9)
Condom use	32	1 (3.1)	11	0 (0.0)	43	1 (2.3)
p value		0.600		---		0.500
2006						
No condom use	156	3 (1.9)	77	1 (1.3)	236	4 (1.7)
Condom use	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.399		1.000		0.442
2007						
No condom use	117	1 (0.9)	75	0 (0.0)	194	1 (0.5)
Condom use	14	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
No condom use	133	2 (1.5)	78	0 (0.0)	212	2 (0.9)
Condom use	15	0 (0.0)	9	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000
2009						
No condom use	224	3 (1.3)	118	0 (0.0)	347	3 (0.9)
Condom use	33	2 (6.1)	8	0 (0.0)	41	2 (4.9)
p value		0.125		---		0.089

\* Total includes people whose gender was not reported or reported as transgender

\*\* Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 116 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No sex work	177	4 (2.3)	83	0 (0.0)	262	4 (1.5)
Sex work	5	0 (0.0)	4	0 (0.0)	9	0 (0.0)
p value		0.700		---		0.700
2006						
No sex work	327	11 (3.7)	123	1 (0.8)	452	12 (2.7)
Sex work	6	0 (0.0)	13	0 (0.0)	20	0 (0.0)
p value		1.000		1.000		1.000
2007						
No sex work	263	10 (3.8)	118	0 (0.0)	383	10 (2.6)
Sex work	8	0 (0.0)	10	0 (0.0)	20	0 (0.0)
p value				---		1.000
2008						
No sex work	300	9 (3.0)	144	0 (0.0)	446	9 (2.0)
Sex work	2	0 (0.0)	11	0 (0.0)	13	0 (0.0)
p value		1.000		---		1.000
2009						
No sex work	545	10 (1.8)	188	0 (0.0)	737	10 (1.4)
Sex work	13	0 (0.0)	16	0 (0.0)	30	0 (0.0)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender

## Queensland

Table 117 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Non Indigenous	176	4 (2.3)	82	0 (0.0)	260	4 (1.5)
Indigenous	10	0 (0.0)	4	0 (0.0)	14	0 (0.0)
p value		0.600		---		0.600
2006						
Non Indigenous	306	9 (2.9)	128	1 (0.8)	434	10 (2.3)
Indigenous	34	2 (5.9)	13	0 (0.0)	48	2 (4.2)
p value		0.303		1.000		0.340
2007						
Non Indigenous	250	8 (3.2)	119	0 (0.0)	372	8 (2.2)
Indigenous	26	2 (7.7)	10	0 (0.0)	37	2 (5.4)
p value		0.240		---		0.226
2008						
Non Indigenous	316	9 (2.9)	136	0 (0.0)	453	9 (1.9)
Indigenous	7	0 (0.0)	20	0 (0.0)	28	0 (0.0)
p value		1.000		---		1.000
2009						
Non Indigenous	495	10 (2.0)	172	0 (0.0)	672	10 (1.5)
Indigenous	67	0 (0.0)	35	0 (0.0)	102	0 (0.0)
p value		0.617		---		0.375

\* Total includes people whose gender was not reported or reported as transgender

Table 118 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Australia	163	3 (1.8)	83	0 (0.0)	248	3 (1.2)
Other Oceania	9	0 (0.0)	0	0 (0.0)	9	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
Other	5	0 (0.0)	0	0 (0.0)	5	0 (0.0)
p value		0.400		---		0.400
2006						
Australia	302	8 (2.7)	125	1 (0.8)	430	9 (2.1)
Other Oceania	14	1 (7.1)	7	0 (0.0)	21	1 (4.8)
Asia	4	0 (0.0)	0	0 (0.0)	4	0 (0.0)
UK & Ireland	15	2 (13.3)	3	0 (0.0)	18	2 (11.1)
Other	6	0 (0.0)	6	0 (0.0)	12	0 (0.0)
p value		0.134		1.000		0.144
2007						
Australia	248	9 (3.6)	118	0 (0.0)	370	9 (2.4)
Other Oceania	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
Asia	0	0 (0.0)	1	0 (0.0)	1	0 (0.0)
UK & Ireland	11	1 (9.1)	3	0 (0.0)	14	1 (7.1)
Other	8	0 (0.0)	2	0 (0.0)	10	0 (0.0)
p value		0.663		---		0.499
2008						
Australia	283	8 (2.8)	138	0 (0.0)	422	8 (1.9)
Other Oceania	8	1 (12.5)	6	0 (0.0)	14	1 (7.1)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	12	0 (0.0)	7	0 (0.0)	19	0 (0.0)
Other	21	0 (0.0)	6	0 (0.0)	27	0 (0.0)
p value		0.459		---		0.455
2009						
Australia	504	10 (2.0)	183	0 (0.0)	692	10 (1.5)
Other Oceania	28	0 (0.0)	12	0 (0.0)	40	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	19	0 (0.0)	5	0 (0.0)	24	0 (0.0)
Other	14	0 (0.0)	7	0 (0.0)	21	0 (0.0)
p value		1.000		---		0.455

\* Total includes people whose gender was not reported or reported as transgender

Table 119 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
English speaking	166	4 (2.4)	79	0 (0.0)	246	4 (1.6)
Non-English speaking	22	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		0.500		---		0.500
2006						
English speaking	323	10 (3.1)	134	1 (0.8)	459	11 (2.4)
Non-English speaking	12	1 (8.3)	4	0 (0.0)	17	1 (5.9)
p value		0.335		1.000		0.357
2007						
English speaking	261	9 (3.5)	126	0 (0.0)	391	9 (2.3)
Non-English speaking	13	1 (7.7)	4	0 (0.0)	17	1 (5.9)
p value		0.390		---		0.351
2008						
English speaking	321	8 (2.5)	156	0 (0.0)	479	8 (1.7)
Non-English speaking	9	1 (11.1)	4	0 (0.0)	13	1 (7.7)
p value		0.223		---		0.216
2009						
English speaking	558	10 (1.8)	199	0 (0.0)	762	10 (1.3)
Non-English speaking	14	0 (0.0)	10	0 (0.0)	24	0 (0.0)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender



## HCV antibody prevalence

Table 120 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	188	105 (56)	86	40 (47)	276	146 (53)
2006	349	185 (53)	142	88 (62)	494	276 (56)
2007	278	158 (57)	129	85 (66)	411	247 (60)
2008	333	182 (55)	159	91 (57)	494	275 (56)
2009	576	244 (42)	209	94 (45)	790	339 (43)
$\chi^2$ trend p value		<0.001		0.072		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 121 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	159	84 (53)	65	32 (49)	225	116 (52)
Bisexual	8	5 (63)	14	4 (29)	22	9 (41)
Homosexual	13	10 (77)	5	3 (60)	18	13 (72)
p value		0.200		0.300		0.100
2006						
Heterosexual	302	165 (55)	104	62 (60)	407	228 (56)
Bisexual	11	4 (36)	22	16 (73)	34	21 (62)
Homosexual	26	12 (46)	12	7 (58)	39	20 (51)
p value		0.345		0.521		0.669
2007						
Heterosexual	248	140 (56)	97	62 (64)	345	202 (59)
Bisexual	7	4 (57)	22	16 (73)	31	22 (71)
Homosexual	18	11 (61)	6	3 (50)	25	15 (60)
p value		0.943		0.553		0.414
2008						
Heterosexual	300	164 (55)	126	67 (53)	427	232 (54)
Bisexual	10	5 (50)	26	18 (69)	36	23 (64)
Homosexual	17	8 (47)	4	3 (75)	21	11 (52)
p value		0.819		0.292		0.556
2009						
Heterosexual	514	222 (43)	162	67 (41)	677	289 (43)
Bisexual	24	7 (29)	37	22 (59)	62	29 (47)
Homosexual	9	3 (33)	1	1 (100)	10	4 (40)
p value		0.375		0.054		0.808

\* Total includes people whose gender was not reported or reported as transgender

Table 122 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	3	0 (0)	4	1 (25)	7	1 (14)
20 – 24	26	5 (19)	10	0 (0)	36	5 (14)
25 – 29	41	16 (39)	22	10 (45)	63	26 (41)
30 + years	118	84 (71)	50	29 (58)	170	114 (67)
p value		<0.001		0.007		<0.001
2006						
< 20 years	11	0 (0)	6	0 (0)	17	0 (0)
20 – 24	35	11 (31)	22	12 (55)	57	23 (40)
25 – 29	68	27 (40)	27	14 (52)	96	42 (44)
30 + years	234	146 (62)	87	62 (71)	323	210 (65)
p value		<0.001		0.002		<0.001
2007						
< 20 years	6	2 (33)	1	0 (0)	7	2 (29)
20 – 24	28	7 (25)	13	6 (46)	41	13 (32)
25 – 29	48	26 (54)	19	11 (58)	67	37 (55)
30 + years	195	122 (63)	96	68 (71)	295	194 (66)
p value		0.001		0.091		<0.001
2008						
< 20 years	11	4 (36)	5	4 (80)	16	8 (50)
20 – 24	27	6 (22)	21	9 (43)	48	15 (31)
25 – 29	54	23 (43)	28	16 (57)	82	39 (48)
30 + years	240	148 (62)	104	62 (60)	346	212 (61)
p value		<0.001		0.425		<0.001
2009						
< 20 years	20	2 (10)	10	1 (10)	31	3 (10)
20 – 24	55	15 (27)	29	14 (48)	85	29 (34)
25 – 29	90	25 (28)	40	21 (53)	130	46 (35)
30 + years	411	202 (49)	130	58 (45)	544	261 (48)
p value		<0.001		0.107		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 123 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	17	3 (18)	6	1 (17)	24	5 (21)
3 to 5 years	25	7 (28)	18	3 (17)	43	10 (23)
6 to 10 years	16	6 (38)	11	3 (27)	27	9 (33)
10 + years	120	85 (71)	46	29 (63)	167	114 (68)
p value		<0.001		0.002		<0.001
2006						
<3 years	25	4 (16)	14	4 (29)	39	8 (21)
3 to 5 years	30	8 (27)	16	4 (25)	46	12 (26)
6 to 10 years	58	24 (41)	36	28 (78)	94	52 (55)
10 + years	218	140 (64)	74	52 (70)	295	195 (66)
p value		<0.001		<0.001		<0.001
2007						
<3 years	23	4 (17)	9	2 (22)	32	6 (19)
3 to 5 years	15	4 (27)	10	5 (50)	25	9 (36)
6 to 10 years	62	26 (42)	23	11 (48)	85	37 (44)
10 + years	168	117 (70)	85	66 (78)	257	187 (73)
p value		<0.001		<0.001		<0.001
2008						
<3 years	19	2 (11)	10	4 (40)	29	6 (21)
3 to 5 years	40	9 (23)	16	5 (31)	56	14 (25)
6 to 10 years	54	19 (35)	45	24 (53)	99	43 (43)
10 + years	214	149 (70)	86	58 (67)	302	209 (69)
p value		<0.001		0.023		<0.001
2009						
<3 years	36	3 (8)	20	3 (15)	57	6 (11)
3 to 5 years	46	11 (24)	19	5 (26)	66	16 (24)
6 to 10 years	81	30 (37)	48	22 (46)	130	52 (40)
10 + years	400	196 (49)	116	63 (54)	518	260 (50)
p value		<0.001		0.002		<0.001

\* Total includes people whose gender was not reported or reported as transgender

## Queensland

Table 124 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	4	2 (50)	74	42 (57)	78	44 (56)
Methamphetamine	13	1 (7)	100	39 (39)	113	40 (36)
More than one	0	0 (0)	8	6 (75)	8	6 (75)
Other/Not reported	6	1 (17)	71	55 (77)	77	52 (73)
p value		0.300		<0.001		<0.001
2006						
Heroin	3	1 (33)	104	73 (70)	113	78 (69)
Methamphetamine	22	2 (9)	165	70 (42)	195	73 (37)
More than one	0	0 (0)	4	3 (75)	4	3 (75)
Other/Not reported	14	5 (36)	162	113 (70)	182	122 (67)
p value		0.093		<0.001		<0.001
2007						
Heroin	4	0 (0)	100	66 (66)	106	67 (63)
Methamphetamine	24	5 (21)	119	63 (53)	143	68 (48)
More than one	0	0 (0)	5	1 (20)	6	1 (17)
Other/Not reported	4	1 (25)	143	103 (72)	156	111 (71)
p value		1.000		0.002		<0.001
2008						
Heroin	2	1 (50)	120	82 (68)	123	84 (68)
Methamphetamine	15	2 (13)	146	62 (42)	162	65 (40)
More than one	1	1 (100)	7	4 (57)	9	5 (56)
Other/Not reported	11	2 (18)	184	118 (64)	200	121 (61)
p value		0.179		<0.001		<0.001
2009						
Heroin	12	3 (25)	202	114 (56)	216	117 (54)
Methamphetamine	22	0 (0)	206	65 (32)	231	65 (28)
More than one	1	0 (0)	27	16 (59)	30	17 (57)
Other/Not reported	22	3 (14)	279	133 (48)	313	140 (45)
p value		0.100		<0.001		<0.001

\* Total includes people who did not report duration of drug injection

Table 125 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	20	4 (20)	133	67 (50)	161	75 (47)
Daily or more	2	1 (50)	104	66 (63)	113	71 (63)
p value		0.300		0.040		0.010
2006						
Less than daily	17	1 (6)	169	93 (55)	192	95 (49)
Daily or more	17	6 (35)	212	137 (65)	241	150 (62)
p value		0.085		0.059		0.009
2007						
Less than daily	20	3 (15)	163	92 (56)	168	98 (53)
Daily or more	10	2 (20)	170	124 (73)	185	130 (70)
p value		1.000		0.002		0.001
2008						
Less than daily	14	4 (29)	199	106 (53)	214	110 (51)
Daily or more	9	2 (22)	213	140 (66)	225	143 (64)
p value		1.000		0.012		0.012
2009						
Less than daily	22	1 (5)	268	105 (39)	294	107 (36)
Daily or more	26	5 (19)	383	186 (49)	417	194 (47)
p value		0.199		0.020		0.009

\* Total includes people who did not report duration of drug injection

Table 126 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	15	4 (27)	168	90 (54)	194	100 (52)
Receptive sharing	1	0 (0)	32	20 (63)	35	21 (60)
p value		0.600		0.400		0.400
2006						
No receptive sharing	30	7 (23)	303	177 (58)	344	189 (55)
Receptive sharing	3	0 (0)	61	41 (67)	71	44 (62)
p value		1.000		0.252		0.296
2007						
No receptive sharing	27	4 (15)	280	175 (63)	313	184 (59)
Receptive sharing	3	1 (33)	46	37 (80)	50	39 (78)
p value		0.433		0.019		0.012
2008						
No receptive sharing	17	3 (18)	356	209 (59)	376	213 (57)
Receptive sharing	6	3 (50)	52	34 (65)	58	37 (64)
p value		0.279		0.450		0.322
2009						
No receptive sharing	33	1 (3)	529	225 (43)	569	228 (40)
Receptive sharing	13	5 (38)	106	57 (54)	123	63 (51)
p value		0.005		0.042		0.027

\* Total includes people who did not report duration of drug injection

## Queensland

Table 127 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	22	4 (18)	199	108 (54)	235	119 (51)
Imprisoned	2	1 (50)	31	20 (65)	34	22 (65)
p value		0.300		0.300		0.100
2006						
Not imprisoned	34	8 (24)	355	200 (56)	405	214 (53)
Imprisoned	3	0 (0)	62	44 (71)	67	45 (67)
p value		1.000		0.036		0.034
2007						
Not imprisoned	31	5 (16)	317	188 (59)	358	199 (56)
Imprisoned	1	1 (100)	39	34 (87)	42	37 (88)
p value		0.188		<0.001		<0.001
2008						
Not imprisoned	26	4 (15)	375	207 (55)	407	213 (52)
Imprisoned	2	2 (100)	50	40 (80)	53	43 (81)
p value		0.040		0.001		<0.001
2009						
Not imprisoned	48	2 (4)	587	250 (43)	648	254 (39)
Imprisoned	7	4 (57)	99	58 (59)	110	64 (58)
p value		0.001		0.004		<0.001

\* Total includes people who did not report duration of drug injection

Table 128 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	24	5(21)	221	124 (56)	260	137 (53)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
p value		---		0.500		0.600
2006						
No sex work	37	8 (22)	394	229 (58)	451	246 (55)
Sex work	0	0 (0)	20	14 (70)	20	14 (70)
p value		---		0.357		0.250
2007						
No sex work	29	6 (21)	341	211 (62)	381	224 (59)
Sex work	1	0 (0)	18	16 (89)	20	17 (85)
p value		1.000		0.023		0.020
2008						
No sex work	27	5 (19)	408	238 (58)	442	246 (56)
Sex work	1	1 (100)	12	6 (50)	13	7 (54)
p value		0.214		0.568		1.000
2009						
No sex work	55	5 (9)	663	294 (44)	732	302 (41)
Sex work	1	1 (100)	26	19 (73)	30	21 (70)
p value		0.107		0.005		0.002

\* Total includes people who did not report duration of drug injection

Table 129 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	176	99 (56)	82	38 (46)	260	138 (53)
Indigenous	10	4 (40)	2	2 (100)	12	6 (50)
p value		0.300		0.100		0.800
2006						
Non Indigenous	305	161 (53)	128	74 (58)	433	235 (54)
Indigenous	34	16 (47)	13	13 (100)	48	30 (63)
p value		0.589		0.002		0.289
2007						
Non Indigenous	249	142 (57)	118	76 (64)	370	221 (60)
Indigenous	26	14 (54)	10	8 (80)	37	23 (62)
p value		0.836		0.492		0.861
2008						
Non Indigenous	314	168 (54)	135	72 (53)	450	241 (54)
Indigenous	7	3 (43)	20	16 (80)	28	20 (71)
p value		0.709		0.030		0.079
2008						
Non Indigenous	490	203 (41)	172	78 (45)	667	282 (42)
Indigenous	67	33 (49)	35	16 (46)	102	49 (48)
p value		0.237		1.000		0.284

\* Total includes people whose gender was not reported or reported as transgender

Table 130 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	163	92 (56)	81	38 (47)	246	131 (53)
Other Oceania	9	3 (33)	0	0 (0)	9	3 (33)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	9	6 (67)	4	2 (50)	13	8 (62)
Other	5	2 (40)	0	0 (0)	5	2 (40)
p value		0.400		0.600		0.700
2006						
Australia	301	160 (53)	125	75 (60)	429	238 (55)
Other Oceania	14	4 (29)	7	7 (100)	21	11 (52)
Asia	4	2 (50)	0	0 (0)	4	2 (50)
UK & Ireland	15	10 (67)	3	2 (67)	18	12 (67)
Other	6	3 (50)	6	3 (50)	12	6 (50)
p value		0.332		0.135		0.875
2007						
Australia	247	141 (57)	117	77 (66)	368	222 (60)
Other Oceania	9	4 (44)	6	3 (50)	15	7 (47)
Asia	0	0 (0)	1	1 (100)	1	1 (100)
UK & Ireland	11	7 (64)	3	2 (67)	14	9 (64)
Other	8	4 (50)	2	2 (100)	10	6 (60)
p value		0.818		0.816		0.821
2008						
Australia	281	154 (55)	137	75 (55)	419	230 (55)
Other Oceania	8	1 (13)	6	5 (83)	14	6 (43)
Asia	4	4 (100)	1	0 (0)	5	4 (80)
UK & Ireland	12	6 (50)	7	3 (43)	19	9 (47)
Other	21	12 (57)	6	6 (100)	27	18 (67)
p value		0.054		0.053		0.425
2009						
Australia	499	215 (43)	183	85 (46)	687	301 (44)
Other Oceania	28	6 (21)	12	5 (42)	40	11 (28)
Asia	4	3 (75)	1	0 (0)	5	3 (60)
UK & Ireland	19	10 (53)	5	2 (40)	24	12 (50)
Other	14	4 (29)	7	1 (14)	21	5 (24)
p value		0.057		0.459		0.071

\* Total includes people whose gender was not reported or reported as transgender



Table 131 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	166	95 (57)	77	34 (44)	244	130 (53)
Non-English speaking	22	10 (45)	9	6 (67)	32	16 (50)
p value		0.300		0.200		0.700
2006						
English speaking	322	169 (52)	134	83 (62)	458	254 (55)
Non-English speaking	12	7 (58)	4	2 (50)	17	10 (59)
p value		0.774		0.638		1.000
2007						
English speaking	260	150 (58)	125	83 (66)	389	237 (61)
Non-English speaking	13	6 (46)	4	2 (50)	17	8 (47)
p value		0.567		0.605		0.313
2008						
English speaking	319	174 (55)	155	89 (57)	476	265 (56)
Non-English speaking	9	5 (56)	4	2 (50)	13	7 (54)
p value		1.000		1.000		1.000
2009						
English speaking	553	231 (42)	199	90 (45)	757	322 (43)
Non-English speaking	14	9 (64)	10	4 (40)	24	13 (54)
p value		0.106		1.000		0.297

\* Total includes people whose gender was not reported or reported as transgender

## South Australia

Table 132 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	7	6	7	7	7
N° surveyed	N=211	N=200	N=220	N=196	N=248
Response (%)	50	40	41	45	53
Gender (%)					
Male	126 (60)	114 (57)	127 (58)	101 (52)	156 (63)
Female	84 (40)	86 (43)	91 (41)	93 (47)	92 (37)
Transgender	1 (<1)	0 (0)	2 (1)	1 (1)	0 (0)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
Sexual identity (%)					
Heterosexual	166 (79)	160 (80)	175 (80)	146 (74)	204 (82)
Bisexual	27 (13)	17 (9)	23 (10)	29 (15)	23 (9)
Homosexual	9 (4)	10 (5)	15 (7)	13 (7)	13 (5)
Not reported	9 (4)	13 (7)	7 (3)	8 (4)	8 (3)
Age and duration of injection (years)					
<i>Median age</i>	33	34	34	36	38
Age range	18-59	16-58	19-58	17-56	16-61
<i>Age group (%)</i>					
<25 years	30 (14)	27 (14)	25 (11)	19 (10)	25 (10)
25+ years	181 (86)	172 (86)	193 (88)	177 (90)	222 (90)
Not reported	0 (0)	1 (<1)	2 (1)	0 (0)	1 (<1)
<i>Median age 1<sup>st</sup> IDU</i>	18	18	18	18	18
Age range	12-50	10-44	10-47	11-45	12-46
Not reported	4	1	5	4	5
<i>Median years IDU</i>	13	14	13	15	17
Range	<1-38	<1-41	<1-41	1-41	<1-44
<i>Duration of drug injection (%)</i>					
<3 years	16 (8)	15 (8)	16 (7)	13 (7)	15 (6)
3+ years	187 (89)	180 (90)	199 (90)	179 (91)	228 (92)
Not reported	8 (4)	5 (3)	5 (2)	4 (2)	5 (2)
Aboriginal and Torres Strait Islander origin (%)					
No	186 (88)	176 (88)	202 (92)	158 (81)	206 (83)
Yes	17 (8)	18 (9)	16 (7)	28 (14)	31 (13)
Not reported	8 (4)	6 (3)	2 (1)	10 (5)	11 (4)
Region/Country of birth (%)					
Australia	183 (87)	167 (84)	186 (85)	160 (82)	219 (88)
Other Oceania	2 (1)	1 (<1)	3 (1)	4 (2)	5 (2)
Asia	2 (1)	5 (3)	2 (<1)	5 (3)	1 (<1)
UK & Ireland	16 (8)	18 (9)	18 (8)	17 (9)	17 (7)
Other	7 (3)	8 (4)	8 (4)	7 (4)	5 (2)
Not reported	1 (0)	1 (<1)	3 (1)	3 (2)	1 (<1)
Main language spoken at home by parents (%)					
English speaking	174 (82)	166 (83)	195 (89)	179 (91)	224 (90)
Non-English speaking	37 (18)	19 (10)	23 (10)	12 (6)	19 (8)
Not reported	0 (0)	15 (8)	2 (1)	5 (3)	5 (2)
Imprisonment last year (%)					
No	179 (85)	174 (87)	173 (79)	158 (81)	199 (80)
Yes	24 (11)	18 (9)	32 (15)	21 (11)	37 (15)
Not reported	8 (4)	8 (4)	15 (7)	17 (9)	12 (5)
Injected in prison (%)	N=24	N=18	N=32	N=21	N=37
Yes	8 (33)	4 (22)	8 (25)	7 (33)	5 (14)
Frequency of injection last month (%)					
Not last month	20 (9)	7 (4)	14 (6)	20 (10)	22 (9)
Less than weekly	42 (20)	37 (19)	40 (18)	30 (15)	38 (15)
Weekly not daily	51 (24)	58 (29)	54 (25)	51 (26)	59 (24)
Daily or more	98 (46)	96 (48)	112 (51)	93 (47)	127 (51)
Not reported	0 (0)	2 (1)	0 (0)	2 (1)	2 (1)

Table 133 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=211	N=200	N=220	N=196	N=248
Anabolic steroids	2 (1)	3 (2)	2 (1)	1 (1)	0 (0)
Cocaine	2 (1)	1 (<1)	2 (1)	4 (2)	3 (1)
Heroin	77 (36)	40 (20)	62 (28)	49 (25)	84 (34)
Methadone	5 (2)	7 (4)	11 (5)	10 (5)	8 (3)
Methamphetamine	88 (42)	101 (51)	95 (43)	100 (51)	91 (37)
Pharm. Opioids	17 (8)	24 (12)	24 (11)	20 (10)	34 (14)
Subutex/Buprenorphine	4 (2)	14 (7)	10 (5)	7 (4)	14 (6)
More than one	6 (3)	3 (2)	6 (3)	2 (1)	5 (2)
Other	1 (<1)	2 (1)	6 (3)	0 (0)	3 (1)
Not reported	7 (3)	5 (2)	2 (1)	3 (2)	6 (2)
N° Injected last month	N=191	N=191	N=206	N=174	N=224
Places injected last month (%)*					
Own home	164 (86)	168 (92)	176 (88)	151 (88)	198 (89)
Friend's home	88 (46)	85 (47)	90 (45)	74 (43)	92 (41)
Dealer's home	28 (15)	39 (21)	32 (16)	35 (20)	24 (11)
Street, park, beach	34 (18)	28 (15)	45 (23)	34 (20)	24 (11)
Car	87 (46)	63 (35)	84 (42)	66 (38)	70 (31)
Public toilet	30 (16)	33 (18)	44 (22)	36 (21)	29 (13)
Commercial injecting room	1 (1)	0 (0)	1 (<1)	1 (1)	0 (0)
Squat	4 (2)	3 (2)	10 (5)	5 (3)	3 (1)
Use of new sterile needles & syringes last month (%)					
All injections	134 (70)	143 (75)	147 (71)	126 (72)	184 (82)
Most of the time	48 (25)	27 (14)	45 (22)	34 (20)	31 (14)
Half of the time	6 (3)	10 (5)	4 (2)	6 (3)	4 (2)
Some of the time	3 (2)	3 (2)	3 (1)	5 (3)	3 (1)
Not last month	0 (0)	2 (1)	0 (0)	1 (1)	0 (0)
Not reported	0 (0)	6 (3)	7 (3)	2 (1)	2 (1)
<b>Re-used another's used needle &amp; syringe last month (%)</b>					
None	163 (85)	157 (82)	166 (81)	138 (79)	197 (88)
Once	8 (4)	5 (3)	11 (5)	7 (4)	7 (3)
Twice	6 (3)	8 (4)	8 (4)	10 (6)	7 (3)
3-5 times	2 (1)	11 (6)	8 (4)	11 (6)	3 (1)
>5 times	4 (2)	5 (3)	4 (2)	2 (1)	4 (2)
Not reported	8 (4)	5 (3)	9 (4)	6 (3)	6 (3)
Number of people needle & syringe was re-used after last month (%)					
None	157 (82)	157 (82)	166 (81)	138 (79)	197 (88)
One	12 (6)	12 (6)	10 (5)	17 (10)	11 (5)
Two	1 (1)	5 (3)	5 (2)	3 (2)	3 (1)
Three to five	1 (1)	0 (0)	3 (1)	0 (0)	0 (0)
More than five	3 (2)	0 (0)	1 (<1)	0 (0)	0 (0)
Don't know	8 (4)	7 (4)	5 (2)	8 (5)	4 (2)
Not reported	9 (5)	10 (5)	16 (8)	8 (5)	9 (4)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	15 (8)	10 (5)	15 (7)	10 (6)	9 (4)
Casual sex partner	1 (<1)	2 (1)	4 (2)	0 (0)	0 (0)
Close friend	5 (3)	7 (4)	2 (1)	7 (4)	3 (1)
Acquaintance	3 (2)	4 (2)	1 (<1)	3 (2)	2 (1)
Other	0 (0)	3 (2)	2 (1)	4 (2)	0 (0)
Equipment used after someone else last month (%)*					
Spoon	35 (18)	35 (19)	47 (24)	25 (16)	36 (18)
Water	37 (19)	32 (17)	39 (20)	36 (23)	28 (14)
Filter	20 (10)	19 (10)	29 (15)	16 (10)	19 (9)
Drug mix	24 (13)	14 (8)	15 (8)	9 (6)	20 (10)
Tourniquet	30 (16)	16 (9)	30 (15)	17 (11)	14 (7)
None**	0 (0)	112 (60)	118 (60)	100 (63)	141 (69)
Injected by someone after that person injected themselves or others last month (%)					
No	150 (79)	146 (75)	167 (81)	143 (82)	183 (82)
Yes	32 (17)	36 (19)	30 (15)	24 (14)	34 (15)
Not reported	9 (5)	9 (5)	9 (4)	7 (4)	7 (3)

\* More than one option could be selected

\*\* New variable in 2006

Table 134 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=211	N=200	N=220	N=196	N=248
Any treatment/therapy for drug use (%)					
No	72 (34)	69 (35)	60 (27)	66 (34)	67 (27)
Yes	136 (64)	127 (64)	158 (72)	123 (63)	176 (71)
Not reported	3 (1)	4 (2)	2 (1)	7 (4)	5 (2)
History of methadone maintenance treatment (%)					
Currently	45 (21)	25 (13)	51 (23)	39 (20)	61 (25)
Previously	48 (23)	64 (32)	57 (26)	40 (20)	46 (19)
Never	114 (54)	108 (54)	109 (50)	112 (57)	135 (54)
Not reported	4 (2)	3 (2)	3 (1)	5 (3)	6 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	26 (13)	40 (16)
Previously	--	--	--	33 (17)	58 (23)
Never	--	--	--	130 (66)	148 (60)
Not reported	--	--	--	7 (4)	2 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	7 (4)	12 (5)
Previously	--	--	--	21 (11)	36 (15)
Never	--	--	--	160 (82)	194 (78)
Not reported	--	--	--	8 (4)	6 (2)

\* New variable in 2008

Table 135 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=164#	N=195#
Source of needles/syringes (%)*		
Chemist/Pharmacy	37 (23)	36 (18)
Needle Syringe Program	141 (86)	150 (77)
Dispensing/Vending Machine	2 (1)	1 (1)
Friend/Dealer	49 (30)	39 (20)
Other	6 (4)	9 (5)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	9 (24)	8 (22)
Needle Syringe Program	89 (63)	105 (70)
Dispensing/Vending Machine	1 (50)	1 (0)
Friend/Dealer	8 (16)	9 (23)
Other	2 (33)	5 (56)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=206	N=224
Secondary exchange	120 (58)	97 (43)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

Table 136 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=211	N=200	N=220	N=196	N=248
Sex with a regular partner last month (%) **					
No	98 (46)	88 (44)	88 (40)	81 (41)	112 (45)
Yes	107 (51)	111 (56)	122 (55)	107 (55)	124 (50)
Not reported	6 (3)	1 (<1)	10 (5)	8 (4)	12 (5)
Condom used with regular partner last month (%)**					
N° surveyed	N=107	N=111	N=122	N=107	N=124
Never	82 (77)	81 (73)	97 (80)	78 (73)	80 (64)
Sometimes	15 (14)	14 (13)	17 (14)	17 (16)	23 (19)
Every time	8 (7)	8 (7)	6 (5)	8 (7)	12 (10)
Not reported	2 (2)	8 (7)	2 (2)	4 (4)	9 (7)
Sex with other partner/s last month (%)**					
No	172 (82)	164 (82)	171 (78)	153 (78)	205 (83)
Yes	34 (16)	30 (15)	42 (19)	31 (16)	31 (13)
Not reported	5 (2)	6 (3)	7 (3)	12 (6)	12 (5)
Condom used with other partner/s last month (%)**					
N° surveyed	N=34	N=30	N=42	N=31	N=31
Never	7 (21)	9 (30)	21 (50)	5 (16)	9 (29)
Sometimes	9 (26)	7 (23)	6 (14)	12 (39)	9 (29)
Every time	17 (50)	12 (40)	14 (33)	14 (45)	13 (42)
Not reported	1 (3)	2 (7)	1 (2)	0 (0)	0 (0)
Sex work last month (%)					
No	195 (92)	182 (91)	194 (88)	170 (87)	229 (92)
Yes	10 (5)	12 (6)	21 (10)	13 (7)	10 (4)
Not reported	6 (3)	6 (3)	5 (2)	13 (7)	9 (4)
Condom used at last sex work last month (%)**					
Yes	24 (96)	8 (80)	13 (72)	11 (85)	9 (90)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 137 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=211	N=200	N=220	N=196	N=248
Previous HIV test (%)					
Yes, last year	107 (51)	99 (50)	116 (53)	94 (48)	130 (52)
> 1 year ago	77 (36)	67 (34)	76 (35)	62 (32)	81 (33)
Never tested	26 (12)	34 (17)	27 (12)	30 (15)	28 (11)
Not reported	1 (<1)	0 (0)	1 (<1)	10 (5)	9 (4)
Previous HCV test (%)					
Yes, last year	113 (54)	117 (59)	123 (56)	104 (53)	139 (56)
> 1 year ago	70 (33)	51 (26)	73 (33)	57 (29)	67 (27)
Never tested	27 (13)	32 (16)	23 (10)	29 (15)	28 (11)
Not reported	1 (<1)	0 (0)	1 (<1)	6 (3)	14 (6)
Any treatment for HCV (%)	N=70	N=68	N=59	N=59	N=102
Interferon	2 (3)	3 (4)	0 (0)	3 (5)	7 (7)
Interferon+Ribarvarin	1 (1)	2 (3)	2 (3)	4 (7)	7 (7)
Other	1 (1)	2 (3)	1 (2)	0 (0)	1 (1)
No treatment	65 (93)	53 (78)	53 (90)	50 (85)	81 (79)
Not reported	1 (1)	8 (12)	3 (5)	2 (3)	6 (6)
Current treatment for HCV	N=2	N=3	N=2	N=1	N=3
Interferon/Interferon+Ribarvirin	1	2	2	1	2
Other	1	1	0	0	1

HIV antibody prevalence

Table 138 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	122	1 (0.8)	82	0 (0.0)	205	1 (0.5)
2006	112	1 (0.9)	85	0 (0.0)	197	1 (0.5)
2007	120	2 (1.7)	89	0 (0.0)	211	2 (1.0)
2008	96	0 (0.0)	92	0 (0.0)	189	0 (0.0)
2009	155	2 (1.3)	91	1 (1.1)	246	3 (1.2)
$\chi^2$ trend p value		0.888		0.838		0.511

\* Total includes people whose gender was not reported or reported as transgender

Table 139 HIV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heterosexual	107	0 (0.0)	55	0 (0.0)	162	0 (0.0)
Bisexual	5	0 (0.0)	21	0 (0.0)	26	0 (0.0)
Homosexual	5	1 (20.0)	2	0 (0.0)	8	1 (12.5)
p value		<0.001		---		<0.001
2006						
Heterosexual	99	1 (1.0)	59	0 (0.0)	158	1 (0.6)
Bisexual	4	0 (0.0)	13	0 (0.0)	17	0 (0.0)
Homosexual	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		1.000		---		1.000
2007						
Heterosexual	103	0 (0.0)	64	0 (0.0)	167	0 (0.0)
Bisexual	5	1 (20.0)	16	0 (0.0)	22	1 (4.6)
Homosexual	8	1 (12.5)	6	0 (0.0)	15	1 (6.7)
p value		0.012		---		0.032
2008						
Heterosexual	84	0 (0.0)	57	0 (0.0)	141	0 (0.0)
Bisexual	6	0 (0.0)	23	0 (0.0)	29	0 (0.0)
Homosexual	3	0 (0.0)	10	0 (0.0)	13	0 (0.0)
p value		---		---		---
2009						
Heterosexual	134	2 (1.5)	68	1 (1.5)	202	3 (1.5)
Bisexual	11	0 (0.0)	12	0 (0.0)	23	0 (0.0)
Homosexual	4	0 (0.0)	9	0 (0.0)	13	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 140 HIV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
< 20 years	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
20 – 24	12	0 (0.0)	11	0 (0.0)	23	0 (0.0)
25 – 29	17	0 (0.0)	22	0 (0.0)	39	0 (0.0)
30 + years	92	1 (1.1)	45	0 (0.0)	138	1 (0.7)
p value		1.000		---		0.900
2006						
< 20 years	1	0 (0.0)	4	0 (0.0)	5	0 (0.0)
20 – 24	8	0 (0.0)	13	0 (0.0)	21	0 (0.0)
25 – 29	17	0 (0.0)	12	0 (0.0)	29	0 (0.0)
30 + years	85	1 (1.2)	56	0 (0.0)	141	1 (0.7)
p value		1.000		---		1.000
2007						
< 20 years	---	---	1	0 (0.0)	1	0 (0.0)
20 – 24	7	0 (0.0)	13	0 (0.0)	21	0 (0.0)
25 – 29	23	0 (0.0)	21	0 (0.0)	44	0 (0.0)
30 + years	89	2 (2.3)	53	0 (0.0)	143	2 (1.4)
p value		1.000		---		1.000
2008						
< 20 years	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
20 – 24	5	0 (0.0)	10	0 (0.0)	15	0 (0.0)
25 – 29	8	0 (0.0)	15	0 (0.0)	23	0 (0.0)
30 + years	82	0 (0.0)	66	0 (0.0)	149	0 (0.0)
p value		---		---		---
2009						
< 20 years	6	0 (0.0)	3	0 (0.0)	9	0 (0.0)
20 – 24	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
25 – 29	10	0 (0.0)	10	0 (0.0)	20	0 (0.0)
30 + years	131	2 (1.5)	70	0 (0.0)	201	2 (1.0)
p value		1.000		---		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 141 HIV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
<3 years	8	1 (12.5)	8	0 (0.0)	16	1 (6.3)
3 to 5 years	11	0 (0.0)	11	0 (0.0)	23	0 (0.0)
6 to 10 years	9	0 (0.0)	16	0 (0.0)	25	0 (0.0)
10 + years	89	0 (0.0)	44	0 (0.0)	133	0 (0.0)
p value		<0.001		---		0.010
2006						
<3 years	5	0 (0.0)	9	0 (0.0)	14	0 (0.0)
3 to 5 years	9	0 (0.0)	9	0 (0.0)	18	0 (0.0)
6 to 10 years	22	0 (0.0)	22	0 (0.0)	44	0 (0.0)
10 + years	72	1 (1.4)	44	0 (0.0)	116	1 (0.9)
p value		1.000		---		1.000
2007						
<3 years	8	0 (0.0)	7	0 (0.0)	15	0 (0.0)
3 to 5 years	9	1 (11.1)	11	0 (0.0)	20	1 (5.0)
6 to 10 years	18	0 (0.0)	22	0 (0.0)	41	0 (0.0)
10 + years	82	1 (1.2)	47	0 (0.0)	130	1 (0.8)
p value		0.293		---		0.350
2008						
<3 years	5	0 (0.0)	7	0 (0.0)	12	0 (0.0)
3 to 5 years	4	0 (0.0)	5	0 (0.0)	9	0 (0.0)
6 to 10 years	13	0 (0.0)	20	0 (0.0)	33	0 (0.0)
10 + years	74	0 (0.0)	57	0 (0.0)	132	0 (0.0)
p value		---		---		---
2009						
<3 years	4	0 (0.0)	10	0 (0.0)	14	0 (0.0)
3 to 5 years	9	0 (0.0)	7	0 (0.0)	16	0 (0.0)
6 to 10 years	17	2 (11.8)	13	0 (0.0)	30	2 (6.7)
10 + years	122	0 (0.0)	59	0 (0.0)	181	0 (0.0)
p value		0.025		---		0.045

\* Total includes people whose gender was not reported or reported as transgender



Table 142 HIV antibody prevalence by last drug injected, gender and year of survey

Last drug injected	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Heroin	39	0 (0.0)	38	0 (0.0)	77	0 (0.0)
Methamphetamine	54	1 (1.9)	30	0 (0.0)	84	1 (1.2)
More than one	5	0 (0.0)	1	0 (0.0)	6	0 (0.0)
Other/Not reported	24	0 (0.0)	13	0 (0.0)	38	0 (0.0)
p value		0.800		---		0.700
2006						
Heroin	24	1 (4.2)	16	0 (0.0)	40	1 (2.5)
Methamphetamine	52	0 (0.0)	47	0 (0.0)	99	0 (0.0)
More than one	2	0 (0.0)	1	0 (0.0)	3	0 (0.0)
Other/Not reported	34	0 (0.0)	21	0 (0.0)	55	0 (0.0)
p value		0.232		---		0.218
2007						
Heroin	37	0 (0.0)	23	0 (0.0)	60	0 (0.0)
Methamphetamine	45	1 (2.2)	45	0 (0.0)	90	1 (1.1)
More than one	3	0 (0.0)	3	0 (0.0)	6	0 (0.0)
Other/Not reported	35	1 (8.9)	18	0 (0.0)	55	1 (1.8)
p value		0.767		---		0.756
2008						
Heroin	26	0 (0.0)	21	0 (0.0)	48	0 (0.0)
Methamphetamine	42	0 (0.0)	53	0 (0.0)	95	0 (0.0)
More than one	2	0 (0.0)	18	0 (0.0)	2	0 (0.0)
Other/Not reported	26	0 (0.0)	92	0 (0.0)	44	0 (0.0)
p value		---		---		---
2009						
Heroin	55	0 (0.0)	28	0 (0.0)	83	0 (0.0)
Methamphetamine	50	0 (0.0)	40	1 (2.5)	90	1 (1.1)
More than one	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
Other/Not reported	46	2 (4.4)	22	0 (0.0)	68	2 (2.9)
p value		0.138		1.000		0.327

\* Total includes people whose gender was not reported or reported as transgender

## South Australia

Table 143 HIV antibody prevalence by frequency of drug injection last month, gender and year of survey

Frequency of drug injection	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Not last month	9	1 (11.1)	9	0 (0.0)	18	1 (5.6)
Less than weekly	22	0 (0.0)	18	0 (0.0)	40	0 (0.0)
Weekly not daily	34	0 (0.0)	16	0 (0.0)	50	0 (0.0)
Daily or more	56	0 (0.0)	38	0 (0.0)	95	0 (0.0)
p value		---		---		---
2006						
Not last month	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
Less than weekly	16	0 (0.0)	20	0 (0.0)	36	0 (0.0)
Weekly not daily	31	1 (3.2)	26	0 (0.0)	57	1 (1.8)
Daily or more	60	0 (0.0)	35	0 (0.0)	95	0 (0.0)
p value		0.464		---		0.513
2007						
Not last month	5	1 (20)	7	0 (0.0)	12	1 (8.3)
Less than weekly	21	0 (0.0)	18	0 (0.0)	39	0 (0.0)
Weekly not daily	31	0 (0.0)	18	0 (0.0)	49	0 (0.0)
Daily or more	63	1 (1.6)	46	0 (0.0)	111	1 (0.9)
p value		0.111		---		0.197
2008						
Not last month	5	0 (0.0)	14	0 (0.0)	19	0 (0.0)
Less than weekly	16	0 (0.0)	14	0 (0.0)	30	0 (0.0)
Weekly not daily	27	0 (0.0)	20	0 (0.0)	47	0 (0.0)
Daily or more	48	0 (0.0)	42	0 (0.0)	91	0 (0.0)
p value		---		---		---
2009						
Not last month	9	0 (0.0)	13	0 (0.0)	22	0 (0.0)
Less than weekly	24	0 (0.0)	14	1 (7.1)	38	1 (2.6)
Weekly not daily	37	0 (0.0)	21	0 (0.0)	58	0 (0.0)
Daily or more	85	2 (2.4)	41	0 (0.0)	126	2 (1.6)
p value		1.000		0.303		0.673

\* Total includes people whose gender was not reported or reported as transgender

Table 144 HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No receptive sharing	93	0 (0.0)	65	0 (0.0)	159	0 (0.0)
Receptive sharing	14	0 (0.0)	5	0 (0.0)	19	0 (0.0)
p value		---		---		---
2006						
No receptive sharing	83	0 (0.0)	71	0 (0.0)	154	0 (0.0)
Receptive sharing	21	1 (4.8)	8	0 (0.0)	29	1 (3.5)
p value		0.202		---		---
2007						
No receptive sharing	93	1 (1.1)	67	0 (0.0)	161	1 (0.6)
Receptive sharing	18	0 (0.0)	10	0 (0.0)	29	0 (0.0)
p value		1.000		---		1.000
2008						
No receptive sharing	71	0 (0.0)	64	0 (0.0)	135	0 (0.0)
Receptive sharing	16	0 (0.0)	12	0 (0.0)	29	0 (0.0)
p value		---		---		---
2009						
No receptive sharing	126	2 (1.6)	69	1 (1.5)	195	3 (1.5)
Receptive sharing	15	0 (0.0)	6	0 (0.0)	21	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 145 HIV antibody prevalence by imprisonment last year, gender and year of survey

Imprisonment last year	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No imprisonment	97	1 (1.0)	76	0 (0.0)	174	1 (0.6)
Imprisonment	17	0 (0.0)	6	0 (0.0)	23	0 (0.0)
p value		0.700		---		0.700
2006						
No imprisonment	96	1 (1.0)	75	0 (0.0)	171	1 (0.6)
Imprisonment	12	0 (0.0)	6	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
No imprisonment	89	2 (2.3)	75	0 (0.0)	165	2 (1.2)
Imprisonment	23	0 (0.0)	9	0 (0.0)	32	0 (0.0)
p value		1.000		---		1.000
2008						
No imprisonment	73	0 (0.0)	80	0 (0.0)	154	0 (0.0)
Imprisonment	16	0 (0.0)	5	0 (0.0)	21	0 (0.0)
p value		---		---		---
2009						
No imprisonment	119	2 (1.7)	78	1 (1.3)	197	3 (1.5)
Imprisonment	28	0 (0.0)	9	0 (0.0)	37	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 146 HIV antibody prevalence by condom use at last sex, gender and year of survey

Condom use at last sex	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005**						
No condom use	44	0 (0.0)	44	0 (0.0)	88	0 (0.0)
Condom use	17	0 (0.0)	11	0 (0.0)	28	0 (0.0)
p value		---		---		---
2006						
No condom use	52	1 (1.9)	41	0 (0.0)	93	1 (1.1)
Condom use	2	0 (0.0)	6	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
No condom use	58	1 (1.7)	51	0 (0.0)	110	1 (0.9)
Condom use	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		---		1.000
2008						
No condom use	43	0 (0.0)	52	0 (0.0)	95	0 (0.0)
Condom use	4	0 (0.0)	4	0 (0.0)	8	0 (0.0)
p value		---		---		---
2009						
No condom use	59	0 (0.0)	43	1 (2.3)	102	1 (1.0)
Condom use	6	0 (0.0)	6	0 (0.0)	12	0 (0.0)
p value		---		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

\*\*Question changed to "condom use with regular partner in last month" in 2005 survey.

Table 147 HIV antibody prevalence by sex work last month, gender and year of survey

Sex work last month	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
No sex work	116	0 (0.0)	72	0 (0.0)	189	0 (0.0)
Sex work	2	0 (0.0)	8	0 (0.0)	10	0 (0.0)
p value		---		---		---
2006						
No sex work	104	1 (1.0)	75	0 (0.0)	179	1 (0.6)
Sex work	3	0 (0.0)	9	0 (0.0)	12	0 (0.0)
p value		1.000		---		1.000
2007						
No sex work	109	2 (1.8)	75	0 (0.0)	185	2 (1.1)
Sex work	9	0 (0.0)	11	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
No sex work	85	0 (0.0)	79	0 (0.0)	165	0 (0.0)
Sex work	3	0 (0.0)	10	0 (0.0)	13	0 (0.0)
p value		---		---		---
2009						
No sex work	144	2 (1.4)	83	1 (1.2)	227	3 (1.3)
Sex work	6	0 (0.0)	4	0 (0.0)	10	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 148 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Non Indigenous	110	0 (0.0)	71	0 (0.0)	182	0 (0.0)
Indigenous	6	0 (0.0)	9	0 (0.0)	15	0 (0.0)
p value		---		---		---
2006						
Non Indigenous	99	1 (1.0)	74	0 (0.0)	173	1 (0.6)
Indigenous	8	0 (0.0)	10	0 (0.0)	18	0 (0.0)
p value		1.000		---		1.000
2007						
Non Indigenous	110	2 (1.8)	82	0 (0.0)	194	2 (1.0)
Indigenous	9	0 (0.0)	6	0 (0.0)	15	0 (0.0)
p value		1.000		---		1.000
2008						
Non Indigenous	76	0 (0.0)	78	0 (0.0)	155	0 (0.0)
Indigenous	17	0 (0.0)	9	0 (0.0)	26	0 (0.0)
p value		---		---		---
2009						
Non Indigenous	128	2 (1.6)	76	1 (1.3)	204	3 (1.5)
Indigenous	20	0 (0.0)	11	0 (0.0)	31	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

## South Australia

Table 149 HIV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
Australia	103	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	2	0 (0.0)	---	0 (0.0)	2	0 (0.0)
Asia	1	0 (0.0)	1	0 (0.0)	2	0 (0.0)
UK & Ireland	11	0 (0.0)	5	0 (0.0)	16	0 (0.0)
Other	5	0 (0.0)	2	0 (0.0)	7	0 (0.0)
p value		1.000		---		1.000
2006						
Australia	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Other Oceania	1	0 (0.0)	---	0 (0.0)	1	0 (0.0)
Asia	4	0 (0.0)	1	0 (0.0)	5	0 (0.0)
UK & Ireland	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
Other	5	0 (0.0)	3	0 (0.0)	8	0 (0.0)
p value		1.000		---		1.000
2007						
Australia	102	1 (1.0)	73	0 (0.0)	177	1 (0.6)
Other Oceania	1	0 (0.0)	2	0 (0.0)	3	0 (0.0)
Asia	2	0 (0.0)	0	0 (0.0)	2	0 (0.0)
UK & Ireland	7	1 (14.3)	11	0 (0.0)	18	1 (5.6)
Other	6	0 (0.0)	2	0 (0.0)	8	0 (0.0)
p value		0.254		---		0.276
2008						
Australia	79	0 (0.0)	75	0 (0.0)	154	0 (0.0)
Other Oceania	2	0 (0.0)	2	0 (0.0)	4	0 (0.0)
Asia	2	0 (0.0)	3	0 (0.0)	5	0 (0.0)
UK & Ireland	8	0 (0.0)	8	0 (0.0)	17	0 (0.0)
Other	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		---		---		---
2009						
Australia	137	2 (1.5)	80	1 (1.3)	217	3 (1.4)
Other Oceania	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
Asia	1	0 (0.0)	0	0 (0.0)	1	0 (0.0)
UK & Ireland	11	0 (0.0)	6	0 (0.0)	17	0 (0.0)
Other	3	0 (0.0)	2	0 (0.0)	5	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

Table 150 HIV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005						
English speaking	94	1 (1.1)	74	0 (0.0)	169	1 (0.6)
Non-English speaking	28	0 (0.0)	8	0 (0.0)	36	0 (0.0)
p value		0.600		---		0.600
2006						
English speaking	90	1 (1.1)	74	0 (0.0)	164	1 (0.6)
Non-English speaking	13	0 (0.0)	6	0 (0.0)	19	0 (0.0)
p value		1.000		---		1.000
2007						
English speaking	102	2 (2.0)	85	0 (0.0)	188	2 (1.1)
Non-English speaking	17	0 (0.0)	3	0 (0.0)	21	0 (0.0)
p value		1.000		---		1.000
2008						
English speaking	88	0 (0.0)	85	0 (0.0)	174	0 (0.0)
Non-English speaking	5	0 (0.0)	6	0 (0.0)	11	0 (0.0)
p value		---		---		---
2009						
English speaking	140	2 (1.4)	83	1 (1.2)	223	3 (1.4)
Non-English speaking	11	0 (0.0)	7	0 (0.0)	18	0 (0.0)
p value		1.000		1.000		1.000

\* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 151 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	122	54 (44)	82	40 (49)	205	95 (46)
2006	112	49 (44)	85	35 (41)	197	84 (43)
2007	120	50 (42)	89	31 (35)	211	82 (39)
2008	95	30 (32)	90	24 (27)	186	54 (29)
2009	155	65 (42)	91	36 (40)	246	101 (41)
$\chi^2$ trend p value		0.511		0.337		0.052

\* Total includes people whose gender was not reported or reported as transgender

Table 152 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	107	47 (44)	55	28 (51)	162	75 (46)
Bisexual	5	2 (40)	21	10 (48)	26	12 (46)
Homosexual	5	1 (20)	2	1 (50)	8	3 (38)
p value		0.600		1.000		0.900
2006						
Heterosexual	99	47 (47)	59	26 (44)	158	73 (46)
Bisexual	4	0 (0)	13	8 (62)	17	8 (47)
Homosexual	2	1 (50)	8	1 (13)	10	2 (20)
p value		0.164		0.089		0.316
2007						
Heterosexual	103	41 (40)	64	26 (41)	167	67 (40)
Bisexual	5	3 (60)	16	3 (19)	22	7 (32)
Homosexual	8	4 (50)	6	2 (33)	15	6 (40)
p value		0.542		0.304		0.759
2008						
Heterosexual	84	29(35)	55	17 (31)	139	46 (33)
Bisexual	5	1 (20)	23	4 (17)	28	5 (18)
Homosexual	3	0 (0)	10	3 (30)	13	3 (23)
p value		0.592		0.462		0.238
2009						
Heterosexual	134	59 (44)	68	27 (40)	202	86 (43)
Bisexual	11	3 (27)	12	6 (50)	23	9 (36)
Homosexual	4	0 (0)	9	3 (33)	13	3 (23)
p value		0.138		0.756		0.410

\* Total includes people whose gender was not reported or reported as transgender



Table 153 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	1	0 (0)	4	1 (25)	5	1 (20)
20 – 24	12	3 (25)	11	4 (36)	23	7 (30)
25 – 29	17	4 (24)	22	7 (32)	39	11 (28)
30 + years	92	47 (51)	45	28 (62)	138	76 (55)
p value		0.060		0.060		0.004
2006						
< 20 years	1	0 (0)	4	0 (0)	5	0 (0)
20 – 24	8	0 (0)	13	2 (15)	21	2 (10)
25 – 29	17	6 (35)	12	7 (58)	29	13 (45)
30 + years	85	42 (49)	56	26 (46)	141	68 (48)
p value		0.016		0.035		0.001
2007						
< 20 years	0	0 (0)	1	0 (0)	1	0 (0)
20 – 24	7	4 (57)	13	4 (31)	21	9 (43)
25 – 29	23	9 (39)	21	7 (33)	44	16 (36)
30 + years	89	36 (40)	53	20 (38)	143	56 (39)
p value		0.709		0.906		0.939
2008						
< 20 years	1	0 (0)	1	0 (0)	2	0 (0)
20 – 24	5	0 (0)	10	2 (20)	15	2 (13)
25 – 29	8	2 (25)	15	1 (7)	23	3 (13)
30 + years	81	28 (35)	64	21 (33)	146	49 (34)
p value		0.376		0.152		0.080
2009						
< 20 years	6	0 (0)	3	0 (0)	9	0 (0)
20 – 24	8	1 (13)	7	4 (57)	15	5 (33)
25 – 29	10	1 (10)	10	3 (30)	20	4 (20)
30 + years	131	63 (48)	70	29 (41)	201	92 (46)
p value		0.002		0.394		0.004

\* Total includes people whose gender was not reported or reported as transgender

Table 154 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	12	1 (8)	8	1 (13)	20	2 (10)
3 to 5 years	11	0 (0)	11	3 (27)	23	4 (17)
6 to 10 years	9	2 (22)	16	6 (38)	25	8 (32)
10 + years	85	48 (56)	44	29 (66)	129	77 (60)
p value		<0.001		0.007		<0.001
2006						
<3 years	5	1 (20)	9	0 (0)	14	1 (7)
3 to 5 years	9	0 (0)	9	1 (11)	18	1 (6)
6 to 10 years	22	4 (18)	22	6 (28)	44	10 (23)
10 + years	72	41 (57)	44	28 (64)	116	69 (59)
p value		<0.001		<0.001		<0.001
2007						
<3 years	8	0 (0)	7	4 (57)	15	4 (27)
3 to 5 years	9	3 (33)	11	2 (18)	20	5 (25)
6 to 10 years	18	6 (33)	22	7 (32)	41	13 (32)
10 + years	82	39 (48)	47	17 (36)	130	57 (44)
p value		0.043		0.405		0.209
2008						
<3 years	5	0 (0)	7	1 (14)	12	1 (8)
3 to 5 years	4	0 (0)	5	1 (20)	9	1 (11)
6 to 10 years	12	4 (33)	19	2 (11)	31	6 (19)
10 + years	74	26 (35)	57	20 (35)	132	46 (35)
p value		0.279		0.146		0.060
2009						
<3 years	4	0 (0)	10	1 (10)	14	1 (7)
3 to 5 years	9	0 (0)	7	1 (14)	16	1 (6)
6 to 10 years	17	4 (24)	13	7 (54)	30	11 (37)
10 + years	122	59 (48)	59	27 (46)	181	86 (48)
p value		0.001		0.056		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 155 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	6	2 (33)	71	40 (56)	77	42 (55)
Methamphetamine	12	0 (0)	72	27 (38)	84	27 (32)
More than one	0	0 (0)	6	5 (83)	6	5 (83)
Other/Not reported	2	0 (0)	36	21 (58)	38	21 (55)
p value		---		---		---
2006						
Heroin	1	0 (0)	39	23 (59)	40	23 (58)
Methamphetamine	8	0 (0)	89	22 (25)	99	22 (22)
More than one	0	0 (0)	3	0 (0)	3	0 (0)
Other/Not reported	5	1 (7)	47	35 (74)	55	39 (71)
p value		0.429		---		---
2007						
Heroin	3	2 (67)	57	29 (51)	60	31 (52)
Methamphetamine	9	1 (11)	78	19 (24)	90	23 (26)
More than one	1	0 (0)	5	1 (20)	6	1 (17)
Other/Not reported	2	1 (50)	51	26 (51)	55	27 (49)
p value		0.169		0.002		0.002
2008						
Heroin	3	1 (33)	45	22 (49)	48	23 (48)
Methamphetamine	7	0 (0)	85	12 (14)	92	12 (13)
More than one	0	0 (0)	2	2 (100)	2	2 (100)
Other/Not reported	2	0 (0)	40	17 (43)	44	17 (39)
p value		0.417		<0.001		<0.001
2009						
Heroin	3	0 (0)	79	40 (51)	83	41 (49)
Methamphetamine	6	1 (17)	83	28 (34)	90	29 (32)
More than one	0	0 (0)	5	3 (60)	5	3 (60)
Other/Not reported	5	0 (0)	60	27 (45)	68	28 (41)
p value		1.000		0.129		0.098

\* Total includes people who did not report duration of drug injection

## South Australia

Table 156 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	15	2 (13)	92	48 (52)	110	51 (46)
Daily or more	5	0 (0)	85	41 (48)	95	44 (46)
p value		0.400		0.600		0.900
2006						
Less than daily	9	1 (11)	84	36 (43)	93	37 (40)
Daily or more	3	0 (0)	89	43 (48)	95	45 (47)
p value		1.000		0.542		0.307
2007						
Less than daily	10	1 (10)	77	33 (43)	88	35 (40)
Daily or more	4	2 (50)	103	40 (39)	111	44 (40)
p value		0.176		0.646		1.000
2008						
Less than daily	6	0 (0)	68	19 (28)	74	19 (26)
Daily or more	4	1 (25)	87	30(34)	91	31 (34)
p value		0.400		0.487		0.307
2009						
Less than daily	6	1 (17)	89	43 (48)	96	44 (46)
Daily or more	5	0 (0)	118	51 (43)	126	53 (42)
p value		1.000		0.484		0.588

\* Total includes people who did not report duration of drug injection

Table 157 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	13	2 (15)	139	67 (48)	159	72 (45)
Receptive sharing	2	0 (0)	17	11 (65)	19	11 (58)
p value		0.600		0.200		0.300
2006						
No receptive sharing	10	0 (0)	141	61 (43)	154	63 (41)
Receptive sharing	1	0 (0)	28	14 (50)	29	14 (48)
p value		---		0.538		0.540
2007						
No receptive sharing	13	2 (15)	145	61 (42)	161	64 (40)
Receptive sharing	1	1 (100)	27	9 (33)	29	11 (38)
p value		0.214		0.523		1.000
2008						
No receptive sharing	7	0 (0)	125	40 (32)	132	40 (30)
Receptive sharing	3	1 (33)	26	8 (31)	29	9 (31)
p value		0.300		1.000		1.000
2009						
No receptive sharing	10	1 (10)	181	85 (47)	195	88 (45)
Receptive sharing	0	0 (0)	21	7 (33)	21	7 (33)
p value		1.000		0.484		0.588

\* Total includes people who did not report duration of drug injection

Table 158 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	18	2 (11)	151	72 (48)	174	75 (43)
Imprisoned	1	0 (0)	20	11 (55)	23	13 (57)
p value		0.700		0.500		0.200
2006						
Not imprisoned	14	0 (0)	153	67 (44)	171	70 (41)
Imprisoned	0	0 (0)	17	8 (47)	18	9 (50)
p value		---		0.803		0.464
2007						
Not imprisoned	12	3 (25)	150	51 (34)	165	55 (33)
Imprisoned	1	0 (0)	30	20 (67)	32	21 (66)
p value		1.000		0.002		0.001
2008						
Not imprisoned	11	1 (9)	139	42 (30)	151	43 (28)
Imprisoned	0	0 (0)	21	8 (38)	21	8 (38)
p value		---		0.460		0.445
2009						
Not imprisoned	13	1 (8)	180	72 (40)	197	74 (38)
Imprisoned	1	0 (0)	35	20 (57)	37	21 (57)
p value		1.000		0.065		0.044

\* Total includes people who did not report duration of drug injection

Table 159 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	19	2 (11)	163	84 (52)	189	89 (47)
Sex work	0	0 (0)	9	5 (56)	10	6 (60)
p value		--		0.800		0.400
2006						
No sex work	12	1 (8)	163	72 (44)	179	75 (42)
Sex work	2	0 (0)	10	6 (60)	12	6 (50)
p value		1.000		0.349		0.764
2007						
No sex work	12	3 (25)	169	70 (41)	185	75 (41)
Sex work	2	0 (0)	18	4 (22)	21	5 (24)
p value		1.000		0.134		0.161
2008						
No sex work	11	1 (9)	150	48 (32)	162	49 (30)
Sex work	0	0 (0)	13	5 (38)	13	5 (38)
p value		---		0.759		0.543
2009						
No sex work	14	1 (7)	208	93 (45)	227	96 (42)
Sex work	0	0 (0)	10	2 (20)	10	2 (20)
p value		---		0.192		0.202

\* Total includes people who did not report duration of drug injection

Table 160 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	110	45 (41)	71	34 (48)	182	80 (44)
Indigenous	6	5 (83)	9	5 (56)	15	10 (67)
p value		0.040		0.700		0.090
2006						
Non Indigenous	99	40 (40)	74	30 (41)	173	70 (41)
Indigenous	8	6 (75)	10	4 (40)	18	10 (56)
p value		0.072		1.000		0.315
2007						
Non Indigenous	110	43 (39)	82	29 (35)	194	73 (38)
Indigenous	9	6 (67)	6	2 (33)	15	8 (53)
p value		0.159		1.000		0.275
2008						
Non Indigenous	75	23 (31)	77	23 (30)	153	46 (30)
Indigenous	17	6 (35)	8	0 (0)	25	6 (24)
p value		0.775		0.101		0.640
2009						
Non Indigenous	128	50 (39)	76	28 (37)	204	78 (38)
Indigenous	20	12 (60)	11	7 (64)	31	19 (61)
p value		0.091		0.109		0.019

\* Total includes people whose gender was not reported or reported as transgender

Table 161 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	103	48 (47)	73	34 (47)	177	83 (47)
Other Oceania	2	0 (0)	0	0 (0)	2	0 (0)
Asia	1	1 (100)	1	1 (100)	2	2 (100)
UK & Ireland	11	4 (36)	5	4 (80)	16	8 (50)
Other	5	1 (20)	2	1 (50)	7	2 (29)
p value		0.300		0.400		0.300
2006						
Australia	90	37 (41)	74	29 (39)	164	66 (41)
Other Oceania	1	0 (0)	0	0 (0)	1	0 (0)
Asia	4	1 (25)	1	0 (0)	5	1 (20)
UK & Ireland	11	7 (64)	7	4 (57)	18	11 (61)
Other	5	3 (60)	3	2 (67)	8	5 (63)
p value		0.442		0.601		0.170
2007						
Australia	102	41 (40)	73	23 (32)	177	65 (37)
Other Oceania	1	0 (0)	2	0 (0)	3	0 (0)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	7	4 (57)	11	7 (64)	18	11 (61)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.361		0.087		0.041
2008						
Australia	79	24 (30)	73	15 (21)	152	39 (26)
Other Oceania	2	1 (50)	2	0 (0)	4	1 (25)
Asia	2	2 (100)	3	2 (67)	5	4 (80)
UK & Ireland	7	1 (14)	8	4 (50)	16	5 (31)
Other	3	2 (67)	2	2 (100)	5	4 (80)
p value		0.091		0.010		0.009
2009						
Australia	137	60 (44)	80	29 (36)	217	89 (41)
Other Oceania	3	2 (67)	2	1 (50)	5	3 (60)
Asia	1	0 (0)	0	0 (0)	1	0 (0)
UK & Ireland	11	3 (27)	6	5 (83)	17	8 (47)
Other	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.345		0.057		0.255

\* Total includes people whose gender was not reported or reported as transgender

Table 162 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	94	40 (43)	74	35 (47)	169	76 (45)
Non-English speaking	28	14 (50)	8	5 (63)	36	19 (53)
p value		0.500		0.400		0.400
2006						
English speaking	90	39 (43)	74	33 (45)	164	72 (44)
Non-English speaking	13	5 (38)	6	1 (17)	19	6 (32)
p value		1.000		0.233		0.338
2007						
English speaking	102	40 (39)	85	30 (35)	188	70 (37)
Non-English speaking	17	9 (53)	3	1 (33)	21	11 (52)
p value		0.301		1.000		0.237
2008						
English speaking	87	26 (30)	83	21 (25)	171	47 (27)
Non-English speaking	5	4 (80)	6	2 (33)	11	6 (55)
p value		0.037		0.646		0.083
2009						
English speaking	140	63 (45)	83	33 (40)	223	96 (43)
Non-English speaking	11	1 (9)	7	2 (29)	18	3 (17)
p value		0.025		0.701		0.044

\* Total includes people whose gender was not reported or reported as transgender



## Tasmania

Table 163 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	3	2	5	4	4
N <sup>o</sup> surveyed	N=137	N=150	N=168	N=57	N=122
Response (%)	--	50	45	25	22
Gender (%)					
Male	86 (63)	94 (63)	111 (66)	33 (58)	74 (61)
Female	51 (37)	56 (37)	57 (34)	24 (42)	47 (39)
Transgender	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	124 (91)	130 (87)	138 (82)	46 (81)	101 (83)
Bisexual	5 (4)	14 (9)	12 (7)	6 (11)	12 (10)
Homosexual	1 (1)	0 (0)	13 (8)	3 (5)	5 (4)
Not reported	7 (5)	6 (4)	5 (3)	2 (4)	4 (3)
Age and duration of injection (years)					
<i>Median age</i>	31	33	34	36	33
Age range	18-53	16-60	15-57	21-58	17-59
Age group (%)					
<25 years	23 (17)	21 (14)	26 (10)	3 (5)	13 (11)
25+ years	114 (83)	129 (86)	152 (90)	54 (95)	109 (89)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	19	18	18	18	19
Age range	11-49	11-47	10-44	11-38	11-44
Not reported	7	0 (0)	3	1	5
<i>Median years IDU</i>	11	12	14	16.5	13
Range	<1-34	<1-40	<1-40	1-41	<1-39
Duration of drug injection (%)					
<3 years	7 (5)	9 (6)	10 (6)	1 (2)	9 (7)
3+ years	122 (89)	137 (91)	155 (92)	55 (96)	108 (89)
Not reported	8 (6)	4 (3)	3 (2)	1 (2)	5 (4)
Aboriginal and Torres Strait Islander origin (%)					
No	121 (88)	121 (81)	141 (84)	50 (88)	100 (82)
Yes	12 (9)	25 (17)	25 (15)	5 (9)	15 (12)
Not reported	4 (3)	4 (3)	2 (1)	2 (4)	7 (6)
Region/Country of birth (%)					
Australia	138 (82)	138 (92)	159 (95)	48 (84)	111 (91)
Other Oceania	0 (0)	1 (<1)	3 (2)	0 (0)	2 (2)
Asia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
UK & Ireland	139 (82)	6 (4)	3 (2)	6 (11)	2 (2)
Other	140 (82)	2 (1)	0 (0)	0 (0)	2 (2)
Not reported	141 (82)	3 (2)	3 (2)	3 (5)	5 (4)
Main language spoken at home by parents (%)					
English speaking	115 (84)	136 (91)	165 (98)	55 (96)	119 (98)
Non-English speaking	22 (16)	2 (1)	3 (2)	2 (4)	1 (1)
Not reported	0 (0)	12 (8)	0 (0)	0 (0)	2 (2)
Imprisonment last year (%)					
No	113 (82)	126 (84)	139 (83)	45 (79)	98 (80)
Yes	18 (13)	19 (13)	25 (15)	7 (12)	17 (14)
Not reported	6 (4)	5 (3)	4 (2)	5 (9)	7 (6)
Injected in prison (%)	N=18	N=19	N=25	N=7	N=17
Yes	89 (61)	3 (16)	11 (44)	3 (43)	6 (35)
Frequency of injection last month (%)					
Not last month	6 (4)	4 (3)	6 (4)	2 (4)	7 (6)
Less than weekly	31 (23)	31 (21)	48 (29)	8 (14)	18 (15)
Weekly not daily	46 (34)	41 (27)	55 (33)	23 (40)	47 (39)
Daily or more	54 (39)	73 (49)	58 (35)	24 (42)	46 (38)
Not reported	0 (0)	1 (<1)	1 (<1)	0 (0)	4 (3)

Table 164 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=137	N=150	N=168	N=57	N=122
Anabolic steroids	1 (<1)	1 (<1)	0 (0)	0 (0)	1 (<1)
Cocaine	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
Heroin	2 (1)	3 (2)	3 (2)	4 (7)	4 (3)
Methadone	30 (22)	35 (23)	54 (32)	24 (42)	40 (33)
Methamphetamine	64 (47)	73 (49)	50 (30)	13 (23)	30 (25)
Pharm. Opioids	27 (20)	24 (16)	43 (26)	12 (21)	33 (27)
Subutex/Buprenorphine	1 (<1)	0 (0)	1 (<1)	1 (2)	2 (2)
More than one	6 (4)	6 (4)	5 (3)	1 (2)	4 (3)
Other	2 (1)	0 (0)	9 (5)	1 (2)	5 (4)
Not reported	4 (3)	5 (3)	3 (2)	1 (2)	3 (2)
N° Injected last month	N=131	N=145	N=161	N=55	N=111
Places injected last month (%)*					
Own home	115 (88)	121 (86)	147 (91)	50 (94)	102 (93)
Friend's home	51 (39)	52 (37)	72 (45)	13 (25)	40 (36)
Dealer's home	11 (8)	11 (8)	17 (11)	6 (11)	5 (5)
Street, park, beach	10 (8)	13 (9)	18 (11)	4 (8)	2 (2)
Car	36 (27)	52 (37)	51 (32)	15 (28)	37 (34)
Public toilet	18 (14)	19 (13)	24 (15)	9 (17)	13 (12)
Commercial injecting room	0 (0)	0 (0)	1 (<1)	0 (0)	0 (0)
Squat	0 (0)	1 (<1)	5 (3)	0 (0)	2 (2)
Use of new sterile needles & syringes last month (%)					
All injections	112 (86)	114 (79)	131 (81)	40 (73)	93 (84)
Most of the time	19 (15)	26 (18)	27 (17)	13 (24)	15 (14)
Half of the time	0 (0)	1 (<1)	0 (0)	0 (0)	2 (2)
Some of the time	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)
Not last month	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	3 (2)	2 (1)	2 (4)	1 (1)
<b>Re-used another's used needle &amp; syringe last month (%)</b>					
None	121 (92)	127 (88)	132 (82)	44 (80)	94 (85)
One	3 (2)	4 (3)	8 (5)	2 (4)	1 (1)
Twice	2 (2)	5 (3)	3 (2)	2 (4)	4 (4)
3-5 times	2 (2)	0 (0)	6 (4)	3 (5)	7 (6)
>5 times	0 (0)	2 (1)	2 (1)	2 (4)	2 (2)
Not reported	0 (0)	7 (5)	10 (6)	2 (4)	3 (3)
Number of people needle & syringe was re-used after last month (%)					
None	114 (87)	127 (88)	132 (82)	44 (80)	94 (85)
One	7 (5)	5 (3)	6 (4)	3 (5)	3 (3)
Two	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Three to five	0 (0)	1 (<1)	0 (0)	1 (2)	1 (1)
More than five	1 (1)	0 (0)	1 (<1)	0 (0)	1 (1)
Don't know	5 (4)	1 (<1)	4 (2)	1 (2)	3 (3)
Not reported	4 (3)	11 (8)	18 (11)	6 (11)	9 (8)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	5 (4)	5 (3)	7 (4)	4 (7)	4 (4)
Casual sex partner	0 (0)	1 (<1)	1 (<1)	0 (0)	0 (0)
Close friend	4 (3)	2 (1)	2 (1)	2 (4)	1 (1)
Acquaintance	1 (1)	1 (<1)	2 (1)	0 (0)	1 (1)
Other	2 (2)	0 (0)	0 (0)	0 (0)	2 (2)
Equipment used after someone else last month (%)*					
Spoon	9 (7)	11 (8)	16 (11)	4 (9)	6 (6)
Water	18 (14)	15 (11)	17 (11)	5 (11)	7 (7)
Filter	9 (7)	3 (2)	10 (7)	0 (0)	6 (6)
Drug mix	11 (8)	6 (4)	5 (3)	1 (2)	3 (3)
Tourniquet	12 (9)	12 (8)	12 (8)	7 (16)	7 (7)
None**	0 (0)	98 (69)	112 (75)	36 (82)	86 (84)
Injected by someone after that person injected themselves or others last month (%)					
No	110 (84)	111 (77)	130 (81)	47 (85)	83 (75)
Yes	14 (11)	27 (19)	21 (13)	4 (7)	27 (24)
Not reported	7 (5)	7 (5)	10 (6)	4 (7)	1 (1)

\* More than one option could be selected

\*\* New variable in 2006

Table 165 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=137	N=150	N=168	N=57	N=122
Any treatment/therapy for drug use (%)					
No	50 (37)	51 (34)	46 (27)	13 (23)	31 (25)
Yes	85 (62)	95 (63)	120 (71)	43 (75)	88 (72)
Not reported	2 (1)	4 (3)	2 (1)	1 (2)	3 (2)
History of methadone maintenance treatment (%)					
Currently	49 (36)	52 (35)	66 (39)	24 (42)	47 (39)
Previously	19 (14)	24 (16)	41 (24)	12 (21)	24 (20)
Never	67 (49)	70 (47)	61 (36)	21 (37)	46 (38)
Not reported	2 (1)	4 (3)	0 (0)	0 (0)	5 (4)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	4 (7)	7 (6)
Previously	--	--	--	10 (18)	27 (22)
Never	--	--	--	39 (68)	85 (70)
Not reported	--	--	--	4 (7)	3 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	2 (4)	5 (4)
Previously	--	--	--	2 (4)	14 (11)
Never	--	--	--	48 (84)	99 (81)
Not reported	--	--	--	5 (9)	4 (3)

\* New variable in 2008

Table 166 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=139#	N=91#
Source of needles/syringes (%)*		
Chemist/Pharmacy	18 (13)	21 (23)
Needle Syringe Program	130 (94)	73 (80)
Dispensing/Vending Machine	3 (2)	3 (3)
Friend/Dealer	15 (11)	15 (16)
Other	0 (0)	1 (1)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	3 (17)	5 (24)
Needle Syringe Program	108 (83)	52 (71)
Dispensing/Vending Machine	0 (0)	0 (0)
Friend/Dealer	3 (20)	1 (7)
Other	0 (0)	0 (0)
Number (%) reporting secondary exchange (onward supply) of needles and syringes last month		
N° Injected last month	N=161	N=111
Secondary exchange	67 (42)	33 (30)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

## Tasmania

Table 167 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=137	N=150	N=168	N=57	N=122
Sex with a regular partner last month (%) **					
No	45 (33)	55 (37)	63 (38)	23 (40)	52 (43)
Yes	88 (64)	91 (61)	103 (61)	34 (60)	59 (48)
Not reported	4 (3)	4 (3)	2 (1)	---	11 (9)
Condom used with regular partner last month (%)**					
N° surveyed	N=88	N=91	N=103	N=34	N=59
Never	67 (76)	70 (77)	74 (72)	21 (62)	51 (86)
Sometimes	9 (10)	9 (10)	15 (15)	5 (15)	1 (2)
Every time	3 (3)	8 (9)	9 (9)	7 (21)	4 (7)
Not reported	9 (10)	4 (4)	5 (5)	1 (3)	3 (5)
Sex with other partner/s last month (%)**					
No	113 (82)	132 (88)	145 (86)	48 (84)	86 (70)
Yes	21 (15)	9 (6)	16 (10)	7 (12)	19 (16)
Not reported	3 (2)	9 (6)	7 (4)	2 (4)	17 (14)
Condom used with other partner/s last month (%)**					
N° surveyed	N=21	N=9	N=16	N=7	N=19
Never	7 (33)	4 (44)	7 (44)	2 (29)	4 (21)
Sometimes	6 (29)	3 (33)	5 (31)	2 (29)	5 (26)
Every time	7 (33)	2 (22)	3 (19)	3 (43)	9 (47)
Not reported	1 (5)	0 (0)	1 (6)	0 (0)	1 (5)
Sex work last month (%)					
No	129 (94)	134 (89)	157 (93)	54 (95)	107 (88)
Yes	4 (3)	5 (3)	3 (2)	2 (4)	2 (2)
Not reported	4 (3)	11 (7)	8 (5)	1 (2)	13 (11)
Condom used at last sex work last month (%)*					
Yes	0 (0)	4 (80)	3 (100)	1 (100)	1 (50)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 168 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=137	N=150	N=168	N=57	N=122
Previous HIV test (%)					
Yes, last year	61 (45)	71 (47)	92 (55)	35 (61)	50 (41)
> 1 year ago	49 (36)	50 (33)	54 (32)	16 (28)	41 (34)
Never tested	25 (18)	25 (17)	22 (13)	5 (9)	18 (15)
Not reported	2 (1)	4 (3)	0 (0)	1 (2)	13 (11)
Previous HCV test (%)					
Yes, last year	70 (51)	81 (54)	99 (59)	37 (65)	71 (58)
> 1 year ago	43 (31)	44 (29)	53 (32)	17 (30)	37 (30)
Never tested	23 (17)	22 (15)	16 (10)	3 (5)	8 (7)
Not reported	1 (1)	3 (2)	0 (0)	0 (0)	6 (5)
Any treatment for HCV (%)	N=2	N=5	N=0	N=31	N=68
Interferon	1 (50)	3 (60)	0 (0)	0 (0)	2 (3)
Interferon+Ribarvarin	0 (0)	2 (40)	0 (0)	1 (3)	4 (6)
Other	1 (50)	0 (0)	0 (0)	29 (94)	1 (1)
No treatment	0 (0)	0 (0)	0 (0)	---	61 (90)
Not reported	0 (0)	0 (0)	0 (0)	1 (3)	0 (0)
Current treatment for HCV	N=0	N=0	N=0	N=0	N=0

HIV antibody prevalence

Table 169 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	86	0 (0.0)	51	0 (0.0)	137	0 (0.0)
2006	94	0 (0.0)	56	0 (0.0)	150	0 (0.0)
2007	110	0 (0.0)	56	0 (0.0)	166	0 (0.0)
2008	33	0 (0.0)	24	0 (0.0)	57	0 (0.0)
2009	73	0 (0.0)	47	0 (0.0)	121	0 (0.0)
$\chi^2$ trend p value		---		---		---

\* Total includes people whose gender was not reported or reported as transgender

HCV antibody prevalence

Table 170 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	86	51 (59)	51	30 (59)	137	81 (59)
2006	93	53 (57)	55	32 (58)	148	85 (57)
2007	91	52 (57)	43	30 (70)	134	82 (61)
2008	32	26 (81)	24	19 (79)	56	45 (80)
2009	73	38 (52)	45	24 (53)	119	63 (53)
$\chi^2$ trend p value		0.884		0.875		0.967

\* Total includes people whose gender was not reported or reported as transgender

Table 171 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	82	48 (59)	42	26 (62)	124	74 (60)
Bisexual	3	2 (67)	2	0 (0)	5	2 (40)
Homosexual		0 (0)	1	1 (100)	1	1 (100)
p value		---		---		---
2006						
Heterosexual	86	51 (59)	43	23 (53)	129	74 (57)
Bisexual	5	2 (40)	8	7 (88)	13	9 (69)
Homosexual	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.646		0.119		0.558
2007						
Heterosexual	83	46 (55)	28	18 (64)	111	64 (58)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	5	4 (80)	4	4 (100)	9	8 (89)
p value		0.626		0.432		
2008						
Heterosexual	31	25 (81)	14	11 (79)	45	36 (80)
Bisexual	0	0 (0)	6	5 (83)	6	5 (83)
Homosexual	1	1 (100)	2	2 (100)	3	3 (100)
p value		1.000		1.000		1.000
2009						
Heterosexual	64	33 (52)	33	18 (55)	98	52 (53)
Bisexual	4	3 (75)	8	5 (63)	12	8 (67)
Homosexual	4	2 (50)	1	0 (0)	5	2 (40)
p value		0.853		0.691		0.602

\* Total includes people whose gender was not reported or reported as transgender

Table 172 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	0	0 (0)	2	0 (0)	2	0 (0)
20 – 24	12	6 (50)	9	4 (44)	21	10 (48)
25 – 29	19	10 (53)	10	7 (70)	29	17 (59)
30 + years	55	35 (64)	30	19 (63)	85	54 (64)
p value		0.500		0.200		0.200
2006						
< 20 years	0	0 (0)	3	1 (33)	3	1 (33)
20 – 24	8	2 (25)	9	4 (44)	17	6 (35)
25 – 29	24	13 (54)	11	6 (55)	35	19 (54)
30 + years	61	38 (62)	32	21 (66)	93	59 (63)
p value		0.137		0.534		0.111
2007						
< 20 years	1	1 (100)	3	0 (0)	4	1 (25)
20 – 24	2	2 (100)	4	3 (75)	6	5 (83)
25 – 29	20	11 (55)	13	9 (69)	33	20 (61)
30 + years	68	38 (56)	23	18 (78)	91	56 (62)
p value		0.720		0.063		0.368
2008						
< 20 years	0	0 (0)	0	0 (0)	0	0 (0)
20 – 24	2	2 (100)	1	1 (100)	3	3 (100)
25 – 29	3	3 (100)	7	6 (86)	10	9 (90)
30 + years	27	21 (78)	16	12 (75)	43	33 (77)
p value		1.000		1.000		0.698
2009						
< 20 years	1	1 (100)	2	0 (0)	3	1 (33)
20 – 24	8	3 (38)	1	0 (0)	9	3 (33)
25 – 29	11	4 (36)	15	9 (60)	26	13 (50)
30 + years	53	30 (57)	27	15 (56)	81	46 (57)
p value		0.370		0.353		0.531

\* Total includes people whose gender was not reported or reported as transgender

Table 173 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	12	2 (17)	2	1 (50)	14	3 (21)
3 to 5 years	12	5 (42)	12	3 (25)	24	8 (33)
6 to 10 years	9	4 (44)	5	3 (60)	14	7 (50)
10 + years	48	37 (77)	29	21 (72)	77	58 (75)
p value		0.001		0.050		<0.001
2006						
<3 years	4	1 (25)	4	1 (25)	8	2 (25)
3 to 5 years	2	1 (50)	11	3 (28)	13	4 (31)
6 to 10 years	24	12 (50)	16	10 (63)	40	22 (55)
10 + years	60	37 (62)	23	18 (78)	83	55 (66)
p value		0.399		0.014		0.018
2007						
<3 years	5	1 (20)	2	0 (0)	7	1 (14)
3 to 5 years	3	1 (33)	5	1 (20)	8	2 (25)
6 to 10 years	17	10 (59)	8	5 (63)	25	15 (60)
10 + years	65	39 (60)	26	22 (85)	91	61 (67)
p value		0.322		0.003		0.007
2008						
<3 years	1	1 (100)	0	0 (0)	1	1 (100)
3 to 5 years	2	2 (100)	0	0 (0)	2	2 (100)
6 to 10 years	3	3 (100)	8	6 (75)	11	9 (82)
10 + years	26	20 (77)	15	12 (80)	41	32 (78)
p value		1.000		1.000		1.000
2009						
<3 years	5	0 (0)	4	1 (25)	9	1 (11)
3 to 5 years	6	4 (67)	7	2 (29)	13	6 (46)
6 to 10 years	10	4 (40)	8	4 (50)	18	8 (44)
10 + years	51	29 (57)	22	15 (68)	74	45 (61)
p value		0.073		0.188		0.028

\* Total includes people whose gender was not reported or reported as transgender

## Tasmania

Table 174 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	0	0 (0)	2	1 (50)	2	1 (2)
Methamphetamine	9	1 (11)	55	29 (53)	64	30 (47)
More than one	1	1 (100)	5	5 (100)	6	6 (100)
Other/Not reported	4	1 (25)	61	43 (70)	65	44 (68)
p value		0.225		0.043		0.008
2006						
Heroin	0	0 (0)	3	2 (67)	3	2 (67)
Methamphetamine	6	0 (0)	65	28 (43)	72	28 (39)
More than one	0	0 (0)	6	3 (50)	6	3 (50)
Other/Not reported	2	2 (100)	62	48 (77)	67	52 (78)
p value		0.036		<0.001		<0.001
2007						
Heroin	0	0 (0)	1	1 (100)	2	2 (100)
Methamphetamine	4	0 (0)	33	15 (45)	38	16 (42)
More than one	0	0 (0)	8	5 (63)	8	5 (63)
Other/Not reported	3	1 (33)	82	57 (70)	86	59 (69)
p value		0.429		0.070		0.023
2008						
Heroin	0	0 (0)	4	4 (100)	4	4 (100)
Methamphetamine	0	0 (0)	12	11 (92)	12	11 (92)
More than one	1	1 (100)	0	0 (0)	1	1 (100)
Other/Not reported	0	0 (0)	38	28 (74)	39	29 (74)
p value		---		0.377		0.547
2009						
Heroin	0	0 (0)	4	3 (75)	4	3 (75)
Methamphetamine	7	0 (0)	23	9 (39)	30	9 (30)
More than one	0	0 (0)	3	2 (67)	3	2 (67)
Other/Not reported	2	1 (50)	75	45 (60)	82	49 (60)
p value		0.222		0.273		0.014

\* Total includes people who did not report duration of drug injection



Table 175 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	10	2 (20)	68	41 (60)	83	46 (55)
Daily or more	4	1 (25)	47	32 (68)	54	35 (65)
p value		0.800		0.400		0.300
2006						
Less than daily	4	1 (25)	66	37 (56)	71	39 (55)
Daily or more	4	1 (25)	65	41 (63)	72	43 (60)
p value		1.000		0.478		0.614
2007						
Less than daily	3	1 (33)	80	53 (66)	84	55 (65)
Daily or more	3	0 (0)	41	25 (61)	45	26 (58)
p value		1.000		0.689		0.446
2008						
Less than daily	0	0 (0)	30	23 (77)	31	24 (77)
Daily or more	1	1 (100)	22	19 (86)	23	20 (87)
p value		---		0.488		0.489
2009						
Less than daily	6	1 (17)	57	34 (60)	65	37 (57)
Daily or more	1	0 (0)	40	23 (58)	44	24 (55)
p value		1.000		0.837		0.846

\* Total includes people who did not report duration of drug injection

Table 176 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	14	3 (21)	101	64 (63)	121	71 (59)
Receptive sharing	0	0 (0)	6	3 (50)	7	4 (57)
p value		-		0.900		0.500
2006						
No receptive sharing	8	2 (25)	113	67 (59)	125	71 (57)
Receptive sharing	0	0 (0)	11	8 (73)	11	8 (73)
p value		---		0.524		0.358
2007						
No receptive sharing	5	1 (20)	98	67 (68)	104	69 (66)
Receptive sharing	0	0 (0)	15	6 (40)	16	7 (44)
p value		---		0.043		0.098
2008						
No receptive sharing	1	1 (100)	42	34 (81)	43	35 (81)
Receptive sharing	0	0 (0)	8	8 (100)	9	9 (100)
p value		---		0.324		0.323
2009						
No receptive sharing	6	1 (17)	82	49 (60)	93	53 (57)
Receptive sharing	1	0 (0)	12	8 (67)	13	8 (62)
p value		1.000		0.759		1.000

\* Total includes people who did not report duration of drug injection

## Tasmania

Table 177 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	12	2 (17)	96	60 (63)	113	64 (57)
Imprisoned	1	1 (100)	15	10 (67)	18	13 (72)
p value		0.060		0.800		0.200
2006						
Not imprisoned	7	1 (14)	113	62 (55)	124	65 (52)
Imprisoned	1	1 (100)	18	15 (83)	19	16 (84)
p value		0.250		0.037		0.012
2007						
Not imprisoned	7	1 (14)	100	60 (60)	110	64 (58)
Imprisoned	0	0 (0)	20	15 (75)	20	15 (75)
p value		---		0.312		0.214
2008						
Not imprisoned	1	1 (100)	43	33 (77)	44	34 (77)
Imprisoned	0	0 (0)	6	6 (100)	7	7 (100)
p value		---		0.324		0.320
2009						
Not imprisoned	8	1 (13)	85	48 (56)	96	51 (53)
Imprisoned	0	0 (0)	15	10 (67)	16	10 (63)
p value		---		0.575		0.592

\* Total includes people who did not report duration of drug injection

Table 178 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	13	3 (13)	109	67 (61)	129	75 (58)
Sex work	0	0 (0)	3	3 (100)	4	3 (75)
p value		---		0.200		0.500
2006						
No sex work	6	2 (33)	123	71 (58)	133	75 (56)
Sex work	1	0 (0)	4	2 (50)	5	2 (40)
p value		1.000		1.000		0.655
2007						
No sex work	7	1 (14)	115	73 (63)	125	77 (62)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		0.536		0.526
2008						
No sex work	1	1 (100)	51	40 (78)	53	42 (79)
Sex work	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
No sex work	9	1 (11)	92	54 (59)	104	57 (55)
Sex work	0	0 (0)	1	1 (100)	2	2 (100)
p value		---		1.000		0.502

\* Total includes people who did not report duration of drug injection

Table 179 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	74	45 (61)	47	26 (55)	121	71 (59)
Indigenous	8	5 (63)	4	4 (100)	12	9 (75)
p value		0.900		0.100		0.300
2006						
Non Indigenous	73	39 (53)	48	28 (58)	121	67 (55)
Indigenous	17	11 (65)	6	3 (50)	23	14 (61)
p value		0.432		1.000		0.655
2007						
Non Indigenous	78	44 (56)	35	24 (69)	113	68 (60)
Indigenous	12	8 (67)	7	5 (71)	19	13 (68)
p value		0.550		1.000		0.614
2008						
Non Indigenous	29	23 (79)	20	16 (80)	49	39 (80)
Indigenous	3	3 (100)	2	1 (50)	5	4 (80)
p value		1.000		0.411		1.000
2009						
Non Indigenous	61	30 (49)	36	20 (56)	98	51 (52)
Indigenous	9	6 (67)	6	3 (50)	15	9 (60)
p value		0.479		1.000		0.593

\* Total includes people whose gender was not reported or reported as transgender

Table 180 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	79	45 (57)	47	27 (57)	126	72 (57)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	4	4 (100)	2	1 (50)	6	5 (83)
Other	2	2 (100)	1	1 (100)	3	3 (100)
p value		0.100		0.700		0.200
2006						
Australia	86	47 (55)	50	30 (60)	136	77 (57)
Other Oceania	0	0 (0)	1	0 (0)	1	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	3	2 (67)	3	2 (67)	6	4 (67)
Other	1	1 (100)	1	0 (0)	2	1 (50)
p value		1.000		0.533		0.769
2007						
Australia	86	48 (56)	39	26 (67)	125	74 (59)
Other Oceania	2	2 (100)	1	1 (100)	3	3 (100)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	2	1 (50)	1	1 (100)	3	2 (67)
Other	0	0 (0)	0	0 (0)	0	0 (0)
p value		0.754		1.000		0.557
2008						
Australia	30	24 (80)	17	13 (76)	47	37 (79)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	5	4 (80)	6	5 (83)
Other	0	0 (0)	1	1 (100)	1	1 (100)
p value		1.000		1.000		1.000
2009						
Australia	68	36 (53)	40	21 (53)	109	58 (53)
Other Oceania	1	0 (0)	1	1 (100)	2	1 (50)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	1	1 (100)	1	1 (100)	2	2 (100)
Other	0	0 (0)	2	1 (50)	2	1 (50)
p value		0.724		1.000		0.874

\* Total includes people whose gender was not reported or reported as transgender

Table 181 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	70	40 (57)	45	27 (60)	115	67 (58)
Non-English speaking	16	11 (69)	6	3 (50)	22	14 (64)
p value		0.600		0.400		0.600
2006						
English speaking	81	45 (56)	53	32 (60)	134	77 (57)
Non-English speaking	2	1 (50)	0	0 (0)	2	1 (50)
p value		1.000		---		1.000
2007						
English speaking	88	50 (57)	43	30 (70)	131	80 (91)
Non-English speaking	3	2 (67)	0	0 (0)	3	2 (67)
p value		1.000		---		1.000
2008						
English speaking	32	26 (81)	22	17 (77)	54	43 (80)
Non-English speaking	0	0 (0)	2	2 (100)	2	2 (100)
p value		---		1.000		1.000
2009						
English speaking	70	37 (53)	44	24 (55)	117	63 (54)
Non-English speaking	0	0 (0)	1	0 (0)	1	0 (0)
p value		---		0.467		0.466

\* Total includes people whose gender was not reported or reported as transgender

## Victoria

Table 182 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	5	4	7	6	6
N° surveyed	N=194	N=195	N=243	N=308	N=334
Response (%)	46	20	35	37	--
Gender (%)					
Male	116 (60)	126 (65)	166 (68)	206 (67)	216 (65)
Female	78 (40)	68 (35)	76 (31)	102 (33)	116 (35)
Transgender	0 (0)	0 (0)	1 (<1)	0 (0)	2 (<1)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	151 (78)	165 (85)	192 (79)	258 (84)	273 (82)
Bisexual	19 (10)	18 (9)	37 (15)	22 (7)	34 (10)
Homosexual	12 (6)	4 (2)	8 (3)	7 (2)	8 (2)
Not reported	12 (6)	8 (4)	6 (2)	21 (7)	19 (6)
Age and duration of injection (years)					
<i>Median age</i>	32	32	33	34	34
Age range	16-53	15-54	14-62	16-65	17-61
<i>Age group (%)</i>					
<25 years	33 (17)	27 (14)	19 (8)	19 (6)	29 (9)
25+ years	161 (83)	167 (86)	224 (92)	289 (94)	305 (91)
Not reported	0 (0)	1 (<1)	0 (0)	0 (0)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	18	18	17	18	18
Age range	11-35	10-41	10-42	10-45	11-51
Not reported	7	1	6	9	9
<i>Median years IDU</i>	12	13	13	15	14
Range	<1-37	<1-35	<1-46	<1-40	<1-40
<i>Duration of drug injection (%)</i>					
<3 years	11 (6)	7 (6)	12 (5)	19 (6)	13 (91)
3+ years	172 (89)	174 (89)	225 (93)	280 (91)	312 (93)
Not reported	11 (6)	14 (7)	6 (2)	9 (3)	9 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	178 (92)	170 (87)	217 (89)	266 (86)	304 (91)
Yes	9 (5)	14 (7)	14 (6)	28 (9)	23 (7)
Not reported	7 (4)	11 (6)	12 (5)	14 (5)	7 (2)
Region/Country of birth (%)					
Australia	156 (80)	160 (82)	202 (83)	259 (84)	285 (85)
Other Oceania	9 (5)	4 (2)	5 (2)	5 (2)	8 (2)
Asia	3 (2)	2 (1)	7 (3)	10 (3)	7 (2)
UK & Ireland	11 (6)	15 (8)	12 (5)	20 (6)	12 (4)
Other	15 (8)	8 (4)	10 (4)	8 (3)	20 (6)
Not reported	0 (0)	6 (3)	7 (3)	6 (2)	2 (<1)
Main language spoken at home by parents (%)					
English speaking	158 (81)	171 (88)	221 (91)	270 (88)	303 (91)
Non-English speaking	36 (19)	10 (5)	17 (7)	32 (10)	23 (7)
Not reported	0 (0)	14 (7)	5 (2)	6 (2)	8 (2)
Imprisonment last year (%)					
No	162 (84)	161 (83)	195 (80)	241 (78)	285 (85)
Yes	22 (11)	20 (10)	30 (12)	40 (13)	39 (12)
Not reported	10 (5)	14 (7)	18 (7)	27 (9)	10 (3)
Injected in prison (%)	N=22	N=20	N=30	N=40	N=39
Yes	10 (45)	5 (25)	9 (30)	12 (30)	12 (31)
Frequency of injection last month (%)					
Not last month	12 (6)	10 (5)	11 (5)	21 (7)	21 (6)
Less than weekly	31 (16)	31 (16)	30 (12)	53 (17)	44 (13)
Weekly not daily	41 (21)	47 (24)	53 (22)	61 (20)	69 (21)
Daily or more	110 (57)	106 (54)	143 (59)	167 (54)	196 (59)
Not reported	0 (0)	1 (<1)	6 (2)	6 (2)	4 (1)

Table 183 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=194	N=195	N=243	N=308	N=334
Anabolic steroids	0 (0)	1 (<1)	1 (<1)	3 (1)	1 (<1)
Cocaine	5 (3)	4 (2)	0 (0)	2 (1)	0 (0)
Heroin	96 (49)	71 (36)	131 (54)	180 (58)	205 (61)
Methadone	3 (2)	3 (2)	6 (2)	8 (3)	9 (3)
Methamphetamine	47 (24)	69 (35)	51 (21)	55 (18)	45 (13)
Pharm. Opioids	7 (4)	10 (5)	8 (3)	22 (7)	21 (6)
Subutex/Buprenorphine	19 (10)	22 (11)	27 (11)	21 (7)	26 (8)
More than one	4 (2)	9 (5)	8 (3)	6 (2)	10 (3)
Other	2 (1)	1 (<1)	6 (2)	2 (1)	11 (3)
Not reported	7 (4)	3 (2)	5 (2)	9 (3)	6 (2)
N <sup>o</sup> Injected last month	N=182	N=184	N=226	N=281	N=309
Places injected last month (%)*					
Own home	145 (80)	155 (89)	187 (85)	231 (84)	256 (83)
Friend's home	77 (42)	80 (46)	100 (46)	112 (41)	117 (38)
Dealer's home	20 (11)	30 (17)	35 (16)	65 (24)	56 (18)
Street, park, beach	54 (30)	56 (32)	82 (37)	91 (33)	109 (35)
Car	67 (37)	82 (47)	81 (37)	107 (39)	130 (42)
Public toilet	61 (34)	63 (36)	77 (35)	106 (39)	106 (34)
Commercial injecting room	--	2 (1)	2 (1)	3 (1)	6 (2)
Squat	11 (6)	14 (8)	21 (10)	30 (11)	28 (9)
Use of new sterile needles & syringes last month (%)					
All injections	131 (72)	117 (64)	150 (66)	186 (66)	224 (72)
Most of the time	47 (26)	48 (26)	64 (28)	76 (27)	69 (22)
Half of the time	3 (2)	8 (4)	3 (1)	7 (2)	7 (2)
Some of the time	0 (0)	5 (3)	2 (1)	6 (2)	5 (2)
Not last month	1 (1)	2 (1)	0 (0)	0 (0)	0 (0)
Not reported	0 (0)	4 (2)	7 (3)	6 (2)	4 (1)
<b>Re-used another's used needle &amp; syringe last month (%)</b>					
None	147 (81)	142 (77)	172 (76)	226 (80)	252 (82)
Once	5 (3)	8 (4)	14 (6)	11 (4)	16 (5)
Twice	7 (4)	9 (5)	9 (4)	19 (7)	13 (4)
3-5 times	5 (3)	10 (5)	9 (4)	11 (4)	9 (3)
>5 times	6 (3)	7 (4)	10 (4)	7 (2)	11 (4)
Not reported	12 (7)	8 (4)	12 (5)	7 (2)	8 (3)
Number of people needle & syringe was re-used after last month (%)					
None	139 (76)	142 (77)	172 (76)	226 (80)	252 (82)
One	20 (11)	19 (10)	24 (11)	27 (10)	26 (8)
Two	2 (1)	2 (1)	2 (1)	2 (1)	1 (<1)
Three to five	1 (1)	0 (0)	3 (1)	1 (<1)	2 (<1)
More than five	0 (0)	3 (2)	2 (1)	0 (0)	1 (<1)
Don't know	5 (3)	5 (3)	8 (4)	13 (5)	7 (2)
Not reported	15 (8)	13 (7)	15 (7)	12 (4)	20 (6)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	18 (10)	16 (9)	21 (9)	19 (7)	24 (8)
Casual sex partner	0 (0)	1 (<1)	2 (1)	0 (0)	0 (0)
Close friend	6 (3)	9 (5)	10 (4)	13 (5)	8 (3)
Acquaintance	5 (3)	3 (2)	6 (3)	2 (1)	2 (<1)
Other	2 (1)	1 (<1)	3 (1)	3 (1)	4 (1)
Equipment used after someone else last month (%)*					
Spoon	52 (29)	63 (36)	70 (34)	96 (36)	105 (36)
Water	42 (23)	34 (19)	43 (21)	56 (21)	55 (19)
Filter	35 (19)	32 (18)	36 (17)	45 (17)	49 (17)
Drug mix	31 (17)	15 (9)	21 (10)	31 (12)	31 (11)
Tourniquet	24 (13)	18 (10)	16 (8)	20 (8)	23 (8)
None**	0 (0)	96 (55)	118 (57)	151 (57)	167 (58)
Injected by someone after that person injected themselves or others last month (%)					
No	147 (81)	155 (84)	182 (81)	234 (83)	246 (80)
Yes	23 (13)	23 (13)	29 (13)	37 (13)	57 (18)
Not reported	12 (7)	6 (3)	15 (7)	10 (4)	6 (2)

\* More than one option could be selected

\*\* New variable in 2006

Victoria

Table 184 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=194	N=195	N=243	N=308	N=334
Any treatment/therapy for drug use (%)					
No	22 (11)	22 (11)	23 (9)	34 (11)	29 (9)
Yes	172 (89)	169 (87)	215 (88)	272 (88)	304 (91)
Not reported	0 (0)	4 (2)	5 (2)	2 (1)	1 (<1)
History of methadone maintenance treatment (%)					
Currently	56 (29)	58 (30)	78 (32)	100 (32)	88 (26)
Previously	66 (34)	66 (34)	81 (33)	104 (34)	125 (37)
Never	72 (37)	67 (34)	79 (33)	99 (32)	114 (34)
Not reported	0 (0)	4 (2)	5 (2)	5 (2)	7 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	40 (13)	52 (16)
Previously	--	--	--	121 (39)	136 (41)
Never	--	--	--	141 (46)	141 (42)
42)Not reported	--	--	--	6 (2)	5 (2)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	38 (12)	54 (16)
Previously	--	--	--	69 (22)	94 (28)
Never	--	--	--	196 (64)	181 (54)
Not reported	--	--	--	5 (2)	5 (2)

\* New variable in 2008

Table 185 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=204#	N=277#
Source of needles/syringes (%)*		
Chemist/Pharmacy	52 (25)	62 (22)
Needle Syringe Program	191 (94)	229 (83)
Dispensing/Vending Machine	0 (0)	2 (1)
Friend/Dealer	52 (25)	64 (23)
Other	9 (4)	13 (5)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	4 (8)	8 (13)
Needle Syringe Program	114 (60)	141 (62)
Dispensing/Vending Machine	0 (0)	0 (0)
Friend/Dealer	7 (13)	6 (9)
Other	0 (0)	2 (15)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=226	N=309
Secondary exchange	114 (50)	111 (36)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.



Table 186 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N° surveyed	N=194	N=195	N=243	N=308	N=334
Sex with a regular partner last month (%) **					
No	86 (44)	85 (44)	115 (47)	146 (47)	140 (42)
Yes	107 (55)	101 (52)	114 (47)	153 (50)	179 (54)
Not reported	1 (1)	9 (5)	14 (6)	9 (3)	15 (4)
Condom used with regular partner last month (%)**					
N° surveyed	N=107	N=101	N=114	N=153	N=179
Never	69 (64)	68 (67)	82 (72)	101 (66)	126 (70)
Sometimes	21 (20)	17 (17)	20 (18)	22 (14)	23 (13)
Every time	12 (11)	12 (12)	7 (6)	19 (12)	24 (13)
Not reported	5 (5)	4 (4)	5 (4)	11 (7)	6 (3)
Sex with other partner/s last month (%)**					
No	156 (80)	158 (81)	194 (80)	259 (84)	273 (82)
Yes	37 (19)	22 (11)	36 (15)	35 (11)	45 (13)
Not reported	1 (1)	15 (8)	13 (5)	14 (5)	16 (5)
Condom used with other partner/s last month (%)**					
N° surveyed	N=37	N=22	N=36	N=35	N=45
Never	7 (19)	6 (27)	8 (22)	9 (26)	14 (31)
Sometimes	5 (14)	6 (27)	13 (36)	14 (40)	10 (22)
Every time	23 (62)	8 (36)	14 (39)	10 (29)	20 (44)
Not reported	2 (5)	2 (9)	1 (3)	2 (6)	1 (2)
Sex work last month (%)					
No	168 (87)	169 (67)	218 (90)	266 (86)	308 (92)
Yes	24 (12)	12 (6)	15 (6)	17 (6)	17 (5)
Not reported	2 (1)	14 (7)	10 (4)	25 (8)	9 (3)
Condom used at last sex work last month (%)*					
Yes	47 (98)	10 (83)	12 (86)	11 (73)	15 (88)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 187 Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N° surveyed	N=194	N=195	N=243	N=308	N=334
Previous HIV test (%)					
Yes, last year	121 (62)	104 (53)	151 (62)	151 (49)	174 (52)
> 1 year ago	55 (28)	66 (34)	65 (27)	109 (35)	121 (36)
Never tested	16 (8)	18 (9)	19 (8)	34 (11)	29 (9)
Not reported	2 (1)	7 (4)	8 (3)	14 (5)	10 (3)
Previous HCV test (%)					
Yes, last year	127 (65)	114 (58)	154 (63)	176 (57)	194 (58)
> 1 year ago	50 (26)	58 (30)	78 (32)	98 (32)	110 (33)
Never tested	15 (8)	15 (8)	6 (2)	20 (6)	14 (4)
Not reported	2 (1)	8 (4)	5 (2)	14 (5)	16 (5)
Any treatment for HCV (%)	N=103	N=101	N=141	N=185	N=201
Interferon	2 (2)	3 (3)	6 (4)	10 (5)	8 (4)
Interferon+Ribarvarin	2 (2)	1 (1)	2 (1)	5 (3)	6 (3)
Other	4 (4)	3 (3)	3 (2)	6 (3)	5 (2)
No treatment	95 (92)	92 (91)	122 (87)	158 (85)	176 (88)
Not reported	0 (0)	2 (2)	8 (6)	6 (3)	6 (3)
Current treatment for HCV	N=5	N=3	N=3	N=5	N=2
Interferon/Interferon+Ribarvirin	1	2	2	3	2
Other	4	1	1	2	0

## HIV antibody prevalence

Table 188 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	102	1 (1.0)	76	0 (0.0)	178	1 (0.6)
2006	122	1 (0.8)	68	0 (0.0)	191	1 (0.5)
2007	163	0 (0.0)	76	0 (0.0)	240	0 (0.0)
2008	199	2 (1.0)	93	0 (0.0)	292	2 (0.7)
2009	215	3 (1.4)	116	0 (0.0)	333	3 (0.9)
$\chi^2$ trend p value		0.510		---		0.467

\* Total includes people whose gender was not reported or reported as transgender

## HCV antibody prevalence

Table 189 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	101	64 (63)	76	55 (72)	177	119 (67)
2006	121	84 (69)	67	50 (75)	189	135 (71)
2007	139	100 (72)	65	48 (74)	205	149 (73)
2008	188	141 (75)	90	58 (64)	278	199 (72)
2009	212	120 (57)	115	60 (52)	329	182 (55)
$\chi^2$ trend p value		0.175		<0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 190 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	83	53 (64)	53	37 (70)	136	90 (66)
Bisexual	6	4 (67)	13	9 (69)	19	13 (68)
Homosexual	6	3 (50)	5	5 (100)	11	8 (73)
p value		---		---		---
2006						
Heterosexual	105	74 (70)	54	38 (70)	160	113 (71)
Bisexual	8	3 (38)	10	9 (90)	18	12 (67)
Homosexual	1	1 (100)	3	3 (100)	4	4 (100)
p value		0.107		0.311		0.590
2007						
Heterosexual	124	91 (73)	37	30 (81)	161	121 (75)
Bisexual	9	5 (56)	24	16 (67)	33	21 (64)
Homosexual	3	2 (67)	2	1 (50)	6	4 (67)
p value		0.470		0.229		0.289
2008						
Heterosexual	165	122 (74)	67	44 (66)	232	166 (72)
Bisexual	5	4 (80)	16	9 (56)	21	13 (62)
Homosexual	4	3 (75)	3	3 (100)	7	6 (86)
p value		1.000		0.435		0.481
2009						
Heterosexual	186	108 (58)	82	40 (49)	270	150 (56)
Bisexual	11	5 (45)	22	14 (64)	33	19 (58)
Homosexual	4	1 (25)	4	2 (50)	8	3 (38)
p value		0.344		0.412		0.637

\* Total includes people whose gender was not reported or reported as transgender

Table 191 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	5	2 (40)	5	5 (100)	10	7 (70)
20 – 24	9	3 (33)	14	8 (57)	23	11 (48)
25 – 29	24	15 (63)	16	12 (75)	40	27 (68)
30 + years	63	44 (70)	41	30 (73)	104	74 (71)
p value		0.100		0.300		0.200
2006						
< 20 years	1	0 (0)	2	0 (0)	3	0 (0)
20 – 24	9	7 (78)	13	9 (69)	22	16 (73)
25 – 29	31	20 (65)	15	12 (80)	46	32 (70)
30 + years	79	56 (71)	37	29 (78)	117	86 (74)
p value		0.472		0.132		0.078
2007						
< 20 years	5	0 (0)	2	1 (50)	7	1 (14)
20 – 24	4	2 (50)	6	3 (50)	10	5 (50)
25 – 29	29	18 (62)	21	16 (76)	50	34 (68)
30 + years	101	80 (79)	36	28 (78)	138	109 (79)
p value		<0.001		0.346		0.001
2008						
< 20 years	2	0 (0)	3	0 (0)	5	0 (0)
20 – 24	7	3 (43)	6	1 (17)	13	4 (31)
25 – 29	34	22 (65)	29	18 (62)	63	40 (63)
30 + years	145	116 (80)	52	39 (75)	197	155 (79)
p value		0.004		0.002		<0.001
2009						
< 20 years	2	0 (0)	2	0 (0)	4	0 (0)
20 – 24	13	2 (15)	12	1 (8)	25	3 (12)
25 – 29	40	17 (43)	28	16 (57)	69	34 (49)
30 + years	157	101 (64)	73	43 (59)	231	145 (63)
p value		<0.001		0.002		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 192 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	10	5 (50)	7	6 (86)	17	11 (65)
3 to 5 years	11	5 (45)	9	5 (56)	20	10 (50)
6 to 10 years	13	8 (62)	13	10 (77)	26	18 (69)
10 + years	64	44 (69)	40	29 (73)	104	73 (70)
p value		0.300		0.600		0.400
2006						
<3 years	4	1 (25)	2	1 (50)	6	2 (33)
3 to 5 years	5	3 (60)	7	1 (14)	12	4 (33)
6 to 10 years	28	16 (57)	17	13 (76)	45	29 (64)
10 + years	75	57 (76)	38	32 (84)	114	90 (79)
p value		0.044		0.001		0.001
2007						
<3 years	7	1 (14)	5	1 (20)	12	2 (17)
3 to 5 years	4	0 (0)	4	2 (50)	8	2 (25)
6 to 10 years	26	14 (54)	20	17 (85)	47	32 (68)
10 + years	97	81 (84)	35	27 (77)	132	108 (82)
p value		<0.001		0.018		<0.001
2008						
<3 years	8	2 (25)	9	4 (44)	17	6 (35)
3 to 5 years	10	1 (10)	9	2 (22)	19	3 (16)
6 to 10 years	25	18 (72)	12	8 (67)	37	26 (70)
10 + years	139	115 (83)	57	43 (75)	196	158 (81)
p value		<0.001		0.007		<0.001
2009						
<3 years	6	2 (33)	6	0 (0)	12	2 (17)
3 to 5 years	10	5 (50)	14	3 (21)	24	8 (33)
6 to 10 years	34	11 (32)	22	10 (45)	57	22 (39)
10 + years	159	101 (64)	68	43 (63)	227	144 (63)
p value		0.003		0.001		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 193 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	5	4 (80)	84	60 (71)	89	64 (72)
Methamphetamine	5	2 (40)	37	21 (57)	42	23 (55)
More than one	0	0 (0)	4	2 (50)	4	2 (50)
Other/Not reported	7	5 (71)	37	27 (73)	44	32 (73)
p value		0.548		0.283		0.150
2006						
Heroin	2	1 (50)	67	54 (81)	70	55 (79)
Methamphetamine	3	1 (33)	58	37 (64)	66	42 (64)
More than one	0	0 (0)	7	5 (71)	8	6 (75)
Other/Not reported	1	0 (0)	39	27 (69)	45	32 (71)
p value		1.000		0.184		0.289
2007						
Heroin	4	2 (50)	101	78 (77)	106	81 (76)
Methamphetamine	4	0 (0)	36	25 (69)	42	27 (64)
More than one	0	0 (0)	5	4 (80)	6	4 (67)
Other/Not reported	4	0 (0)	45	35 (78)	51	37 (73)
p value		0.273		0.816		0.458
2008						
Heroin	6	3 (50)	151	114 (76)	161	120 (75)
Methamphetamine	7	3 (43)	42	29 (69)	50	32 (64)
More than one	0	0 (0)	6	5 (83)	6	5 (83)
Other/Not reported	4	0 (0)	53	39 (74)	61	42 (69)
p value		0.304		0.807		0.450
2009						
Heroin	4	0 (0)	194	117 (60)	201	119 (59)
Methamphetamine	1	0 (0)	41	18 (44)	45	21 (47)
More than one	1	1 (100)	9	5 (56)	10	6 (60)
Other/Not reported	6	1 (17)	64	34 (53)	73	36 (49)
p value		0.409		0.255		0.282

\* Total includes people who did not report duration of drug injection

Table 194 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	6	2 (33)	67	47 (70)	76	51 (67)
Daily or more	11	9 (82)	83	54 (65)	101	68 (67)
p value		0.500		0.050		0.900
2006						
Less than daily	3	1 (33)	68	48 (71)	74	52 (70)
Daily or more	3	1 (33)	92	69 (75)	104	77 (74)
p value		1.000		0.590		0.612
2007						
Less than daily	4	0 (0)	59	45 (76)	66	48 (73)
Daily or more	7	1 (14)	115	88 (77)	124	91 (73)
p value		1.000		1.000		1.000
2008						
Less than daily	8	3 (38)	96	74 (77)	108	79 (73)
Daily or more	5	2 (40)	137	101 (74)	147	107 (73)
p value		1.000		0.645		1.000
2009						
Less than daily	5	0 (0)	104	62 (60)	111	64 (58)
Daily or more	7	2 (29)	182	100 (55)	193	104 (54)
p value		0.470		0.459		0.551

\* Total includes people who did not report duration of drug injection

Table 195 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	13	10 (77)	112	77 (69)	133	93 (70)
Receptive sharing	3	1 (33)	16	8 (50)	21	10 (48)
p value		0.100		0.100		0.040
2006						
No receptive sharing	4	1 (25)	127	89 (70)	138	95 (69)
Receptive sharing	2	1 (50)	28	24 (86)	33	28 (85)
p value		1.000		0.105		0.084
2007						
No receptive sharing	8	0 (0)	129	97 (75)	140	100 (71)
Receptive sharing	2	1 (50)	36	28 (78)	39	30 (77)
p value		0.200		0.829		0.549
2008						
No receptive sharing	13	5 (38)	188	140 (74)	209	150 (72)
Receptive sharing	0	0 (0)	40	32 (80)	41	33 (80)
p value		---		0.547		0.335
2009						
No receptive sharing	11	2 (18)	234	135 (58)	249	140 (56)
Receptive sharing	1	0 (0)	44	23 (52)	47	24 (51)
p value		1.000		0.512		0.526

\* Total includes people who did not report duration of drug injection

Table 196 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	14	8 (57)	127	83 (65)	147	95 (65)
Imprisoned	2	2 (100)	14	13 (93)	20	18 (90)
p value		0.200		0.040		0.020
2006						
Not imprisoned	6	2 (33)	142	98 (69)	158	108 (68)
Imprisoned	0	0 (0)	17	14 (82)	18	15 (83)
p value		---		0.399		0.279
2007						
Not imprisoned	10	1 (10)	149	111 (75)	163	115 (71)
Imprisoned	1	1 (100)	26	20 (77)	28	22 (79)
p value		0.182		1.000		0.498
2008						
Not imprisoned	15	6 (40)	198	141 (71)	220	152 (69)
Imprisoned	1	0 (0)	33	27 (82)	35	27 (77)
p value		1.000		0.291		0.427
2009						
Not imprisoned	12	2 (17)	261	140 (54)	282	148 (52)
Imprisoned	0	0 (0)	38	28 (74)	38	28 (74)
p value		---		0.023		0.015

\* Total includes people who did not report duration of drug injection

Table 197 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	16	10 (63)	130	83 (64)	153	98 (64)
Sex work	1	1 (100)	18	16 (89)	22	19 (86)
p value		0.400		0.030		0.040
2006						
No sex work	6	2 (33)	146	102 (70)	163	113 (69)
Sex work	0	0 (0)	12	10 (83)	12	10 (83)
p value		---		0.511		0.514
2007						
No sex work	9	0 (0)	170	129 (76)	183	133 (73)
Sex work	2	1 (100)	11	8 (73)	13	10 (77)
p value		0.018		0.730		1.000
2008						
No sex work	15	6 (40)	219	164 (75)	241	175 (73)
Sex work	0	0 (0)	14	11 (79)	15	11 (73)
p value		---		1.000		1.000
2009						
No sex work	11	2 (18)	284	160 (56)	303	168 (55)
Sex work	1	0 (0)	15	8 (53)	17	8 (47)
p value		1.000		1.000		0.618

\* Total includes people who did not report duration of drug injection

Table 198 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	93	57 (61)	70	50 (71)	163	107 (66)
Indigenous	5	4 (80)	4	3 (75)	9	7 (78)
p value		0.400		0.900		0.500
2006						
Non Indigenous	105	72 (69)	59	45 (76)	165	118 (72)
Indigenous	7	6 (86)	6	4 (67)	13	10 (77)
p value		0.673		0.631		1.000
2007						
Non Indigenous	123	87 (71)	60	46 (77)	184	134 (73)
Indigenous	9	9 (100)	3	0 (0)	12	12 (75)
p value		0.113		0.017		1.000
2008						
Non Indigenous	165	121 (73)	77	50 (65)	242	171 (71)
Indigenous	16	14 (88)	10	6 (60)	26	20 (77)
p value		0.366		0.739		0.650
2009						
Non Indigenous	195	52 (51)	102	52 (51)	299	164 (55)
Indigenous	12	8 (73)	11	8 (73)	23	15 (65)
p value		1.000		0.213		0.389

\* Total includes people whose gender was not reported or reported as transgender



Table 199 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	79	46 (58)	64	47 (73)	143	93 (65)
Other Oceania	3	2 (67)	5	2 (40)	8	4 (50)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	8	7 (88)	2	2 (100)	10	9 (90)
Other	9	9 (100)	4	4 (100)	13	13 (100)
p value		0.020		0.100		0.030
2006						
Australia	96	67 (70)	57	42 (74)	154	110 (71)
Other Oceania	4	2 (50)	0	0 (0)	4	2 (50)
Asia	0	0 (0)	2	2 (100)	2	2 (100)
UK & Ireland	10	8 (80)	5	4 (80)	15	12 (80)
Other	6	3 (50)	2	1 (50)	8	4 (50)
p value		0.516		0.885		0.406
2007						
Australia	114	85 (75)	56	40 (71)	171	126 (74)
Other Oceania	2	2 (100)	1	0 (0)	3	2 (67)
Asia	4	3 (75)	1	1 (100)	5	4 (80)
UK & Ireland	9	6 (67)	2	2 (100)	11	8 (73)
Other	5	1 (20)	4	4 (100)	9	5 (56)
p value		0.092		0.371		0.753
2008						
Australia	159	120 (75)	76	47 (62)	235	167 (71)
Other Oceania	2	0 (0)	2	1 (50)	4	1 (25)
Asia	5	4 (80)	1	1 (100)	6	5 (83)
UK & Ireland	11	7 (64)	8	8 (100)	19	15 (79)
Other	9	8 (89)	3	1 (33)	12	9 (75)
p value		0.142		0.068		0.311
2009						
Australia	180	105 (58)	99	51 (52)	281	158 (56)
Other Oceania	5	3 (60)	2	1 (50)	7	4 (57)
Asia	5	2 (40)	2	1 (50)	7	3 (43)
UK & Ireland	7	3 (43)	5	4 (80)	12	7 (58)
Other	14	6 (43)	6	3 (50)	20	9 (45)
p value		0.650		0.873		0.832

\* Total includes people whose gender was not reported or reported as transgender

Table 200 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	80	51 (64)	64	45 (70)	144	96 (67)
Non-English speaking	21	13 (62)	12	10 (83)	33	23 (70)
p value		0.900		0.400		0.700
2006						
English speaking	104	72 (69)	62	45 (73)	167	118 (71)
Non-English speaking	6	3 (50)	3	3 (100)	9	6 (67)
p value		0.380		0.561		0.725
2007						
English speaking	126	92 (73)	60	43 (72)	187	136 (73)
Non-English speaking	10	7 (70)	4	4 (100)	14	11 (79)
p value		1.000		0.566		0.763
2008						
English speaking	162	120 (74)	85	57 (67)	247	177 (72)
Non-English speaking	21	17 (81)	5	1 (20)	26	18 (69)
p value		0.601		0.052		0.821
2009						
English speaking	193	107 (55)	103	54 (52)	298	163 (55)
Non-English speaking	16	11 (69)	7	3 (43)	23	14 (61)
p value		0.432		0.702		0.666

\* Total includes people whose gender was not reported or reported as transgender

## Western Australia

Table 201 Number (percentage) of respondents by demographic characteristics and year of survey

Demographic characteristics	2005	2006	2007	2008	2009
Number of sites	3	3	2	2	2
N° surveyed	N=169	N=160	N=110	N=196	N=222
Response (%)	48	53	51	73	80
Gender (%)					
Male	110 (65)	104 (65)	71 (65)	123 (63)	134 (60)
Female	59 (35)	55 (34)	39 (35)	73 (37)	87 (39)
Transgender	0 (0)	1 (<1)	0 (0)	0 (0)	1 (<1)
Not reported	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Sexual identity (%)					
Heterosexual	137 (81)	135 (84)	93 (85)	158 (81)	185 (83)
Bisexual	14 (8)	14 (9)	8 (7)	22 (11)	15 (7)
Homosexual	8 (5)	7 (4)	7 (6)	7 (4)	10 (5)
Not reported	10 (6)	4 (3)	2 (2)	9 (5)	12 (5)
Age and duration of injection (years)					
<i>Median age</i>	36	35	36.5	35	36
Age range	17-57	16-68	16-55	17-65	15-62
<i>Age group (%)</i>					
<25 years	30 (18)	18 (11)	10 (9)	12 (6)	16 (7)
25+ years	139 (82)	142 (89)	100 (91)	183 (93)	206 (93)
Not reported	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)
<i>Median age 1<sup>st</sup> IDU</i>	18	18	18	18	18
Age range	12-40	12-46	12-49	11-47	11-52
Not reported	3	0 (0)	2	5	7
<i>Median years IDU</i>	15	15	15	15	16
Range	<1-37	<1-41	<1-37	<1-42	<1-44
<i>Duration of drug injection (%)</i>					
<3 years	5 (3)	5 (3)	8 (7)	3 (2)	9 (4)
3+ years	154 (91)	153 (96)	100 (91)	188 (96)	206 (93)
Not reported	10 (6)	2 (1)	2 (2)	5 (3)	7 (3)
Aboriginal and Torres Strait Islander origin (%)					
No	156 (93)	153 (96)	102 (93)	179 (91)	208 (94)
Yes	10 (6)	4 (3)	5 (5)	9 (5)	12 (5)
Not reported	2 (1)	3 (2)	3 (3)	8 (4)	2 (1)
Region/Country of birth (%)					
Australia	138 (82)	130 (81)	90 (82)	149 (76)	179 (81)
Other Oceania	6 (4)	3 (2)	1 (1)	16 (8)	8 (4)
Asia	2 (1)	0 (0)	1 (1)	2 (1)	5 (2)
UK & Ireland	16 (9)	12 (8)	9 (8)	18 (9)	18 (8)
Other	6 (4)	11 (7)	5 (5)	7 (4)	7 (3)
Not reported	1 (1)	4 (3)	4 (4)	4 (2)	5 (2)
Main language spoken at home by parents (%)					
English speaking	143 (85)	144 (90)	105 (95)	186 (95)	216 (97)
Non-English speaking	26 (15)	6 (4)	2 (2)	10 (5)	5 (2)
Not reported	0 (0)	10 (6)	3 (3)	0 (0)	1 (<1)
Imprisonment last year (%)					
No	146 (86)	130 (81)	85 (77)	168 (86)	193 (87)
Yes	18 (11)	21 (13)	18 (16)	21 (11)	21 (9)
Not reported	6 (4)	9 (6)	7 (6)	7 (4)	8 (4)
Injected in prison (%)	N=18	N=21	N=18	N=21	N=21
Yes	11 (61)	7 (33)	6 (33)	8 (38)	7 (33)
Frequency of injection last month (%)					
Not last month	7 (4)	5 (3)	6 (5)	7 (4)	6 (3)
Less than weekly	18 (11)	20 (13)	9 (8)	15 (8)	22 (10)
Weekly not daily	38 (22)	42 (26)	21 (19)	49 (25)	43 (19)
Daily or more	106 (63)	92 (58)	73 (66)	124 (63)	150 (68)
Not reported	0 (0)	1 (<1)	1 (1)	1 (1)	1 (<1)

Table 202 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2005	2006	2007	2008	2009
Last drug injected (%)	N=170	N=160	N=110	N=196	N=222
Anabolic steroids	0 (0)	2 (1)	0 (0)	0 (0)	1 (<1)
Cocaine	0 (0)	0 (0)	0 (0)	0 (0)	2 (1)
Heroin	48 (28)	30 (19)	28 (25)	62 (32)	74 (33)
Methadone	6 (4)	9 (6)	4 (4)	5 (3)	12 (5)
Methamphetamine	57 (34)	72 (45)	34 (31)	54 (28)	43 (19)
Pharm. Opioids	24 (14)	22 (14)	23 (21)	42 (21)	37 (17)
Subutex/Buprenorphine	19 (11)	16 (10)	7 (6)	18 (9)	16 (7)
More than one	3 (2)	4 (3)	5 (5)	10 (5)	11 (5)
Other	5 (3)	1 (<1)	6 (6)	0 (0)	18 (8)
Not reported	7 (4)	1 (<1)	3 (3)	5 (3)	8 (4)
N <sup>o</sup> Injected last month	N=162	N=154	N=103	N=188	N=215
Places injected last month (%)*					
Own home	129 (80)	142 (96)	91 (93)	171 (92)	196 (91)
Friend's home	57 (35)	73 (49)	48 (49)	100 (54)	107 (50)
Dealer's home	28 (17)	32 (22)	31 (32)	56 (30)	49 (23)
Street, park, beach	25 (15)	27 (18)	23 (23)	55 (30)	51 (24)
Car	49 (30)	57 (39)	41 (42)	80 (43)	75 (35)
Public toilet	23 (14)	26 (18)	19 (19)	45 (24)	60 (28)
Commercial injecting room	0 (0)	1 (<1)	0 (0)	2 (1)	1 (<1)
Squat	2 (1)	2 (1)	8 (8)	18 (10)	19 (9)
Use of new sterile needles & syringes last month (%)					
All injections	103 (64)	102 (66)	58 (56)	119 (63)	148 (69)
Most of the time	44 (27)	40 (26)	29 (28)	56 (30)	56 (26)
Half of the time	5 (3)	6 (4)	6 (6)	5 (3)	4 (2)
Some of the time	4 (2)	3 (2)	7 (7)	3 (2)	3 (1)
Not last month	1 (1)	1 (<1)	0 (0)	3 (2)	1 (<1)
Not reported	6 (3)	2 (1)	3 (3)	2 (1)	3 (1)
Re-used another's needle & syringe last month (%)					
None	124 (78)	127 (82)	75 (73)	150 (80)	168 (78)
One	7 (4)	8 (5)	10 (10)	11 (6)	13 (6)
Twice	9 (6)	4 (3)	1 (1)	10 (5)	12 (6)
3-5 times	8 (5)	5 (3)	11 (11)	8 (4)	12 (6)
>5 times	3 (2)	6 (4)	3 (3)	8 (4)	6 (3)
Not reported	9 (5)	4 (3)	3 (3)	1 (1)	4 (2)
Number of people needle & syringe was re-used after last month (%)					
None	119 (73)	127 (82)	75 (73)	150 (80)	168 (78)
One	17 (10)	14 (9)	13 (13)	16 (9)	23 (11)
Two	3 (2)	0 (0)	1 (1)	2 (1)	5 (2)
Three to five	1 (1)	1 (<1)	1 (1)	1 (1)	1 (<1)
More than five	2 (1)	3 (2)	1 (1)	0 (0)	1 (<1)
Don't know	5 (3)	4 (3)	4 (4)	8 (4)	6 (3)
Not reported	16 (9)	5 (3)	9 (9)	11 (6)	11 (5)
Relationship to people needle & syringe was re-used after last month (%)*					
Regular sex partner	15 (9)	9 (6)	12 (12)	16 (9)	18 (8)
Casual sex partner	2 (1)	0 (0)	1 (1)	3 (2)	0 (0)
Close friend	11 (7)	9 (6)	7 (7)	8 (4)	13 (6)
Acquaintance	4 (2)	1 (<1)	0 (0)	3 (2)	5 (2)
Other	3 (1)	0 (0)	1 (1)	2 (1)	5 (2)
Equipment used after someone else last month (%)*					
Spoon	31 (19)	25 (16)	22 (22)	37 (23)	48 (24)
Water	31 (19)	27 (18)	14 (14)	29 (18)	37 (19)
Filter	25 (16)	23 (15)	13 (13)	20 (12)	35 (18)
Drug mix	16 (10)	17 (11)	12 (12)	20 (12)	20 (10)
Tourniquet	20 (12)	22 (14)	17 (17)	23 (14)	20 (10)
None**	0 (0)	97 (63)	63 (64)	100 (61)	131 (66)
Injected by someone after that person injected themselves or others last month (%)					
No	126 (78)	129 (84)	83 (81)	150 (80)	172 (80)
Yes	24 (15)	22 (14)	16 (16)	30 (16)	39 (18)
Not reported	13 (7)	3 (2)	4 (4)	8 (4)	4 (2)

\* More than one option could be selected

\*\* New variable in 2006

Table 203 Number (percentage) of respondents by treatment for drug use and year of survey

Treatment for drug use	2005	2006	2007	2008	2009
N° surveyed	N=169	N=160	N=110	N=196	N=222
Any treatment/therapy for drug use (%)					
No	40 (24)	41 (26)	31 (28)	54 (28)	57 (26)
Yes	125 (74)	113 (71)	76 (69)	139 (71)	158 (71)
Not reported	5 (2)	6 (4)	3 (3)	3 (2)	7 (3)
History of methadone maintenance treatment (%)					
Currently	50 (30)	30 (19)	21 (19)	39 (20)	53 (24)
Previously	34 (20)	43 (27)	27 (25)	55 (28)	52 (23)
Never	82 (49)	84 (53)	60 (55)	99 (51)	112 (50)
Not reported	4 (2)	3 (2)	2 (2)	3 (2)	5 (2)
History of buprenorphine (Subutex®) treatment (%)*					
Currently	--	--	--	21 (11)	27 (12)
Previously	--	--	--	59 (30)	43 (19)
Never	--	--	--	111 (57)	149 (67)
Not reported	--	--	--	5 (3)	3 (1)
History of buprenorphine-naloxone (Suboxone®) treatment (%)*					
Currently	--	--	--	18 (9)	25 (11)
Previously	--	--	--	24 (12)	28 (13)
Never	--	--	--	149 (76)	164 (74)
Not reported	--	--	--	5 (3)	5 (2)

\* New variable in 2008

Table 204 Number (percentage) of respondents by source of needle and syringe acquisition in the last month

	2007	2009
N° surveyed	N=79#	N=178#
Source of needles/syringes (%)*		
Chemist/Pharmacy	36 (27)	72 (40)
Needle Syringe Program	52 (25)	102 (57)
Dispensing/Vending Machine	1 (0)	0 (0)
Friend/Dealer	35 (44)	46 (26)
Other	2 (3)	5 (3)
Of those obtaining needles/syringes from a specific source in last month, number (percentage) that obtained exclusively from that source *		
Chemist/Pharmacy	6 (17)	26 (36)
Needle Syringe Program	30 (58)	61 (60)
Dispensing/Vending Machine	0 (0)	0 (0)
Friend/Dealer	6 (17)	9 (20)
Other	1 (50)	1 (20)
Number (%) reporting secondary exchange (onward supply) of needles/syringes last month		
N° Injected last month	N=103	N=215
Secondary exchange	66 (64)	89 (41)

\*\* More than one could be selected

# Excludes pick up at time of survey completion and missing data.

## Western Australia

Table 205 Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey

Sexual behaviour	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=169	N=160	N=110	N=196	N=222
Sex with a regular partner last month (%) **					
No	86 (51)	77 (48)	42 (38)	81 (41)	103 (46)
Yes	82 (49)	77 (48)	66 (60)	113 (58)	113 (51)
Not reported	2 (1)	6 (4)	2 (2)	2 (1)	6 (3)
Condom used with regular partner last month (%)**					
N <sup>o</sup> surveyed	N=82	N=77	N=66	N=113	N=113
Never	59 (72)	57 (74)	46 (70)	80 (71)	89 (79)
Sometimes	8 (10)	9 (12)	8 (12)	12 (11)	12 (11)
Every time	11 (13)	5 (6)	8 (12)	14 (12)	5 (4)
Not reported	5 (5)	6 (8)	4 (6)	7 (6)	7 (6)
Sex with other partner/s last month (%)**					
No	133 (79)	124 (78)	97 (88)	164 (84)	180 (81)
Yes	32 (19)	29 (18)	11 (10)	29 (15)	32 (14)
Not reported	4 (2)	7 (4)	2 (2)	3 (2)	10(5)
Condom used with other partner/s last month (%)**					
N <sup>o</sup> surveyed	N=32	N=29	N=11	N=29	N=32
Never	8 (25)	10 (34)	2 (18)	6 (21)	12 (38)
Sometimes	10 (31)	3 (10)	4 (36)	14 (48)	9 (28)
Every time	13 (41)	14 (48)	5 (45)	7 (24)	11 (34)
Not reported	1 (3)	2 (7)	0 (0)	2 (7)	0 (0)
Sex work last month (%)					
No	159 (94)	145 (91)	99 (90)	177 (90)	203 (91)
Yes	8 (5)	10 (6)	4 (4)	11 (6)	11 (5)
Not reported	2 (1)	5 (3)	7 (6)	8 (4)	8 (4)
Condom used at last sex work last month (%)*					
Yes	12 (92)	7 (88)	4 (100)	9 (82)	8 (73)

\* Percentages exclude missing data

\*\* New variable format commenced in 2005

Table 206 Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey

	2005	2006	2007	2008	2009
N <sup>o</sup> surveyed	N=170	N=160	N=110	N=196	N=222
Previous HIV test (%)					
Yes, last year	96 (56)	83 (52)	58 (53)	99 (51)	111 (50)
> 1 year ago	48 (28)	61 (38)	38 (35)	75 (38)	78 (35)
Never tested	25 (15)	12 (8)	12 (11)	14 (7)	26 (12)
Not reported	1 (1)	4 (3)	2 (2)	8 (4)	7 (3)
Previous HCV test (%)					
Yes, last year	103 (61)	94 (59)	62 (56)	108 (55)	128 (58)
> 1 year ago	45 (27)	52 (33)	34 (31)	65 (33)	71 (32)
Never tested	19 (11)	11 (7)	11 (10)	15 (8)	15 (7)
Not reported	2 (1)	3 (2)	3 (3)	8 (4)	8 (4)
Any treatment for HCV (%)	N=66	N=65	N=31	N=90	N=92
Interferon	1 (2)	3 (5)	2 (6)	5 (6)	5 (5)
Interferon+Ribarvarin	2 (3)	2 (3)	0 (0)	4 (4)	8 (9)
Other	1 (2)	2 (3)	1 (3)	4 (4)	1 (1)
No treatment	62 (94)	54 (83)	27 (87)	75 (83)	72 (78)
Not reported	0 (0)	4 (6)	1 (3)	2 (2)	6 (7)
Current treatment for HCV	N=2	N=2	N=1	N=5	N=5
Interferon/Interferon+Ribarvirin	2	1	1	3	5
Other	0	1	0	2	0

## HIV antibody prevalence

Table 207 HIV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2005	100	3 (3.0)	55	0 (0.0)	156	3 (1.9)
2006	82	1 (1.2)	49	0 (0.0)	132	1 (0.8)
2007	54	1 (1.9)	31	0 (0.0)	85	1 (1.2)
2008	106	2 (1.9)	62	0 (0.0)	168	2 (1.2)
2009	126	1 (0.8)	85	1 (1.2)	212	2 (0.9)
$\chi^2$ trend p value		0.299		0.251		0.525

\* Total includes people whose gender was not reported or reported as transgender

## HCV antibody prevalence

Table 208 HCV antibody prevalence by gender and year of survey

Year of survey	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005	101	59 (58)	55	31 (56)	156	90 (58)
2006	82	46 (56)	49	30 (61)	132	76 (58)
2007	54	23 (43)	31	14 (45)	85	37 (44)
2008	101	59 (58)	59	32 (54)	160	91 (57)
2009	125	60 (48)	85	42 (49)	211	102 (48)
$\chi^2$ trend p value		0.205		0.293		0.097

\* Total includes people whose gender was not reported or reported as transgender

Table 209 HCV antibody prevalence by sexual identity, gender and year of survey

Sexual identity	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heterosexual	89	56 (63)	37	21 (57)	126	77 (61)
Bisexual	4	0 (0)	10	5 (50)	14	5 (36)
Homosexual	4	1 (25)	3	1 (33)	7	2 (29)
p value		0.020		0.700		0.060
2006						
Heterosexual	73	43 (59)	36	22 (61)	109	65 (60)
Bisexual	4	2 (50)	8	6 (75)	13	8 (62)
Homosexual	1	0 (0)	5	2 (40)	6	2 (33)
p value		0.601		0.497		0.465
2007						
Heterosexual	50	23 (46)	23	11 (48)	73	34 (47)
Bisexual	1	0 (0)	4	1 (25)	5	1 (20)
Homosexual	3	0 (0)	3	1 (33)	6	1 (17)
p value		0.253		0.828		0.257
2008						
Heterosexual	91	53 (58)	39	19 (49)	130	72 (55)
Bisexual	4	2 (50)	14	10 (71)	18	12 (67)
Homosexual	3	1 (33)	4	2 (50)	7	3 (43)
p value		0.707		0.332		0.509
2009						
Heterosexual	109	52 (48)	68	32 (47)	177	84 (47)
Bisexual	3	2 (67)	9	7 (78)	12	9 (75)
Homosexual	4	2 (50)	6	2 (17)	10	4 (40)
p value		0.851		0.143		0.162

\* Total includes people whose gender was not reported or reported as transgender

Table 210 HCV antibody prevalence by age group, gender and year of survey

Age group	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
< 20 years	1	0 (0)	2	1 (50)	3	1 (33)
20 – 24	13	5 (38)	9	3 (33)	22	8 (36)
25 – 29	10	6 (60)	7	1 (14)	17	7 (41)
30 + years	77	48 (62)	37	26 (70)	114	74 (65)
p value		0.030		0.010		0.001
2006						
< 20 years	2	0 (0)	1	1 (100)	3	1 (33)
20 – 24	6	5 (83)	3	2 (67)	9	7 (78)
25 – 29	15	7 (47)	8	5 (63)	23	12 (52)
30 + years	59	34 (58)	37	22 (60)	97	56 (58)
p value		0.202		1.000		0.492
2007						
< 20 years	2	0 (0)	1	0 (0)	3	0 (0)
20 – 24	4	2 (50)	2	0 (0)	6	2 (33)
25 – 29	7	1 (14)	8	4 (50)	15	5 (33)
30 + years	41	20 (49)	20	10 (50)	61	30 (49)
p value		0.211		0.643		0.309
2008						
< 20 years	1	0 (0)	1	0 (0)	2	0 (0)
20 – 24	4	1 (25)	4	0 (0)	8	1 (13)
25 – 29	11	4 (36)	14	9 (64)	25	13 (52)
30 + years	84	53 (63)	40	23 (58)	124	76 (61)
p value		0.079		0.059		0.011
2009						
< 20 years	4	0 (0)	4	0 (0)	8	0 (0)
20 – 24	4	2 (50)	2	0 (0)	6	2 (33)
25 – 29	11	7 (64)	18	12 (67)	29	19 (66)
30 + years	106	51 (48)	61	30 (49)	168	81 (48)
p value		0.223		0.034		0.005

\* Total includes people whose gender was not reported or reported as transgender



Table 211 HCV antibody prevalence by duration of drug injection, gender and year of survey

Duration of drug injection	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
<3 years	5	1 (20)	2	0 (0)	5	1 (20)
3 to 5 years	10	5 (50)	4	1 (25)	10	5 (50)
6 to 10 years	17	5 (29)	8	4 (50)	17	5 (29)
10 + years	114	74 (65)	80	50 (63)	114	74 (65)
p value		0.100		0.010		0.010
2006						
<3 years	1	0 (0)	0	0 (0)	2	0 (0)
3 to 5 years	5	2 (40)	5	2 (40)	10	4 (40)
6 to 10 years	18	9 (50)	10	5 (50)	28	14 (50)
10 + years	57	35 (61)	33	22 (67)	90	57 (63)
p value		0.419		0.418		0.111
2007						
<3 years	4	0 (0)	3	0 (0)	7	0 (0)
3 to 5 years	4	2 (50)	3	1 (33)	7	3 (43)
6 to 10 years	12	2 (17)	8	1 (13)	20	3 (15)
10 + years	33	18 (55)	17	12 (71)	50	30 (60)
p value		0.036		0.006		<0.001
2008						
<3 years	0	0 (0)	2	1 (50)	2	1 (50)
3 to 5 years	10	2 (20)	5	1 (20)	15	3 (20)
6 to 10 years	13	6 (46)	12	4 (33)	25	10 (40)
10 + years	74	48 (65)	40	26 (65)	114	74 (65)
p value		0.019		0.078		0.001
2009						
<3 years	4	0 (0)	5	1 (20)	9	1 (11)
3 to 5 years	5	0 (0)	8	0 (0)	13	0 (0)
6 to 10 years	15	6 (40)	14	7 (50)	29	13 (45)
10 + years	95	52 (55)	58	34 (59)	154	86 (56)
p value		0.010		0.005		<0.001

\* Total includes people whose gender was not reported or reported as transgender

Table 212 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey

Last drug injected	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Heroin	1	1 (100)	46	30 (65)	47	31 (66)
Methamphetamine	3	0 (0)	47	22 (47)	50	22 (44)
More than one	0	0 (0)	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0)	55	35 (64)	56	35 (63)
p value		0.400		0.232		0.106
2006						
Heroin	1	0 (0)	26	20 (77)	27	20 (74)
Methamphetamine	0	0 (0)	59	29 (49)	60	30 (50)
More than one	0	0 (0)	3	2 (67)	3	2 (67)
Other/Not reported	1	0 (0)	40	24 (60)	42	24 (57)
p value		---		0.093		0.185
2007						
Heroin	0	0 (0)	22	17 (77)	23	18 (78)
Methamphetamine	4	0 (0)	22	5 (23)	26	5 (19)
More than one	1	0 (0)	3	1 (33)	4	1 (25)
Other/Not reported	2	0 (0)	30	13 (43)	32	13 (41)
p value		---		0.002		<0.001
2008						
Heroin	1	1 (100)	49	34 (69)	52	37 (71)
Methamphetamine	1	0 (0)	40	13 (14)	42	13 (31)
More than one	0	0 (0)	8	6 (75)	8	6 (75)
Other/Not reported	0	0 (0)	57	34 (60)	58	35 (60)
p value		1.000		0.003		0.001
2009						
Heroin	1	1 (100)	70	38 (54)	71	39 (55)
Methamphetamine	3	0 (0)	36	7 (19)	41	7 (17)
More than one	1	0 (0)	10	5 (50)	11	5 (45)
Other/Not reported	4	0 (0)	80	49 (61)	88	51 (58)
p value		0.222		<0.001		<0.001

\* Total includes people who did not report duration of drug injection

Table 213 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Less than daily	2	0 (0)	52	29 (56)	57	30 (53)
Daily or more	3	1 (33)	89	55 (62)	99	60 (61)
p value		0.400		0.500		0.300
2006						
Less than daily	2	0 (0)	48	27 (56)	51	27 (53)
Daily or more	0	0 (0)	74	45 (61)	75	46 (61)
p value		---		0.707		0.364
2007						
Less than daily	5	0 (0)	20	7 (35)	25	7 (28)
Daily or more	2	0 (0)	51	26 (51)	54	27 (50)
p value		---		0.293		0.088
2008						
Less than daily	1	0 (0)	50	27 (52)	52	27 (52)
Daily or more	1	1 (100)	100	59 (59)	104	63 (61)
p value		1.000		0.602		0.309
2009						
Less than daily	5	0 (0)	56	23 (41)	62	23 (37)
Daily or more	3	1 (33)	138	76 (55)	144	79 (55)
p value		0.375		0.084		0.023

\* Total includes people who did not report duration of drug injection

Table 214 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey

Re-used <b>someone else's used</b> needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No receptive sharing	3	1 (33)	103	59 (57)	115	64 (56)
Receptive sharing	1	0 (0)	23	17 (74)	25	18 (72)
p value		0.500		0.100		0.100
2006						
No receptive sharing	1	0 (0)	103	56 (54)	106	57 (54)
Receptive sharing	1	0 (0)	16	13 (81)	17	13 (76)
p value		---		0.057		0.113
2007						
No receptive sharing	5	0 (0)	55	26 (47)	61	27 (44)
Receptive sharing	2	0 (0)	13	6 (46)	15	6 (40)
p value		---		1.000		1.000
2008						
No receptive sharing	2	1 (50)	121	70 (58)	127	74 (58)
Receptive sharing	0	0 (0)	28	16 (57)	28	16 (57)
p value		---		1.000		1.000
2009						
No receptive sharing	7	1 (14)	150	73 (49)	160	75 (47)
Receptive sharing	1	0 (0)	40	24 (60)	42	25 (60)
p value		1.000		0.218		0.167

\* Total includes people who did not report duration of drug injection

Table 215 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey

Imprisonment last year	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Not imprisoned	5	1 (20)	120	67 (56)	133	71 (53)
Imprisoned	0	0 (0)	15	13 (87)	17	15 (88)
p value		---		0.020		0.001
2006						
Not imprisoned	2	0 (0)	104	55 (53)	107	56 (52)
Imprisoned	0	0 (0)	17	14 (82)	18	14 (78)
p value		---		0.033		0.070
2007						
Not imprisoned	7	0 (0)	59	27 (46)	66	27 (41)
Imprisoned	0	0 (0)	14	7 (50)	15	8 (53)
p value		---		1.000		0.402
2008						
Not imprisoned	2	1 (50)	133	74 (56)	139	78 (56)
Imprisoned	0	0 (0)	18	12 (67)	18	12 (67)
p value		---		0.453		0.456
2009						
Not imprisoned	9	1 (11)	172	82 (48)	185	85 (46)
Imprisoned	0	0 (0)	19	15 (79)	20	15 (75)
p value		---		0.014		0.018

\* Total includes people who did not report duration of drug injection

Table 216 HCV antibody prevalence by sex work last month, duration of drug injection and year of survey

Sex work last month	<3 years IDU		3+ years IDU		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
No sex work	5	1(20)	131	78 (60)	146	84 (58)
Sex work	0	0 (0)	8	4 (50)	8	4 (50)
p value		--		0.100		0.300
2006						
No sex work	2	0 (0)	117	67 (57)	121	68 (56)
Sex work	0	0 (0)	7	5 (71)	7	5 (71)
p value		---		0.698		0.698
2007						
No sex work	5	0 (0)	69	32 (46)	75	33 (44)
Sex work	1	0 (0)	3	1 (33)	4	1 (25)
p value		---		1.000		0.630
2008						
No sex work	2	1 (50)	140	79 (56)	146	83 (57)
Sex work	0	0 (0)	9	4 (44)	9	4 (44)
p value		---		0.510		0.507
2009						
No sex work	9	1 (11)	178	90 (51)	193	93 (48)
Sex work	0	0 (0)	10	5 (50)	10	5 (50)
p value		---		1.000		1.000

\* Total includes people who did not report duration of drug injection

Table 217 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey

Aboriginal and Torres Strait Islander origin	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Non Indigenous	93	53 (57)	51	29 (57)	144	82 (57)
Indigenous	6	4 (67)	4	2 (50)	10	6 (60)
p value		0.600		0.800		0.800
2006						
Non Indigenous	81	45 (56)	46	27 (59)	128	72 (56)
Indigenous	1	1 (100)	1	1 (100)	2	2 (100)
p value		1.000		1.000		0.506
2007						
Non Indigenous	51	21 (41)	28	12 (43)	79	33 (42)
Indigenous	2	1 (50)	3	2 (67)	5	3 (60)
p value		1.000		0.576		0.647
2008						
Non Indigenous	93	54 (58)	53	31 (58)	146	85 (58)
Indigenous	4	1 (25)	4	1 (25)	8	2 (25)
p value		0.313		0.309		0.079
2009						
Non Indigenous	122	57 (47)	78	39 (50)	201	96 (48)
Indigenous	1	1 (100)	7	3 (43)	8	4 (50)
p value		0.472		1.000		1.000

\* Total includes people who did not report duration of drug injection

Table 218 HCV antibody prevalence by region/country of birth, gender and year of survey

Region/Country of birth	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
Australia	84	48 (57)	43	25 (58)	127	73 (57)
Other Oceania	4	1 (25)	1	0 (0)	5	1 (20)
Asia	1	0 (0)	1	0 (0)	2	0 (0)
UK & Ireland	8	7 (88)	8	5 (63)	16	12 (75)
Other	3	2 (67)	2	1 (50)	5	3 (60)
p value		0.200		0.600		0.100
2006						
Australia	68	37 (54)	36	24 (67)	104	61 (59)
Other Oceania	0	0 (0)	3	1 (33)	3	1 (33)
Asia	0	0 (0)	0	0 (0)	0	0 (0)
UK & Ireland	6	3 (50)	4	3 (75)	11	6 (55)
Other	7	5 (71)	4	0 (0)	11	5 (45)
p value		0.670		0.034		0.733
2007						
Australia	43	18 (42)	26	13 (50)	69	31 (45)
Other Oceania	0	0 (0)	0	0 (0)	0	0 (0)
Asia	1	1 (100)	0	0 (0)	1	1 (100)
UK & Ireland	6	1 (17)	3	1 (33)	9	2 (22)
Other	3	2 (67)	2	0 (0)	5	2 (40)
p value		0.230		0.607		0.397
2008						
Australia	77	44 (57)	43	24 (56)	120	68 (57)
Other Oceania	6	1 (17)	7	2 (29)	13	3 (23)
Asia	2	2 (100)	0	0 (0)	2	2 (100)
UK & Ireland	8	6 (75)	5	4 (80)	13	10 (77)
Other	7	5 (71)	4	2 (50)	11	7 (64)
p value		0.139		0.374		0.042
2009						
Australia	102	46 (45)	67	34 (51)	169	80 (47)
Other Oceania	3	1 (33)	5	3 (60)	8	4 (50)
Asia	4	3 (75)	0	0 (0)	5	3 (60)
UK & Ireland	9	7 (78)	9	2 (22)	18	9 (50)
Other	4	2 (50)	3	2 (67)	7	4 (57)
p value				0.364		0.972

\* Total includes people whose gender was not reported or reported as transgender

Table 219 HCV antibody prevalence by main language spoken at home by parents, gender and year of survey

Main language spoken at home by parents	Male		Female		Total *	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2005						
English speaking	84	48 (57)	50	28 (56)	134	76 (57)
Non-English speaking	17	11 (65)	5	3 (60)	22	14 (64)
p value		0.600		0.900		0.500
2006						
English speaking	71	41 (58)	46	28 (61)	118	69 (58)
Non-English speaking	5	3 (60)	1	0 (0)	6	3 (50)
p value		1.000		0.404		0.695
2007						
English speaking	52	22 (42)	30	14 (47)	82	36 (44)
Non-English speaking	1	0 (0)	1	0 (0)	2	0 (0)
p value		1.000		1.000		0.504
2008						
English speaking	95	55 (58)	58	32 (55)	153	87 (57)
Non-English speaking	6	4 (67)	1	0 (0)	7	4 (57)
p value		1.000		0.458		1.000
2009						
English speaking	120	55 (46)	85	42 (49)	205	97 (47)
Non-English speaking	4	4 (100)	0	0 (0)	5	4 (80)
p value		0.049		---		0.198

\* Total includes people whose gender was not reported or reported as transgender





## Methodological Notes

All clients attending selected Needle and Syringe Program (NSP) sites during a one or two week period in October were asked to complete a brief, self-administered questionnaire and to provide a capillary blood sample for HIV and hepatitis C antibody testing. NSP sites were initially selected on the basis of volume of syringes distributed, coverage of all Australian jurisdictions and willingness to participate, with subsequent expansion based on size, geographic coverage and sub-populations targeted. NSP staff recorded sex, age group and survey participation for all clients at the NSP during the survey period to assess response rate and representativeness of the survey sample. Some clients visited the site more than once during the survey week. Consequently, it was also necessary to record whether each attendance at the NSP was the first that week for each client so that only one attendance per person was included in the response rate denominator. Ethical approval for the survey was obtained from ethics committees associated with the investigators and participating sites, and verbal rather than written informed consent was obtained to assure the anonymity of participants.

Demographic characteristics and behavioural data, including information on injecting drug use, injecting risk behaviours, needle and syringe acquisition, pharmacotherapy treatment for drug use, sexual behaviour, and HIV and hepatitis C testing history, were captured using a brief, self-administered, anonymous questionnaire. Capillary blood was obtained by finger-prick using disposable lancets and cotton-fibre blotting paper. Dried blood samples were kept at room temperature at the survey sites and couriered to a central laboratory every second or third day. HIV antibody was detected using Genetic Systems HIV-1 ELISA tests. Repeatedly reactive specimens were subjected to Western blot confirmatory testing (Bio-Rad New LAV blot 1, France).


A modified third generation enzyme immunoassay (Monolisa anti-HCV Plus Version 2 EIA, Biorad, France) was used to test for HCV antibody. A modified cut off value for optical density was calculated to capture greater than 95% of the seronegative population. Specimens were considered positive for HCV antibody if the optical density to cut off ratio was greater than or equal to one on initial and subsequent testing.

Data were analysed using the Stata, Version 10 (Stata Corporation, College Station TX). Changes for HIV and HCV antibody prevalence overtime were assessed using the  $\chi^2$  test for linear trends. Associations between demographic, behavioural variables, syringe use, and HIV/HCV antibody prevalence were assessed using the  $\chi^2$  test or Fisher's exact test where expected frequencies were less than five. Spearman's rho (non parametric equivalent of Pearson's correlation) was used to measure the correlation between HCV antibody prevalence and age and between HCV prevalence and time since onset of injecting. Percentage values may not add to 100 due to rounding.

As discussed on page 8, a substantial decline in HCV antibody prevalence nationally was observed in 2009, and the extent to which this may have been attributable to changes in the survey methodology was investigated. While the survey methodology was unchanged from previous years in the majority of jurisdictions, there were two changes in 2009 that may have had some influence on patterns of recruitment.

Firstly, there was a relatively minor change to survey methodology in South Australia. In this state, movie vouchers had historically been provided as reimbursement for survey participation and these were replaced with shopping vouchers in 2009. A second, and more significant change to reimbursement procedures occurred at Biala Alcohol and Drug Service in Queensland. At this site, survey respondents are not provided with reimbursement, and while this did not change, following completion of the ANSPS in 2009, respondents were offered the opportunity to participate in a quality of life assessment for which financial reimbursement was offered. A substantial increase in both ANSPS participant numbers and the response rate occurred at Biala as a result. Weighted HCV antibody prevalence was calculated to account for annual fluctuations in the number of participants recruited at each site. Weighting did not alter the national prevalence of HCV antibody in 2009 (unweighted 50% versus weighted 49%), nor did weighting alter the direction of HCV prevalence trends in any individual jurisdiction (Figure 11, data shown for NSW, QLD & SA).

Figure 11 Weighted HCV antibody prevalence (%) by selected state, 2005 - 2009



As an additional quality control measure, dried blood samples from three sentinel NSP sites were selected for HCV antibody retesting. Of the 217 samples selected, 214 (8% of the total survey) contained sufficient quantities of dried blood for retesting. There were no discernable differences in HCV antibody prevalence following the retest. Bio-Rad Laboratories (suppliers of Monolisa anti-HCV Plus test kits) advised that there were no significant changes to the format and constituents of the test kit. A parallel re-validation of the assay was undertaken for the retesting which confirmed there was no significant difference in the assay performance.

Further information is available in:

Iversen J, Wand H, Gonnermann A, Maher, L. (in press). Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008.

*International Journal of Drug Policy* doi:10.1016/j.drugpo.2010.04.004

Topp L, Iversen JL, Wand H, Day CA, Kaldor JM, Maher L. Representativeness of injecting drug users who participate in HIV surveillance: Results from Australia's Needle and Syringe Program Survey. *Journal of Acquired Immune Deficiency Syndrome* 2008; 47:632–638.

Topp L, Iversen JL, Conroy A, Salmon A, Maher L. Prevalence and predictors of injecting-related injury and disease among clients of Australia's Needle and Syringe Programs. *Australian and New Zealand Journal of Public Health* 2008; 32:34-37.

Day CA, Topp L, Iversen J, Maher L. Collaboration of Australian NSPs. Blood-borne virus prevalence and risk among steroid injectors: results from the Australian Needle and Syringe Program Survey. *Drug Alcohol Review* 2008; 27:559-561

Falster K, Kaldor JM, Maher L, on behalf of the collaboration of Australian Needle and Syringe Programs. Hepatitis C virus acquisition among injecting drug users: a cohort analysis of a national repeated cross-sectional survey of needle and syringe program attendees in Australia, 1995-2004. *J Urban Health* 2008; 86:106-118

National Centre in HIV Epidemiology and Clinical Research. *HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009*. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW. 2009.

White, B., Day, C., & Maher, L. Self reported risk behaviour among injecting drug users: self versus assisted questionnaire completion. *AIDS Care*, 2007; 19(3), 441-447.

MacDonald MA, Wodak AD, Dolan KA, et al. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. *Medical Journal of Australia* 2000;172(2): 57-61.

MacDonald M, Wodak A, Ali R, et al. HIV prevalence and risk behaviour in needle exchange attenders: a national study. *Medical Journal of Australia* 1997; 166: 237-240.

## Australian NSP Survey 2009

**Thank you for your help.**

This is a national study, endorsed by the Australian Injecting & Illicit Drug Users League (AIVL) and local user groups.

**BLOOD SPOTS**

When you have finished the questionnaire, please supply a blood spot.

**QUESTIONNAIRE**

Fill in this questionnaire and return it to the open (non-sealed) section of the plastic bag.

Shade bubbles like this: ●

Not like this: X ✓ ↓ =

You may use a pencil or blue/black pen.



1. Are you
  - Male
  - Female
  - Transgender
  
2. Do you identify as
  - Heterosexual
  - Bisexual
  - Gay/lesbian
  
3. How old are you? \_\_\_\_\_
  
4. How old were you when you first injected drugs? \_\_\_\_\_
  
5. What was the **LAST drug you INJECTED?** (MARK ONE ONLY)
  - Heroin
  - Methamphetamine (Speed, Base, Ice)
  - Cocaine
  - Methadone
  - Morphine
  - Anabolic steroids
  - Subutex/Buprenorphine
  - Suboxone
  - Other (please specify) \_\_\_\_\_
  
6. How often did you inject **last month**?
  - More than 3 times most days
  - 2 to 3 times most days
  - Once a day
  - More than weekly, not daily
  - Less than weekly (on 1 to 5 days)
  - Did not inject in the last month • **Go to Q11**
  
- 6a. Mark all the places where you injected **last month**.
  - Own home
  - Friend's home
  - Dealer's home
  - Street, park or beach
  - Car
  - Public toilet
  - Commercial "shooting" room
  - MSIC (KX injecting centre)
  - Squat
  - Other (please specify) \_\_\_\_\_
  
- 6b. How often did you use a **NEW** sterile needle and syringe **last month**?
  - All injections
  - Most of the time
  - Half of the time
  - Some of the time
  - Not last month
  
- 6c. Mark any equipment that you used after anyone else **last month**.
 

<input type="radio"/> Spoon	<input type="radio"/> Tourniquet
<input type="radio"/> Water	<input type="radio"/> Drug solution/mix
<input type="radio"/> Filter	<input type="radio"/> Did not share any of the above last month
  
- 6d. How many **TIMES last month** did someone else inject you after injecting themselves or others?
 

<input type="radio"/> More than 5 times	<input type="radio"/> 3 to 5 times
<input type="radio"/> Once or twice	<input type="radio"/> None

If you **did NOT** inject last month, go to Q11.

If you did inject last month, please continue.



7. Excluding today, have you obtained needles and syringes from any other source in the **last week**?

Yes

No

If yes, answer questions 8 to 8c in the column below



If no, answer questions 9 to 9c in the column below



8. In the last week, **how many times** have you obtained needles and syringes from the following sources? (write "0" if none)

Pharmacy/chemist \_\_\_\_\_  
 Needle/syringe program \_\_\_\_\_  
 Vending machine \_\_\_\_\_  
 Friend/family/dealer \_\_\_\_\_  
 Other \_\_\_\_\_

9. In the last month, **how many times** have you obtained needles and syringes from the following sources? (Write "0" if none)

Pharmacy/chemist \_\_\_\_\_  
 Needle/syringe program \_\_\_\_\_  
 Vending machine \_\_\_\_\_  
 Friend/family/dealer \_\_\_\_\_  
 Other \_\_\_\_\_

8a. Excluding today, the **last time** you obtained needles and syringes from the following sources, how many did you get and how many did you give away or sell? (If you got a "box" specify the number of syringes in the box. Write "0" if none)

	How many did you get?	How many did you give away or sell?
Pharmacy/chemist	_____	_____
Needle/syringe program	_____	_____
Vending machine	_____	_____
Friend/family/dealer	_____	_____
Other	_____	_____

9a. Excluding today, the **last time** you obtained needles and syringes from the following sources, how many did you get and how many did you give away or sell? (If you got a "box" specify the number of syringes in the box. Write "0" if none")

	How many did you get?	How many did you give away or sell?
Pharmacy/chemist	_____	_____
Needle/syringe program	_____	_____
Vending machine	_____	_____
Friend/family/dealer	_____	_____
Other	_____	_____

8b. In the last week, how many times have you injected? (write total number of times)

\_\_\_\_\_

9b. In the last month, how many times have you injected? (write total number of times).

\_\_\_\_\_

8c. How many needles and syringes are you picking up today? (If you are picking up a "box" specify the number of needles/syringes)

\_\_\_\_\_

9c. How many needles and syringes are you picking up today? (If you are picking up a "box" specify the number of needles and syringes)

\_\_\_\_\_

← Go to Q10  
 (do not answer questions 9 to 9c).

← Go to Q10.

10. How many **TIMES in the last month** did you re-use a needle & syringe **after** someone else had used it, including your sex partner (even if it was cleaned)?
- More than 5 times     3 to 5 times  
 Twice     Once  
 None ◀ **Go to Q11**
- 10a. How many different people (including your sex partner) have used a needle before you in the last month (even if cleaned)?
- More than 5 people  
 3 to 5 people  
 2 people  
 1 person  
 Don't know how many
- 10b. Who were these people?
- Regular sex partner  
 Other sex partners  
 Close friend  
 Acquaintance  
 Other, (please specify)  
 \_\_\_\_\_
11. Have you **EVER** been in prison?
- Yes     No ◀ **Go to Q12**
- 11a. If **YES**, were you in prison in the last 12 months?
- Yes     No ◀ **Go to Q12**
- 11b. If **YES**, did you inject drugs in prison?
- Yes     No
12. Have you had sex with a regular partner in the **last month**?
- Yes     No ◀ **Go to Q13**
- 12a. If **YES**, how often did you use a condom?
- Never     Sometimes  
 Every time
13. Have you had sex with other partners in the **last month**?
- Yes     No ◀ **Go to Q14**
- 13a. If **YES**, how often did you use a condom?
- Never     Sometimes  
 Every time
14. Have you been paid for sex in the **last month**?
- Yes     No ◀ **Go to Q15**
- 14a. If **YES**, did you use condoms the **last time** you were paid for sex?
- Yes     No
15. Have you ever been tested for HIV?
- Yes, in the last year  
 Yes, more than a year ago  
 Never tested ◀ **Go to Q16**
- 15a. If **YES**, what was the result of your last HIV test?
- Did not have HIV ◀ **Go to Q16**  
 I have HIV infection  
 Don't know result ◀ **Go to Q16**
- 15b. What year did you find out you had HIV?  
 \_\_\_\_\_
16. Have you ever been tested for hepatitis C?
- Yes, in the last year  
 Yes, more than a year ago  
 Never tested ◀ **Go to Q17**
- 16a. Have you ever been told that you have hepatitis C infection?
- Yes     No ◀ **Go to Q17**
- 16b. If **YES**, what is your current hepatitis C status?
- I have hepatitis C  
 I cleared the virus spontaneously  
 I cleared the virus with treatment  
 Don't know

- 16c. What year did you find out you had hep C?  
\_\_\_\_\_
- 16d. Have you **EVER** had any treatment for your hep C?  
 No treatment **Go to Q17**  
 Yes, interferon  
 Yes, interferon + ribavirin  
 Other, specify \_\_\_\_\_
- 16e. If **YES**, are you on any treatment for your hep C **NOW**?  
 No treatment     Yes, interferon  
 Yes, interferon + ribavirin  
 Other, specify \_\_\_\_\_
17. Have you ever been prescribed methadone?  
 Yes, am on it now  
 Yes, in the past  
 No, never
- 17a. Have you ever been prescribed Buprenorphine or Subutex?  
 Yes, am on it now  
 Yes, in the past  
 No, never
- 17b. Have you ever been prescribed Suboxone?  
 Yes, am on it now  
 Yes, in the past  
 No, never
- 17c. Have you ever had any other treatment or therapy for drug use? e.g. detox, rehab, counselling, NA?  
 Yes, am on it now  
 Yes, in the past  
 No, never
18. What was the main language spoken at home by your parents?  
 English  
 Other (please specify) \_\_\_\_\_
19. In which country were you born?  
 Australia  
 Other (please specify) \_\_\_\_\_
20. When were you born? \_\_\_\_\_ / \_\_\_\_\_  
month    year
21. Are you  
 Aboriginal     Torres Strait Islander  
 Both     Neither
22. Have you been in this survey before?  
 Yes     No
23. What are the first two letters of your **FIRST** name? \_\_\_\_\_
- 23a. What are the first two letters of your **LAST** name? \_\_\_\_\_
24. Who completed the questionnaire?  
 Self  
 Assisted by NSP staff  
 Assisted by other (please specify) \_\_\_\_\_
- All questions are voluntary. The name code (Q23) is used to see how drug use changes over time. We cannot identify you from the code. If you have been in the survey before, please use the same code. If you use initials other than your own, please use code you will remember for next time.

**Place the completed questionnaire in the open (non-sealable) section of the plastic bag. Please complete the blood spot now.**

## Participating NSP sites

Year		05	06	07	08	09
Number of NSP sites		52	45	52	52	51
<i>Australian Capital Territory</i>		1	1	1	1	1
Canberra	Directions ACT	✓	✓	✓	✓	✓
<i>New South Wales</i>		20	19	20	22	20
Albury	Albury Community Health Centre, GSAHS	✓	✓		✓	✓
Ballina/Byron	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Blacktown	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Coffs Harbour/Grafton	Harm Reduction Services, NCAHS				✓	✓
Canterbury	Resource and Education Program for IDUs, SSWAHS	✓	✓	✓	✓	
Gosford	Gosford Needle Syringe Program, NSCCAHS			✓	✓	✓
Liverpool	Health ConneXions, SSWAHS	✓	✓	✓	✓	✓
Long Jetty	Long Jetty Needle Syringe Program, NSCCAHS			✓	✓	✓
Kings Cross	K2 Health Service, SEIAHS	✓	✓	✓	✓	✓
Kings Cross	Kirketon Road Centre, SEIAHS	✓	✓	✓	✓	✓
Kogarah	St. George NSP, SEIAHS		✓	✓	✓	✓
Merrylands	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓			
Mt Druitt	Kelly Close Needle Syringe Program, SWAHS	✓		✓	✓	✓
Murwillumbah/Tweed	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
Nepean	South Court Primary Care NSP, SWAHS	✓	✓	✓	✓	✓
Newcastle	Hunter Harm Reduction Services, HNEAHS	✓	✓	✓	✓	✓
Newcastle	AIDS Council of NSW Hunter	✓	✓	✓	✓	✓
Nimbin/Lismore	Harm Reduction Services, NCAHS	✓	✓	✓	✓	✓
North Sydney	Responsive User Services in Health, NSCCAHS	✓	✓	✓	✓	
Parramatta	HIV/Hepatitis C Prevention Service, SWAHS	✓	✓	✓	✓	✓
Illawarra	First Step Program, SEIAHS (Port Kembla and Nowra)	✓	✓	✓	✓	✓
Redfern	Resource and Education Program for IDUs, SSWAHS	✓	✓	✓	✓	✓
Surry Hills	AIDS Council of New South Wales	✓				
Surry Hills	NSW Users and AIDS Association	✓	✓	✓	✓	✓
<i>Northern Territory</i>		3	2	3	3	3
Alice Springs	Northern Territory AIDS & Hepatitis Council	✓		✓	✓	✓
Darwin	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
Palmerston	Northern Territory AIDS & Hepatitis Council	✓	✓	✓	✓	✓
<i>Queensland</i>		7	7	7	8	8
Brisbane	Biala Community Alcohol and Drug Services	✓	✓	✓	✓	✓
Brisbane	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Cairns	Cairns ATODS NSP	✓	✓	✓	✓	✓
Gold Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Ipswich	West Moreton Sexual Health Service	✓	✓	✓	✓	✓
Sunshine Coast	Queensland Injectors Health Network	✓	✓	✓	✓	✓
Toowoomba	Kobi House	✓	✓	✓	✓	✓
Townsville	Townsville ATODS NSP				✓	✓



Participating NSP sites continued.

Year		05	06	07	08	09
<i>South Australia</i>		7	6	7	7	7
Adelaide	South Australia Voice for Intravenous Education (SAVIVE) AIDS Council -Norwood	✓	✓	✓	✓	✓
Adelaide	SAVIVE, Parks Community Health Service	✓	✓	✓	✓	✓
Adelaide	Noarlunga Community Health Service	✓	✓	✓	✓	✓
Adelaide	Nunukuwarrin Yunti Community Health Centre	✓		✓	✓	✓
Hindmarsh	Hindmarsh Centre	✓	✓	✓	✓	✓
Port Adelaide	SAVIVE, Port Adelaide Community Health Service	✓	✓	✓	✓	✓
Salisbury	SAVIVE, Northern Metropolitan Community Health Service NSP and Shopfront	✓	✓	✓	✓	✓
<i>Tasmania</i>		3	2	5	4	4
Clarence	Clarence Community Health Centre			✓	✓	✓
Devonport	Devonport Community Health Centre	✓				
Glenorchy	Tasmanian Council on AIDS, Hepatitis and Related Diseases	✓	✓	✓	✓	✓
Hobart	Tasmanian Council on AIDS, Hepatitis and Related Diseases	✓	✓	✓	✓	✓
Hobart	The Link - Youth Health Service			✓		
Launceston	Salvation Army Launceston			✓	✓	✓
<i>Victoria</i>		4	4	7	6	6
Barwon	Barwon Health Drug and Alcohol Services			✓	✓	✓
Bendigo	Bendigo NSP Services			✓		
Collingwood	InnerSpace NSP	✓	✓	✓	✓	✓
Dandenong	South East Alcohol and Drug Service	✓	✓			
Footscray	Health Works	✓				
Frankston	Southern Hepatitis/HIV/AIDS Resource & Prevention Service	✓	✓	✓	✓	✓
North Richmond	North Richmond NSP Services			✓	✓	✓
Northcote	Northcote NSP Services			✓	✓	✓
St Kilda	St Kilda NSP	✓	✓	✓	✓	✓
<i>Western Australia</i>		3	3	2	2	2
Bunbury	Western Australia Substance Users Association (WASUA)	✓	✓			
Northbridge	Western Australia Substance Users Association (WASUA)	✓	✓	✓	✓	✓
Perth	WA AIDS Council Mobile Exchange	✓	✓	✓	✓	✓

## List of Tables

### National

Table 1	Number (percentage) of respondents by demographic characteristics and year of survey.....	11
Table 2	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey.....	12
Table 3	Number (percentage) of respondents by treatment for drug use and year of survey.....	13
Table 4	Number (percentage) of respondents by source of needle and syringe acquisition in the last month.....	13
Table 5	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey.....	14
Table 6	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey.....	14
Table 7	HIV antibody prevalence by gender and year of survey.....	15
Table 8	HIV antibody prevalence by sexual identity, gender and year of survey.....	15
Table 9	HIV antibody prevalence by age group, gender and year of survey.....	16
Table 10	HIV antibody prevalence by duration of drug injection, gender and year of survey.....	17
Table 11	HIV antibody prevalence by last drug injected, gender and year of survey.....	18
Table 12	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	19
Table 13	HIV antibody prevalence by re-use of someone else’s used needle and syringe last month, gender and year of survey.....	20
Table 14	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	20
Table 15	HIV antibody prevalence by condom use at last sex with regular partner, gender and year of survey.....	21
Table 16	HIV antibody prevalence by sex work last month, gender and year of survey.....	21
Table 17	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	22
Table 18	HIV antibody prevalence by region/country of birth, gender and year of survey.....	23
Table 19	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	24
Table 20	HCV antibody prevalence by gender and year of survey.....	25
Table 21	HCV antibody prevalence by sexual identity, gender and year of survey.....	25
Table 22	HCV antibody prevalence by age group, gender and year of survey.....	26
Table 23	HCV antibody prevalence by duration of drug injection, gender and year of survey.....	27
Table 24	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	28
Table 25	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	29
Table 26	HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, duration of drug injection and year of survey.....	29
Table 27	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey.....	30
Table 28	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey.....	30
Table 29	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	31
Table 30	HCV antibody prevalence by region/country of birth, gender and year of survey.....	32
Table 31	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	33

## Australian Capital Territory

Table 32	Number (percentage) of respondents by demographic characteristics and year of survey .....	34
Table 33	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	35
Table 34	Number (percentage) of respondents by treatment for drug use and year of survey .....	36
Table 35	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	36
Table 36	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	37
Table 37	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	37
Table 38	HIV antibody prevalence by gender and year of survey .....	38
Table 39	HCV antibody prevalence by gender and year of survey .....	38
Table 40	HCV antibody prevalence by sexual identity, gender and year of survey .....	38
Table 41	HCV antibody prevalence by age group, gender and year of survey .....	39
Table 42	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	40
Table 43	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	41
Table 44	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	42
Table 45	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	42
Table 46	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	43
Table 47	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	43
Table 48	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	44
Table 49	HCV antibody prevalence by region/country of birth, gender and year of survey .....	45
Table 50	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	46

New South Wales

Table 51	Number (percentage) of respondents by demographic characteristics and year of survey.....	47
Table 52	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey.....	48
Table 53	Number (percentage) of respondents by treatment for drug use and year of survey.....	49
Table 54	Number (percentage) of respondents by source of needle and syringe acquisition in the last month.....	49
Table 55	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey.....	50
Table 56	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey.....	50
Table 57	HIV antibody prevalence by gender and year of survey.....	51
Table 58	HIV antibody prevalence by sexual identity, gender and year of survey.....	51
Table 59	HIV antibody prevalence by age group, gender and year of survey.....	52
Table 60	HIV antibody prevalence by duration of drug injection, gender and year of survey.....	53
Table 61	HIV antibody prevalence by last drug injected, gender and year of survey.....	54
Table 62	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	55
Table 63	HIV antibody prevalence by re-use of someone else’s used needle & syringe last month, gender and year of survey.....	56
Table 64	HIV antibody prevalence by imprisonment last year, gender and year of survey.....	56
Table 65	HIV antibody prevalence by condom use at last sex, gender and year of survey.....	57
Table 66	HIV antibody prevalence by sex work last month, gender and year of survey.....	57
Table 67	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	58
Table 68	HIV antibody prevalence by region/country of birth, gender and year of survey.....	59
Table 69	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	60
Table 70	HCV antibody prevalence by gender and year of survey.....	61
Table 71	HCV antibody prevalence by sexual identity, gender and year of survey.....	61
Table 72	HCV antibody prevalence by age group, gender and year of survey.....	62
Table 73	HCV antibody prevalence by duration of drug injection, gender and year of survey.....	63
Table 74	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	64
Table 75	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	65
Table 76	HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, duration of drug injection and year of survey.....	65
Table 77	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey.....	66
Table 78	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey.....	66
Table 79	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey.....	67
Table 80	HCV antibody prevalence by region/country of birth, gender and year of survey.....	68
Table 81	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	69

## Northern Territory

Table 82	Number (percentage) of respondents by graphic characteristics and year of survey .....	70
Table 83	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	71
Table 84	Number (percentage) of respondents by treatment for drug use and year of survey .....	72
Table 85	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	72
Table 86	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	73
Table 87	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	73
Table 88	HIV antibody prevalence by gender and year of survey .....	74
Table 89	HCV antibody prevalence by gender and year of survey .....	74
Table 90	HCV antibody prevalence by sexual identity, gender and year of survey .....	74
Table 91	HCV antibody prevalence by age group, gender and year of survey .....	75
Table 92	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	76
Table 93	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	77
Table 94	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	78
Table 95	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	78
Table 96	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	79
Table 97	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	79
Table 98	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	80
Table 99	HCV antibody prevalence by region/country of birth, gender and year of survey .....	81
Table 100	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	82

Queensland

Table 101	Number (percentage) of respondents by demographic characteristics and year of survey .....	83
Table 102	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey.....	84
Table 103	Number (percentage) of respondents by treatment for drug use and year of survey .....	85
Table 104	Number (percentage) of respondents by source of needle and syringe acquisition in the last month.....	85
Table 105	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	86
Table 106	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	86
Table 107	HIV antibody prevalence by gender and year of survey.....	87
Table 108	HIV antibody prevalence by sexual identity, gender and year of survey .....	87
Table 109	HIV antibody prevalence by age group, gender and year of survey .....	88
Table 110	HIV antibody prevalence by duration of drug injection, gender and year of survey.....	89
Table 111	HIV antibody prevalence by last drug injected, gender and year of survey.....	90
Table 112	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey.....	91
Table 113	HIV antibody prevalence by re-use of someone else’s used needle and syringe last month, gender and year of survey.....	92
Table 114	HIV antibody prevalence by imprisonment last year, gender and year of survey .....	92
Table 115	HIV antibody prevalence by condom use at last sex, gender and year of survey .....	93
Table 116	HIV antibody prevalence by sex work last month, gender and year of survey .....	93
Table 117	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	94
Table 118	HIV antibody prevalence by region/country of birth, gender and year of survey.....	95
Table 119	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	96
Table 120	HCV antibody prevalence by gender and year of survey .....	97
Table 121	HCV antibody prevalence by sexual identity, gender and year of survey.....	97
Table 122	HCV antibody prevalence by age group, gender and year of survey.....	98
Table 123	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	99
Table 124	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	100
Table 125	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	101
Table 126	HCV antibody prevalence by re-use of someone else’s used needle and syringe last month, duration of drug injection and year of survey .....	101
Table 127	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey.....	102
Table 128	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey.....	102
Table 129	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	103
Table 130	HCV antibody prevalence by region/country of birth, gender and year of survey .....	104
Table 131	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey.....	105

## South Australia

Table 132	Number (percentage) of respondents by demographic characteristics and year of survey .....	106
Table 133	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	107
Table 134	Number (percentage) of respondents by treatment for drug use and year of survey .....	108
Table 135	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	108
Table 136	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	109
Table 137	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	109
Table 138	HIV antibody prevalence by gender and year of survey .....	110
Table 139	HIV antibody prevalence by sexual identity, gender and year of survey .....	110
Table 140	HIV antibody prevalence by age group, gender and year of survey .....	111
Table 141	HIV antibody prevalence by duration of drug injection, gender and year of survey .....	112
Table 142	HIV antibody prevalence by last drug injected, gender and year of survey .....	113
Table 143	HIV antibody prevalence by frequency of drug injection last month, gender and year of survey .....	114
Table 144	HIV antibody prevalence by re-use of someone else's used needle and syringe last month, gender and year of survey .....	115
Table 145	HIV antibody prevalence by imprisonment last year, gender and year of survey .....	115
Table 146	HIV antibody prevalence by condom use at last sex, gender and year of survey .....	116
Table 147	HIV antibody prevalence by sex work last month, gender and year of survey .....	116
Table 148	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	117
Table 149	HIV antibody prevalence by region/country of birth, gender and year of survey .....	118
Table 150	HIV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	119
Table 151	HCV antibody prevalence by gender and year of survey .....	120
Table 152	HCV antibody prevalence by sexual identity, gender and year of survey .....	120
Table 153	HCV antibody prevalence by age group, gender and year of survey .....	121
Table 154	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	122
Table 155	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	123
Table 156	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	124
Table 157	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	124
Table 158	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	125
Table 159	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	125
Table 160	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	126
Table 161	HCV antibody prevalence by region/country of birth, gender and year of survey .....	127
Table 162	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	128

Tasmania

Table 163	Number (percentage) of respondents by demographic characteristics and year of survey .....	129
Table 164	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	130
Table 165	Number (percentage) of respondents by treatment for drug use and year of survey .....	131
Table 166	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	131
Table 167	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	132
Table 168	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	132
Table 169	HIV antibody prevalence by gender and year of survey .....	133
Table 170	HCV antibody prevalence by gender and year of survey .....	133
Table 171	HCV antibody prevalence by sexual identity, gender and year of survey .....	133
Table 172	HCV antibody prevalence by age group, gender and year of survey .....	134
Table 173	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	135
Table 174	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	136
Table 175	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	137
Table 176	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	137
Table 177	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	138
Table 178	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	138
Table 179	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	139
Table 180	HCV antibody prevalence by region/country of birth, gender and year of survey .....	140
Table 181	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	141



## Victoria

Table 182	Number (percentage) of respondents by demographic characteristics and year of survey .....	142
Table 183	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	143
Table 184	Number (percentage) of respondents by treatment for drug use and year of survey .....	144
Table 185	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	144
Table 186	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	145
Table 187	Number and (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	145
Table 188	HIV antibody prevalence by gender and year of survey .....	146
Table 189	HCV antibody prevalence by gender and year of survey .....	146
Table 190	HCV antibody prevalence by sexual identity, gender and year of survey .....	146
Table 191	HCV antibody prevalence by age group, gender and year of survey .....	147
Table 192	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	148
Table 193	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	149
Table 194	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	150
Table 195	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	150
Table 196	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	151
Table 197	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	151
Table 198	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	152
Table 199	HCV antibody prevalence by region/country of birth, gender and year of survey .....	153
Table 200	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	154

Western Australia

Table 201	Number (percentage) of respondents by demographic characteristics and year of survey .....	155
Table 202	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey .....	156
Table 203	Number (percentage) of respondents by treatment for drug use and year of survey .....	157
Table 204	Number (percentage) of respondents by source of needle and syringe acquisition in the last month .....	157
Table 205	Number (percentage) of respondents by sexual behaviour in the month prior to survey and year of survey .....	158
Table 206	Number (percentage) of respondents reporting previous testing for HIV and HCV infection and HCV treatment by year of survey .....	158
Table 207	HIV antibody prevalence by gender and year of survey .....	159
Table 208	HCV antibody prevalence by gender and year of survey .....	159
Table 209	HCV antibody prevalence by sexual identity, gender and year of survey .....	159
Table 210	HCV antibody prevalence by age group, gender and year of survey .....	160
Table 211	HCV antibody prevalence by duration of drug injection, gender and year of survey .....	161
Table 212	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey .....	162
Table 213	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey .....	163
Table 214	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey .....	163
Table 215	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey .....	164
Table 216	HCV antibody prevalence by sex work last month, duration of drug injection and year of survey .....	164
Table 217	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey .....	165
Table 218	HCV antibody prevalence by region/country of birth, gender and year of survey .....	166
Table 219	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey .....	167